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Abstract
Our contemporary concept of schizophrenia represents an evolution of Kraepelin's
'dementia praecox'. Kraepelin believed that he had identified a natural disease entity
reflecting a single underlying morbid process. However, the heterogeneity of symptoms and
course, together with the absence of any pathognomonic biological markers for the disorder,
has led critics to question the validity of schizophrenia as a scientific construct. In the first
section of this thesis structural brain imaging is presented as a powerful tool for investigating
the biological correlates of schizophrenia, thereby informing the ongoing evolution of the
concept. The major pathophysiological hypotheses of schizophrenia are discussed from the
perspective of structural brain imaging. The contemporary literature is then reviewed before
three potential strategies for future structural imaging research are presented: (1) imaginative
clinical study design employing carefully selected sub-groups from within the schizophrenic
population; (2) adoption of newly developed approaches to MRI data acquisition and
analysis; (3) utilisation of novel structural imaging techniques. In the second part of this
thesis three studies are presented, each illustrating one of the strategies described above.
Study 1: Structural magnetic resonance imaging (MRI) of the brain in presumed
carriers of gene(s) for schizophrenia, their affected and unaffected siblings.
The aim of this study was to establish if the gene(s) for schizophrenia are associated with
specific abnormalities of brain structure. Six sib-ships from multiply affected families were
recruited. Each sib-ship consisted of one patient with schizophrenia, one 'obligate carrier'
without the disorder but with an affected child and one 'non-affected non-carrier'. MRI was
conducted with a semi-automated region of interest analysis. Between-group comparisons
were tested by repeated measures analysis of variance. Reductions in volumes of cortical
structures and of whole brain were found only in schizophrenics and therefore appear to be
associated with phenotype. In contrast, reduced volume of the amygdalo-hippocampal
complex (AHC) was found in both schizophrenics and obligates and therefore appears to be
associated with genetic risk for the disorder even in the absence of disease. Reduced AHC
volume may therefore represent an endophenotypic marker for schizophrenia.
Study 2: A voxel based morphometry (VBM) and region of interest (ROI) analysis of
the genotypic and phenotypic neuroanatomy of schizophrenia.
The aim of this study was to explore the likely impact of a new method of data analysis upon
future structural brain imaging research. The MRI data set from study 1 (above) was
analysed using a voxel-based statistical technique (VBM) and a conventional ROI approach.
The results obtained by the two methods were then compared. Overall, the results obtained
by VBM were compatible with those obtained by ROI. However, the extent of the overlap
varied according to the statistical methods employed. Reassuringly, maximal agreement was
found when the 'optimal', most methodologically appropriate, VBM analysis was compared
with the 'optimal' ROI analysis (from study 1).
Study 3: Diffusion tensor imaging (DTI) and proton magnetic resonance spectroscopy
('H-MRS) in schizophrenic subjects and normal controls.
This study was included to illustrate the challenges inherent in the adoption of novel imaging
techniques. The study was designed to identify anatomical correlates of functional
dysconnectivity between the pre-frontal and temporal regions in schizophrenia. Ten patients
with DSM-IV schizophrenia were compared with ten healthy controls. Diffusion anisotropy
and NAA concentrations were measured in the same pre-frontal white matter region. DTI
revealed no differences in diffusion anisotropy between schizophrenics and controls
suggesting intact white matter cytoarchitecture. 'H-MRS revealed non-significant but
consistently reduced NAA concentrations (by 10-15%) in the pre-frontal white matter in
schizophrenic subjects suggesting abnormal function of structurally intact neurons.
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This thesis would not have been possible without the good will of the volunteers who
kindly agreed to answer innumerable questions and to lie in a noisy magnetic
resonance imaging (MRI) scanner. I am greatly indebted to everyone who took part.
Prior to consenting, each potential subject was offered a comprehensive written and
verbal explanation of the rationale behind the study and of the likely practicalities of
participation. On signing the consent form, one of the volunteers asked "so this
machine will take a picture ofmy brain which will show my schizophrenia - is that
right?" To my eternal shame I answered "yes." The problem with my answer lies
not in the description of an MRI scan as a "picture of the brain", but in the intimation
that schizophrenia exists as a physical entity amenable to imaging. Schizophrenia is
a concept, a collection of ideas and theories, which attempts to encapsulate a host of
observations and subjective experiences. An MRI scan can no more "show" a
person's schizophrenia than a DNA sequence can "show" his humanity.
This is not to say that "pictures of the brain" are irrelevant. In this thesis I outline the
role that structural brain imaging has played in advancing our understanding of
schizophrenia. I also describe three of my own studies that illustrate the use of
imaging as a research tool. However, the utility of this body of research is inevitably
limited by the unsatisfactory nature of the concept it seeks to elucidate. I shall
therefore begin my thesis by outlining the origins and evolution of contemporary
operational definitions of schizophrenia.
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1A. Origins of the Contemporary Concept of'Schizophrenia'
Kraepelin and Dementia Praecox
Although the term 'Schizophrenia' is conventionally credited to the Swiss
psychiatrist Eugen Bleuler1, modern operational definitions such as those listed in
DSM-IV2 and ICD-103 (see figures lAvi and lAvii) owe more to the work of
Bleuler's German contemporary Emil Kraepelin. The modern concept of
schizophrenia is an evolution of Kraepelin's concept of 'Dementia Praecox' .
Kraepelin asserted that a "tangible morbid process"4 was responsible for the
syndrome that he had described. He believed that, with time, the pathology
underlying dementia praecox would be revealed. All subsequent research into the
biological correlates of schizophrenia can be regarded as contributing to the search
for Kraepelin's "tangible morbid process". An appreciation of the environment in
which Kraepelin worked, the methods that he employed and the way in which his
ideas evolved are therefore prerequisites for any meaningful interpretation of
contemporary research in this field.
As we enter the 21st century, medical practice strives to be 'evidence-based'.
However, 19th century medicine could more accurately be described as 'eminence-
based'. It was de rigueur for the ambitious clinical academic to establish his
reputation by describing a new syndrome (which was frequently given an eponymous
epithet). The core clinical skills of history taking and examination were held in high
regard and scientific papers consisted of detailed clinical case reports. The 'Medical
Model' proposed that a group of patients with similar symptoms and signs were
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likely to share a common underlying pathology. The first step in understanding any
disease process was the accurate identification and description of the clinical
syndrome.
By the second half of the 19th century the rigorous application of this medical model
was proving highly productive. The relatively new sciences of microbiology and
histopathology were making enormous advances. The accepted wisdom amongst
medical academics decreed that signs and symptoms resulted from "disease entities"
each of which resulted from a single necessary and sufficient causative agent. The
discovery, by Robert Koch, of the Anthrax and Tubercle Bacilli reinforced this view.
Also described during this period were the now familiar syndromes of 'Broca's
aphasia', 'Wernicke's encephalopathy' and 'Korsakoffs psychosis'. In 1863,
Rudolph Virchow, Professor of pathology in Berlin, stated confidently "all
disturbances of function and structure in disease are due to cellular abnormalities . . .
the phenomena of a particular disease are brought about by a series of cellular
changes"5.
Meanwhile psychiatry was still in the process of securing its position as a reputable
medical specialty. Academic psychiatry was in its infancy. Although lecturing in
psychiatry had begun with Johann Heinroth in 1811 in Leipzig and with Jean-Etienne
Esquirol in 1817 in Paris, the first autonomous University Department was not
established until 1832 at the Charite Hospital in Berlin6. What we would now
recognise as the modern model for an academic department (a department situated
close to other medical departments, dedicated to teaching and research where
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professors could admit patients for those purposes) was first established by Wilhelm
Griesinger, professor of psychiatry in Berlin from 1865-1868. In his preface to the
first edition of Archive for Psychiatry and Nervous Diseases (the world's first
biological psychiatry journal) in 1867, Griesinger wrote "psychiatry has undergone a
transformation in its relationship to the rest of medicine, this transformation rests
principally on the realisation that patients with so-called 'mental illnesses' are really
individuals with illnesses of the nerves and the brain"1.
Griesinger and his contemporaries such as Ludwig Meyer in Hamburg and Theodor
Meynert in Vienna subjected post-mortem specimens of their deceased patients'
brains to pathological and histopathological investigation. The primary aim of this
research is clearly stated in Meynert's text of 1890 "the more that psychiatry seeks,
and finds, its scientific basis in a deep and finely grained understanding of the
anatomical structure of the brain, the more it elevates itself to the status of a science
that deals with causes."8 The early biological psychiatrists had some notable
successes. The brain pathology associated with the syndrome of 'dementia
paralytica'9, first described by Esquirol in 1814, was gradually elucidated (although
direct evidence that the syndrome, now called tertiary syphilis, was caused by
syphilitic spirochetes in the brain was not published until almost 100 years later10).
The gross and microscopic brain changes associated with senile dementia were also
identified (although Alzheimer's seminal paper11 was not published until 1906).
Unfortunately most psychiatric patients did not appear to have any demonstrable
brain pathology.
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Academic psychiatry was faced with a dilemma: if as Griesinger stated "patients
with so-called 'mental illnesses' are really individuals with illnesses of the nerves
and the brain" then why were researchers unable to identify pathological changes in
the brains of many sufferers? The majority of biological psychiatrists were
presumably confident (as we are today) that technological progress would ultimately
produce techniques capable of revealing the biological correlates of insanity.
However, the first step in the successful application of the medical model is the
identification of clinical syndromes, that is groups of patients with similar symptoms
and signs. Rather than wait passively for advances in laboratory science, a number
of 19th century psychiatrists set about the task of defining clinical syndromes and
devising systems of classification. Many of the nomenclatures proposed were based
upon highly speculative aetiological assumptions. The result was a plethora of
imaginatively titled syndromes and classificatory chaos. Kraepelin's principle
achievement was that he brought order to this chaos.
Kraepelin was something of a psychiatric polymath. After graduating from the
University of Wiirzburg in 1878, he worked in Munich for four years as resident to
the brain biologist Bernhard von Gudden. Here he trained in neuroanatomy and
neuro-histopathology but was unable to participate fully in experimental work
because an eye problem prevented him from spending long periods looking down
microscopes12 (unlike his friend Alois Alzheimer and fellow resident Franz Nissl).
While in Munich, he became interested in the work of experimental psychologist
Wilhelm Wundt and in 1882 he joined Wundt's newly founded psychological
13
laboratory in Leipzig. In 1883, at the age of 27, he wrote his first textbook
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(apparently because he intended to marry and needed the money14). He then worked
as an asylum physician for two years before being appointed to the chair of
psychiatry at the University of Dorpat in Estonia. Kraepelin did not speak Estonian
and was therefore not in a position to make detailed studies of patients'
psychopathology. Instead, he developed an interest in physical signs (such as
abnormal movements) and in the longitudinal course of psychiatric illness. In 1890
he was appointed professor of psychiatry in Heidelberg where he continued his work
on illness trajectories. He was also instrumental in bringing Alzheimer and Nissl to
Heidelberg and was an important collaborator on Alzheimer's studies into the
histopathology of dementia15. From 1904 to 1922 he was professor of psychiatry in
Munich.
The principal tool that Kraepelin employed in his clinical studies was the 'data
card'16. The clinical details of each patient were recorded on a card at the time of
admission. The card was then placed in a 'diagnosis box'. Once Kraepelin and his
colleagues had had time to study the patient, they would take the card from the box
and add the revised diagnosis together with an explanation. This process would be
repeated when the patient was discharged. Kraepelin also kept a separate list of the
names and discharge diagnoses of all of his patients. Kraepelin explained the
rationale behind his cards and lists "in this manner we were able to get an overview
and see which diagnoses had been incorrect and the reasons that had led us to this
false conception"17. The clinical observations contained on the cards included most
of the components of a modern mental state examination such as abnormal
appearance, movements, speech, affect, thoughts and perceptions as well as an
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assessment of cognitive ability. In 1893 Kraepelin incorporated his observations into
the fourth edition of his textbook. In the preface he explained that data gathered
from patients underpinned every assertion that he made and that his ultimate aim was
to "try to cut nature at the joints: to identify natural disease entities."18 By 1919
when Kraepelin published the eighth edition of his textbook, he and his team had
gathered longitudinal data from over a thousand patients19.
Kraepelin's classification evolves with each successive edition of his Lehrbuch.
Many of the concepts are borrowed from other eminent psychiatrists of the era,
Kraepelin's contribution is that he synthesises them into a workable model. The
term 'dementia praecox'20 first appears in the fifth edition (1896), whilst the central
tenant of his legacy (that the 'functional' psychoses can be divided into two
21*
disorders: manic-depressive psychosis and dementia praecox) is first proposed in
the sixth edition (1899).
Despite Kraepelin's stated reliance upon empirical clinical data, the systems of
classification described in the third and fourth editions do not stand out from those
proposed by his contemporaries. The focus is on symptoms and the groupings are
arranged according to presumed brain pathology. Kraepelin does, intriguingly,
introduce the concept of a "psychic process of degeneration"22 leading to, amongst
other things, "premature dementia". In the fifth edition the idea of degeneration is
abandoned, Kraepelin describes dementia praecox as a "metabolic disorder". He
subdivides dementia praecox into mild and severe forms, and 'hebephrenia' whilst
classifying 'catatonia' and 'dementia paranoides' separately. This edition marks a
7
decisive shift in Kraepelin's method - "I have abandoned any effort to classify
[psychosis] on the basis of the clinical presentation."20 He also acknowledges the
problems inherent in classifications based upon putative environmental causes (such
as 'masturbatory insanity'23 and 'wedding-night psychosis'23) - "as long as we are
unable clinically to group illnesses on the basis of cause, and to separate dissimilar
causes, our views about aetiology will necessarily remain unclear and
contradictory."20 Instead he argues that the "inner nature" of psychiatric disorders is
"manifest in their course and outcome"20.
In the sixth edition Kraepelin proposes a classification system dividing psychiatric
illness into 13 major groups, each of which represents a distinct clinical picture
unfolding and elaborating over time "each according to its own fundamental law" .
One group, called 'dementia praecox' incorporates the previously described
syndromes of 'hebephrenia', 'catatonia' and 'dementia paranoides'. Kraepelin
justifies this grouping on the basis that each syndrome typically affects patients in
early life and that the course of each is inevitably chronic and deteriorating. He
argues that these three syndromes are all manifestations of a common endogenous
brain disorder (either metabolic or possibly endocrinological in nature)4. The
symptoms themselves represent a "disruption of mental operations". Another group,
called 'manic depressive psychosis' incorporates 'mania', 'melancholia', 'periodical
insanity' and 'circular psychosis'. Kraepelin writes of this grouping, "in the course
of the years I have become more and more convinced that all are really just
manifestations of a single disease process." As in previous editions of his Lehrbuch,
Kraepelin cites evidence from his data cards to support his arguments.
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It is clear from the sixth edition of his textbook that Kraepelin recommended making
diagnoses according to the overall clinical picture. By way of illustration he presents
detailed accounts of his patients' symptomatology together with precise definitions
of key psychopathological terms. He suggests that symptoms are central to diagnosis
and stresses that a diagnosis ought to have prognostic value, "the doctor's first task at
the bedside is being able to form a judgement about the probable further course of
the case. People always ask him this. The value of a diagnosis for the practical
activity of the psychiatrist consists of letting him give a reliable look at the future."4
The notion that Kraepelin differentiated his cases purely on the basis of course is a
misconception. Rather he observed the differences in outcome and used this
observation as evidence in support of his theory that the two psychoses reflect two
distinct pathological processes, that each is a "natural disease entity".
Clearly Kraepelin did not work in a scientific vacuum. As noted above, many of his
contemporaries proposed their own classification systems and Kraepelin
incorporated many of their ideas into his own work. He continued to evolve his
classification system in the seventh and eighth editions of his Lehrbuch (and the
ninth which was published posthumously)24'25. Figure lAi below shows the
symptoms of dementia praecox as listed in the eighth edition of Kraepelin's
Lehbruch19. The enduring influence of his work can probably be attributed to the
insights contained in the sixth edition, most notably the emphasis upon course and
outcome as the keys to the "inner nature" of psychiatric disorders.
9
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From Dementia Praecox to Contemporary Operational Criteria for Schizophrenia
The conceptual framework laid down by Kraepelin proposes a pathological process
(possibly metabolic) leading to disruption of normal mental processes: This
disruption taking a variety of forms (and thereby producing a variety of symptoms)
but invariably beginning in adolescence or early adulthood and progressing to
dementia4. His textbooks contain detailed case reports that serve to illustrate his
main points and also act as a guide to readers attempting to replicate his diagnostic
methods. He does not, however, attempt to operationalise his diagnostic criteria,
preferring to weave clinical description into his theoretical framework. In the
following extract Kraepelin deals with phenomena that we would now call 'negative
symptoms': "There are apparently two principal groups of disorders that characterise
the malady. On the one hand we observe a weakening to those emotional activities
which permanently form the mainsprings of volition . . . Mental activity and instinct
for occupation become mute. The result of this highly morbid process is emotional
dullness, failure ofmental activities, loss ofmastery over volition, of endeavour, and
ability for independent action . . . The second group of disorders consist in the loss of
the inner unity of activities of intellect, emotion, and volition in themselves and
among one another . . . The near connection between thinking and feeling, between
deliberation and emotional activity on the one hand, and practical work on the other
is more or less lost. Emotions do not correspond to ideas. The patient laughs and
weeps without recognisable cause, without any relation to their circumstances and
their experiences, smile as they narrate a tale of their attempted suicide . . ,"19
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In later editions of his Lehbuch, Kraepelin reiterates his belief that the tangible
morbid process underlying dementia praecox will ultimately be revealed but his
optimism is not shared by all of his contemporaries. In 1908 Nissl writes "it was a
bad mistake not to realise that the findings of brain anatomy bore no relationship to
psychiatric findings."26 Eugen Bleuler shared Kraepelin's belief in the biological
basis of symptoms (although he suggests the mechanism is toxic rather than
metabolic)1 but he argues that certain symptoms, rather than being the product of
disrupted mental processes are a direct result of the morbid process. He suggests that
these 'fundamental' symptoms hold the key to understanding the illness. Whilst
27other 'accessory' symptoms are secondary phenomena and therefore less important .
Bleuler's ideas are reflected in the name he chooses for the condition "I call
dementia praecox schizophrenia because, as I hope to show, the splitting of the
different psychic functions is one of its most important features"26. "In each case
there is a more or less clear splitting of the psychological functions: as the disease
becomes distinct, the personality loses its unity"27. Kraepelin does not appear to
have put up much of a fight in defending his (borrowed) terminology. In the eighth
edition of his textbook he acknowledges for the first time that 'dementia praecox' is
a translation of the French 'demence precoce' proposed by Belgian psychiatrist
Benedict Morel in I86028. Kraepelin then writes "it has since been found that the
assumptions upon which the name chosen rested are at least doubtful . . . the
possibility cannot in the present state of our knowledge be disputed that a certain
number of cases of dementia praecox attain to complete and permanent recovery and
also the relations to the period of youth do not appear to be without exception."19
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Bleuler's concept of 'the group of schizophrenias' is broader than Kraepelin's
dementia praecox. The most overt evidence of this widening of the concept is the
incorporation of 'paraphrenia' and the introduction of the notion of 'simple'
schizophrenia. Bleuler outlines his ideas in his famous monograph of 1911. Here is
his introduction: "Certain symptoms of schizophrenia are present in every case and at
every period of the illness even though, as with every other disease symptom, they
must have attained a certain degree of intensity before they can be recognised with
any certainty. Here, of course, we are discussing only large symptom-complexes as
a whole. For example, the peculiar association disturbance is always present, but not
each and every aspect of it. Sometimes the anomalies of association may manifest
themselves in 'blocking', or in the splitting of ideas; at other times in different
schizophrenic symptoms." "Besides these specific permanent or fundamental
symptoms, we can find a host of other, more accessory manifestations such as
delusions, hallucinations or catatonic symptoms. These may be completely lacking
during certain periods, or even throughout the entire course of the disease; at other
times, they alone may determine the clinical picture."29 He goes on to outline his
view of the fundamental symptoms of schizophrenia as alterations of the simple and
compound functions of the brain. He illustrates his theory with clinical examples.
Bleuler's ideas attracted considerable support, particularly in North America30.
However, the application of his theory to clinical practice is problematic. His
fundamental symptoms (see figure lAii below) are poorly defined and by Bleuler's
own admission "exist in varying degrees and shadings on the entire scale from
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pathological to normal"29. Hence in Bleuler's model the boundaries between
schizophrenia and normality are blurred. The degree of interpretation required in
deciding whether or not Bleuler's fundamental symptoms are present leads to poor
diagnostic precision. The inevitable consequence is that modern operational
definitions of schizophrenia, whilst retaining Bleuler's term, make only indirect
references to his concept.
Figure 1 Aii - Bleuler's "Fundamental" symptoms of Schizophrenia
Loss of Continuity of Associations




Pressure of thoughts; clang associations
Loss of Affective Responsiveness
Lack of depth to the affect; restricted affect
Lack of consistency of affective manifestation
Inappropriate or blunted affect
Loss of Attention
Lack of selectivity of attention
Impaired active attention
Ambivalence
Affective ambivalence: the same concept is accompanied
simultaneously by pleasant and unpleasant feelings
Ambivalence of will: the patient wishes and does not wish the
same thing at the same time
Intellectual ambivalence: the patient expresses contradictory
thoughts in the same sentence
Autism
The German psychiatrist and philosopher Karl Jaspers explores the tension between
31
theory and practice in his 1913 work "General Psychopathology" . Jaspers makes
the philosophical distinction between 'explanation' and 'understanding'. He argues
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that theories and classifications are necessary for explanation but that in order to
understand the uniquely human characteristics of his patient the psychiatrist must
first adopt an empathic stance. Jaspers is highly critical of contemporary theories,
which he dismisses as "theoretical transformations of anatomical cerebral structures
into fantastic constructs of parallel psychic events which prove most
uninformative"32. He warns that "theory has a limited usefulness but it is often
superfluous and like some creeping plant it tends on the whole to suffocate real
insight, lively observation and all scientific progress"33.
Jaspers suggests that the clinician who views mental illness from his own perspective
will only have access to the external manifestations, the objective 'pathology'. This
clinician may be able to explain what he sees in terms of symptoms, syndromes and
diagnosis but he will not understand his patient. In contrast, the clinician who
empathises (places himself in the subjective scene of the patient's experience) will
have access to the patient's state of mind, the subjective 'phenomenology'. The
encompassing phenomenological description obtained through empathy offers a
degree of understanding of the patient as an individual, the essential features of his
existence ('existenz'). Jaspers argues that, from a phenomenological perspective, the
defining characteristic of psychosis is that the patient's experiences are
'nonunderstandable', that is the empathic clinician is unable to share in them because
he can not readily imagine experiencing them himself.
The empathic approach to psychiatric assessment is now regarded as standard
psychiatric practice and modern classifications are largely based upon
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phenomenology. It is ironic that the man who stressed the importance of
understanding (vis-a-vis explanation) in psychiatry should have contributed so much
to subsequent attempts at explanation. As discussed below, one of the criticisms of
operational classifications is their inability to cope with in-between cases (Jaspers
referred to these as 'psychoses in combination'). Jaspers warns of the dangers of
rigid application of structures derived from explanatory theories "there should be no
obscuring of what is still unknown. Contradictions should come clearly to light. It is
preferable to have a decisiveness which provokes discontent than satisfaction with a
pseudo-knowledge won by approximations and a purely logical arrangement."34
Amongst the many academic psychiatrists influenced by Jaspers was Kurt Schneider.
Schneider shared Bleuler's desire to identify symptoms that are fundamental to
schizophrenia but adopted Jasper's empathic approach in his search for
'comprehension by interaction'. His 'symptomatic comprehension' of the disorder is
based upon the idea that the non-understandable components of schizophrenia relate
to an inability to recognise boundaries between self and not-self. Schneider's theory
culminates in 1959 with the publication of his list of eleven 'symptoms of the first
rank'35 each of which is characterised by a loss of autonomy (see figure 1Aiii below).
Schneider argues that because these symptoms reflect the subjective experience that
is central to schizophrenia, they are likely to be pathognomic of the condition in the
absence of overt brain disease. In contrast to the fundamental symptoms proposed
by Bleuler, Schneider's first rank symptoms are essentially all-or-none phenomena.
A trained interviewer adopting an empathic stance ought to be capable of making a
confident judgement as to their presence or absence. They therefore lend themselves
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to incorporation into operational definitions of schizophrenia as they have the
potential to allow a group of patients to be identified reliably and with precision.
(Subsequent to their incorporation into standardised diagnostic instruments,
Schneider's first rank symptoms have been repeatedly misrepresented as entirely
empirical, with no theoretical basis.)
Figure 1 Aiii - Schneider's 'First Rank' symptoms of Schizophrenia
Auditory Hallucinations
Patient's own thoughts spoken aloud
Voices discussing or arguing about patient
Voices describing patient's activity as it takes place
Delusional Perception




Passivity of emotions and feelings
Passivity of desires or impulses
Passivity of movement
By the 1970's Kraepelin's original concept of Dementia Praecox had evolved in a
number of different directions. The term schizophrenia was being used in different
ways in different countries. Various 'schools' of psychiatrists were emerging each
following its own favoured theory. Attempts to produce a universally accepted
nomenclature had been unsuccessful. This caused particular problems for
researchers who were finding it increasingly difficult to make comparisons between
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studies that employed markedly different inclusion criteria. In 1972 researchers at
Washington University published the first operational diagnostic criteria for
schizophrenia36 (see figure lAiv below). The 'Feighner Criteria' had been validated
by follow-up and family studies, rather than by clinical judgement and experience
and were designed primarily as inclusion criteria for researchers wishing to study
schizophrenia. The emphasis upon chronicity and poor psychosocial outcome rather
than specific symptoms suggests that Feighner's view of schizophrenia owes more to
Kraepelin than to Bleuler or Schneider.
Figure 1Aiv - Feighner criteria for Schizophrenia
A - Both of the following are necessary:
1. A chronic illness with at least six months of symptoms prior
to the index evaluation without return to the premorbid level
of psychosocial adjustment.
2. Absence of a period of depressive or manic symptoms
sufficient to qualify for affective disorder or probable
affective disorder.
B - The patient must have at least one of the following:
1. Delusions or hallucinations without significant perplexity or
disorientation associated with them.
2. Verbal production that makes communication difficult
because of a lack of logical or understandable organization.
(In the presence of muteness the diagnostic decision must
be deferred.)
C - At least three of the following manifestations must be present for
a diagnosis of "definite" schizophrenia, and two for a diagnosis
of "probable" schizophrenia.
1. Single
2. Poor premorbid social adjustment or work history
3. Family history of schizophrenia
4. Absence of alcoholism or drug abuse within one year of
onset of psychosis
5. Onset of illness prior to age 40
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At this time it was not clear whether the different ways in which the term
schizophrenia was being used in different countries was a consequence of genuine
regional variations in symptomatology (or even entirely different diseases). The
"US-UK Diagnostic Project"37 and later "International Pilot Study of
Schizophrenia"38 (IPSS) were designed to shed light on this issue. The designers of
these ambitious studies, recognising the necessity for high inter-rater reliability,
developed a structured interview for use by the researchers in different countries.
This structured interview, the "Present State Examination" (PSE)39, incorporated
Schneider's first rank symptoms. When Robert Spitzer and colleagues from the
Columbia University in New York designed a shorter semi-structured interview, the
"Schedule for Affective Disorders and Schizophrenia" (SADS)40, they stuck to the
successful formula of the PSE. Spitzer and colleagues also used the findings of the
PSE-based IPSS to 'refine' the Feighner Criteria, publishing their "Research
Diagnostic Criteria" (RDC)41 (see figure lAv below) in 1978. In reality the RDC
bear little relation to the Feighner criteria. The emphasis on chronicity and poor
psychosocial functioning are replaced by a list of psychotic phenomena closely
resembling Schneider's list of first rank symptoms.
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Figure 1Av - Research Diagnostic Criteria for Schizophrenia
A. During an active phase of the illness at least two of the following
are required for definite and one for probable diagnosis of
schizophrenia:
1. Thought broadcasting, insertion, or withdrawal
2. Delusions of being controlled or influenced, other bizarre
delusions, or multiple delusions
3. Somatic, grandiose, religious, nihilistic, or other delusions
without persecutory or jealous content lasting at least one
week
4. Delusions of any type if accompanied by hallucinations of
any type for at least one week
5. Auditory hallucinations in which either a voice keeps up a
running commentary on the subject's behaviours or
thoughts as they occur, or two or more voices converse with
each other
6. Non-affective verbal hallucinations spoken to the subject
7. Hallucinations of any type throughout the day for several
days or intermittently for at least one month
8. Definite instances of marked formal thought disorder (as
defined in this manual) accompanied by either blunted or
inappropriate affect, delusions or hallucinations of any type,
or grossly disorganized behaviour
B. Signs of the illness have lasted at least two weeks from the onset
of a noticeable change in the subject's usual condition.
C. At no time during the active period of illness being considered has
the subject met the full criteria for either probable or definite manic
or depressive syndrome to such a degree that it was a prominent
part of the illness.
These rigid operational criteria for research stood in stark contrast to the looser
descriptive nomenclatures published by the World Health Organisation42 and the
American Psychiatric Association43. As a highly respected figure in American
psychiatry, Spitzer had been invited to head the American Psychiatric Association
task force44 commissioned to produce the third edition of the Diagnostic and
Statistical Manual (DSM-III)45. The result was a ground-breaking document
containing both detailed descriptions and operational diagnostic criteria for a
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comprehensive range of psychiatric disorders. The DSM-III criteria for
schizophrenia are essentially a combination of the Feighner criteria and the RDC.
These have subsequently evolved through a revised version (DSM-III R)46 to their
current form in the fourth edition (DSM-IV)47 and the latest "text revision" (DSM-IV
TR)2 (see figure lAv below).
Figure 1Avi - DSM-IV (TR) diagnostic criteria for Schizophrenia
A. Characteristic symptoms: Two or more of the following, each
present for a significant portion of time during a 1-month period (or
less if successfully treated)
1. Delusions
2. Hallucinations
3. Disorganized speech (e.g. frequent derailment or
incoherence)
4. Grossly disorganized or catatonic behaviour
5. Negative symptoms (i.e. affective flattening, alogia or
avolition)
Only one Criterion A symptom is required if delusions are bizarre or
hallucinations consist of a voice keeping up a running commentary on
the person's behaviour or thoughts, or two or more voices are
conversing with each other.
B. Social/occupational dysfunction: for a significant portion of the time
since the onset of the disturbance, one or more major areas of
functioning such as work, interpersonal relations, or self-care are
markedly below the level achieved prior to the onset (or, when the
onset is in childhood or adolescence, failure to achieve the
expected level of interpersonal, academic or occupational
achievement).
C. Duration: Continuous signs of the disturbance persist for at least 6
months, of which at least one month should be of symptoms that
meet Criterion A. The 6 months may include periods of prodromal
and residual symptoms. During these prodromal or residual
periods, the signs of disturbance may be manifested by only
negative symptoms or two or more symptoms listed in Criterion A
present in an attenuated form (e.g. odd beliefs, unusual perceptual
experiences).
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D. Schizoaffective and mood disorder exclusion: Schizoaffective
disorder and mood disorder with psychotic features have been
ruled out because either no major depressive, manic, or mixed
episodes have occurred concurrently with the active-phase
symptoms, or if mood episodes have occurred during active-phase
symptoms, their total duration has been brief relative to the active
and residual periods.
E. Substance/general medical condition exclusion: The disturbance is
not due to the direct physiological effects of a substance or a
general medical condition.
F. Relationship to a pervasive developmental disorder: if there is a
history of autistic disorder or another pervasive developmental
disorder, the additional diagnosis of schizophrenia is made only if
prominent delusions or hallucinations are also present for at least a
month (or less if successfully treated).
When DSM-III was published in 1980, its contemporary rival, ICD-948 was
effectively rendered redundant. The rivalry stretched back to the publication by the
World Health Organisation in 1948 of the 6th revision of the International Statistical
Classification of Diseases, Injuries and Causes of Death (ICD-6)49 (itself a revision
of the fifth International List of Causes of Death published by the International
Statistical Institute)50. The American Psychiatric Association, rather than adopt ICD-
6, had established its own "Committee on Naming"51, which published the first
edition of DSM52 in 1952. The WHO-appointed committee preparing ICD-10
acknowledged the breakthrough that DSM-III represented and borrowed heavily
from its format, structure and content (see figure lAvii below). The APA-appointed
team preparing DSM-IV returned the complement by borrowing from ICD-10. The
two classifications are clearly not identical; however, in their current forms the
similarities are striking.
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Figure 1 Avii - ICD-10 diagnostic criteria for Schizophrenia
A. Either at least one of the syndromes, symptoms, and signs listed
under (1) below or at least two of the symptoms and signs listed
under (2) should be present for most of the time during an episode
of psychotic illness lasting for at least 1 month (or at some time
during most of the days)
(1) At least one of the following must be present:
1. Thought echo, thought insertion or withdrawal, or thought
broadcasting
2. Delusions of control, influence, or passivity, clearly referred
to body or limb movements or specific thoughts, actions, or
sensations; delusional perception
3. Hallucinatory voices giving a running commentary on the
patient's behaviour, or discussing the patient among
themselves, or other types of hallucinatory voices coming
from some part of the body
4. Persistent delusions of other kinds that are culturally
inappropriate and completely impossible
(2) Or at least two of the following:
1. Persistent hallucinations in any modality, when occurring
every day for at least 1 month, when accompanied by
delusions without clear affective content, or by persistent
over-valued ideas
2. Neologisms, breaks, or interpolations in the train of thought,
resulting in incoherence or irrelevant speech
3. Catatonic behaviour, such as excitement, posturing, or waxy
flexibility, negativism, mutism, or stupor
4. "Negative" symptoms, such as marked apathy, paucity of
speech, and blunting or incongruity of emotional responses
B. Exclusion clauses:
1. If the patient also meets criteria for manic episode or
depressive episode, the criteria listed under (1) and (2)
above must have been met before the disturbance of mood
developed
2. The disorder is not attributable to organic brain disease, or
to alcohol- or drug-related intoxication, dependence, or
withdrawal.
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One interesting concept introduced in ICD-10 and carried over into DSM-IV is the
description of symptoms as either 'positive' or 'negative'. These terms were
probably first used by the 19th century English neurologist John Hughlings-Jackson
who wrote "Disease is said to 'cause' the symptoms of insanity, I submit that disease
only produces negative mental symptoms, answering to the dissolution, and that all
elaborate positive mental symptoms (illusions, hallucinations, delusions, and
extravagant conduct) are the outcome of activity of nervous elements untouched by
any pathological process; that they arise during activity on the lower level of
evolution remaining."53 The way in which the terms 'positive' and 'negative' are
used in current editions of ICD and DSM is not substantially different from the way
in which Hughlings-Jackson used them. However, his theoretical model (in which
symptoms are explained according to the Darwinian evolution of brain structures)
has not been retained.
In time both the ICD-10 and DSM-IV-TR classifications will be superseded.
However, for contemporary schizophrenia researchers they represent the current
'state of the art' in the attempt to provide a robust definition of an infuriatingly
ethereal clinical entity. The divergent evolution of Kraepelin's concept that
prompted Feighner and colleagues36 to produce strict operational diagnostic criteria
has been successfully reversed. Researchers across the globe can now be confident
that the 'schizophrenia' they are studying is the same as the 'schizophrenia' they read
about in journals. Unfortunately many of the questions faced by Kraepelin remain
unanswered. In particular, his 'tangible morbid process' has not been identified. The
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IB. Problems 'Schizophrenia' Presents to Structural Imaging Researchers
The value of any scientific experiment is intrinsically limited by the reliability of the
observations and the validity of the study design. Schizophrenia researchers are
faced with fundamental issues relating to the reliability and validity of the very
concept that they are attempting to expound. These problems are an inevitable
consequence of the way in which the concept of schizophrenia has evolved.
The ultimate goal of medical classification is, as Kraepelin wrote, "to cut nature at
the joints: to identify natural disease entities." A natural disease entity ought to be
amenable to study. Patients diagnosed with such a disorder would share specific,
pathognomic disease markers. But no such marker has yet been identified for
schizophrenia. Indeed much of the research into biological correlates of
schizophrenia is characterised by heterogeneity2. To some this brings into question
the validity of 'schizophrenia' as a scientific concept3'4. Certainly the "patchwork"5
nature of the diagnostic criteria listed in ICD and DSM bring to mind a series of
stabs at nature rather than a single decisive cut: the broad categorisations pay homage
to Kraepelin; the recommended method for ascertaining the symptomatology is
Jaspers' 'empathic interview'; the lists of'defining features' are adaptations of those
proposed by Schneider and, to a lesser, extent Bleuler; individual symptoms are
labelled as 'positive' or 'negative' in accordance with Hughlings-Jackson.
Furthermore, the basic premise underlying Kraepelin's diagnostic categories (an
emphasis upon course and outcome) has been dropped; Jaspers saw empathic
interviewing as a tool for promoting 'understanding' which he considered to be the
antithesis of the 'explanation' offered by diagnosis; and the potpourri of defining
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symptoms chosen from the works of Schneider, Bleuler and Hughlings-Jackson
appear without reference to the (mutually incompatible) aetiological theories from
which they were originally derived. As it is currently defined, 'schizophrenia' is the
camel ofmedicine - a disorder designed by committee.
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Reliability
Different researchers employing different diagnostic criteria for schizophrenia will
inevitably disagree about the diagnosis in a proportion of cases. (Indeed even a
single researcher applying different diagnostic criteria simultaneously will eventually
disagree with himself!) For this reason, the mere existence of competing diagnostic
criteria, results in a diagnosis that is less than perfectly reliable. To make matters
worse, the criteria change periodically. In practice this represents less of a problem
to contemporary schizophrenia researchers than one might think. There is a great
deal of overlap between the various nomenclatures. For example, a study by
McGlashan6 in 1984, comparing various diagnostic systems, found a concordance
rate between DSM-III and RDC of k = 0.88. Although the author is not aware of an
equivalent study specifically designed to measure the concordance between DSM-IV
and ICD-10, both nomenclatures are evolutions ofDSM-III and both were developed
with the help of field trials to ensure good reliability. It seems likely that the
concordance rate, if measured, would be very high. There is one important proviso
to this statement: DSM-IV criteria specify a period of disturbed functioning of no
less than six months; this is not replicated in ICD-10; hence concordance rates for
first episode cases may be low. The danger of further divergence with each
subsequent revision remains, but it is essential that the concepts evolve if they are to
succeed in incorporating new research findings.
The subjective nature of the psychiatric interview brings with it the risk of poor inter-
rater reliability. Kraepelin acknowledges this problem in the 8th edition of his
textbook: "the statements of different observers can in the first place not be
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compared at all"7. Much of the variation in assessment has been eliminated from
modern schizophrenia research with the introduction of structured psychiatric
interviews such as the PSE8. Indeed, any contemporary study of schizophrenia that
fails to employ a structured interview will struggle to be accepted by a respected peer
review journal and studies that employ a number of clinical interviewers routinely
include calculations of inter-rater reliability. When piloting the PSE, Wing and
colleagues found that psychiatrists trained in its use agreed upon the diagnosis of
schizophrenia in 92% of cases9. Reliability of diagnosis is therefore no longer a
major problem in well conducted studies of schizophrenia. As Kendell writes in the
'Companion': "In skilled hands, psychiatric diagnoses are now as reliable as the
clinical judgements made in other branches ofmedicine, and sometimes more so."10
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Validity
The ability reliably to diagnose schizophrenia may be a necessary prerequisite for
meaningful scientific study but, as Kendell explains: "Reliability can be high while
validity remains trivial and in such a situation high reliability is of very limited
value."11 Kendell distinguishes the two: "Reliability is concerned with the defining
characteristics of a class, validity with the correlates of class membership."11
Researchers involved in imaging studies are searching for correlations between the
diagnosis of schizophrenia and brain structure. Their findings will therefore have a
direct bearing upon the validity of the concept of schizophrenia (consistent,
meaningful correlations will enhance it whilst inconsistent, heterogeneous findings
will undermine it). Conversely the validity of structural imaging research is entirely
dependent upon the validity of the concept under study. To put this another way, if
Kraepelin was incorrect in his assertion that dementia praecox is a natural disease
entity then the search for his tangible morbid process may be headed up a blind alley.
It is interesting to note that although Kraepelin proposed thirteen diagnostic
categories, the only ones to have survived in any recognisable form are 'dementia
praecox' and 'manic-depressive psychosis'. Whilst the durability of these two
categories may reflect the validity of Kraepelin's original scientific concepts, one has
to acknowledge alternative explanations for their continued acceptance (such as
chance, professional convenience or even collective intellectual sloppiness).
Kraepelin was undoubtedly more scientifically rigorous than many of his
contemporaries. However, critics argue that when his methods are scrutinised, using
modem scientific criteria, fundamental problems are revealed3. Some commonly
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expressed criticisms of Kraepelin's work in developing his concept of dementia
praecox are summarised below (Figure IBi).
Figure 1 Bi - Criticisms of Kraepelin's Work
1. Little scientific method to observations
In his texts, Kraepelin does not present systematically gathered
data but instead relies upon his own personal experience and
beliefs. He reports the patterns that he has observed in his
cards and lists but makes no attempt to demonstrate that the
associations he identifies occur more frequently than would be
expected by chance (i.e. reach statistical significance). Also
Kraepelin knew many of the patients well and was therefore not
a blind, impartial observer.
2. Pathological explanations proposed without evidence
Kraepelin repeatedly asserts that he is attempting to classify
psychiatric patients according to underlying brain pathology. He
argues that dementia praecox is a natural disease entity,
probably a metabolic or endocrine disorder. However, at the
time he was writing there was no empirical evidence of any
metabolic, endocrine or other biological disturbance in these
patients. Critics could argue that his explanations are personal
declarations of faith rather than objective statements of fact.
3. Terms poorly defined
It is clear that Kraepelin used very different criteria for
diagnosing dementia praecox in different patients. In his texts
he argues that he is making the diagnosis upon the basis of the
total clinical picture and provides detailed descriptions of
individual cases. However, critics argue that he does not define
his terms with sufficient clarity to enable readers to reliably
replicate his observations12.
4. Texts contain many internal inconsistencies
Kraepelin's concepts and nomenclature change with each
edition of his text. Certain revisions directly contradict his
previous writings, for example, 'catatonia', 'dementia
paranoides' and 'dementia praecox' are presented as separate
conditions in the 5th edition but are grouped together as
"manifestations of a single disease process" in the 6th edition.
The majority of these contradictions can be dismissed as
necessary steps in the evolution of a sophisticated theory.
However, occasionally Kraepelin proposes a revision that
appears to undermine a central tenet of his theory. For
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example, in the 8th edition he writes "a certain number of cases
of dementia praecox attain to complete recovery and also the
relations to the period of youth do not appear to be without
exception."7
5. Population not comparable to modern populations
In Kraepelin's descriptions there is a greater emphasis upon
physical abnormalities (e.g. gait, tremor, pupillary response)
than is found in modern psychiatric texts. Kraepelin's neurology
colleagues argued that a number of his patients were suffering
from Encephalitis Lethargica13. One modern critic contends "the
referents of 'schizophrenia' gradually changed until the term
came to be applied to a population who bore only a slight and
superficial resemblance to Kraepelin's and Bleuler's."
Criticisms of Kraepelin's work are only immediately relevant if they help to
highlight problems with our current concept of schizophrenia. As has already been
demonstrated the problems of reliability that Kraepelin faced have largely been
resolved. The problems of validity are more challenging. Towards the end of his
life, Kraepelin himself expresses doubts about the validity of the diagnostic
categories he had proposed. In 1920 he writes of dementia praecox (now renamed
'schizophrenia'): "There is no doubt that schizophrenic symptoms may also occur
without any damage to cerebral tissue, . . . this fact is of great importance because it
points to the possibility that other curable illnesses may in certain circumstances
assume schizophrenic forms."15 He even questions the validity of the core
assumption upon which his entire system of classification (and arguably all modern
psychiatry) is based: "we must seriously consider how far the phenomena on which
we normally base our diagnosis really do afford insight into the basic pathological
process."15
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Establishing validity is not as straight forward as establishing reliability. The
American Psychological Association distinguishes between four different types of
validity: content, concurrent, predictive and construct16. Although their criteria were
originally devised for assessing the validity of psychometric tests, they can be
adapted for assessing the validity of diagnostic categories17. The criticisms of
Kraepelin's work listed in Figure IBi incorporate challenges to all four types of
validity (content in 2 & 5; concurrent in 3; predictive in 4; construct in 1 & 4). The
contemporary construct of'schizophrenia', including modern operational definitions,
will now be evaluated in accordance with these four criteria.
Content Validity
The American Psychological Association defines the content validity of a
psychometric test as follows: "If a test performance is to be interpreted as a sample
of performance or a definition of performance in some universe of situations, the
manual should indicate clearly what universe is represented and how adequate is the
sampling."1 Kendell adapts this definition for clinical diagnoses defining the content
validity of a diagnosis as "the demonstration that the defining characteristics of a
given disorder are indeed enquired into and elicited before that diagnosis is made."11
The widespread adoption of standardised structured psychiatric interviews together
with operational research diagnostic criteria guarantees a high level of content




Establishing the concurrent validity of schizophrenia involves demonstrating that
independent techniques for arriving at the diagnosis produce the same patient
groupings. It is axiomatic that high concordance between different diagnostic
criteria and high inter-rater reliability are prerequisites for concurrent validity.
However such a demonstration of reliability of diagnosis is not in itself sufficient
because the techniques employed to arrive at the diagnosis are closely related (i.e.
not independent). A potentially more convincing method of establishing concurrent
validity is 'cluster analysis'.
'Cluster analysis' is the generic term for a range of statistical techniques designed to
separate a single heterogeneous population into a number of discrete, relatively
homogenous 'clusters'. Each cluster is comprised of individuals who share certain
characteristics. Critics of this approach argue that the clusters that emerge are
determined by the rules laid down at the start of the analysis and point to the fact that
different statistical rules produce very different clusters. Furthermore the clusters are
only likely to be useful if the shared characteristics are clinically relevant (and
recognisable). The cluster analysis literature relating to schizophrenia is probably
best described as inconclusive. The largest and most robustly designed analysis to
date is the transatlantic study conducted by Everitt, Gourlay and Kendell in 197119.
The authors interpret the results as supportive of the distinction between
schizophrenia and manic-depression, pointing out that two different methods of
analysis in two different populations of patients (giving four analyses altogether) all
produced separate clusters clearly identifiable with the depressive and manic phases
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of manic-depression, with acute paranoid schizophrenia and with chronic
schizophrenia. However, critics argue that the relationship between clusters and
diagnosis in their data is weak, pointing to the fact that over 60% of patients from
every diagnostic group fell into two or three 'dustbin' clusters4. An intriguing
addition to this literature is a retrospective study of almost 200 of Kraepelin's
original patients. Jablensky and colleagues derived clinical symptoms (consistent
with PSE definitions) from the original case material and performed a cluster




As noted in the previous chapter, Kraepelin himself considered predictive validity to
be the most clinically important characteristic of a diagnosis: "The value of a
diagnosis for the practical activity of the psychiatrist consists of letting him give a
reliable look at the future."21 Kendell shares this view: "In the last resort all
diagnostic concepts stand or fall by the strength of the prognostic and therapeutic
implications they embody."11
Unfortunately the literature suggests that a diagnosis of schizophrenia is of limited
prognostic value. As the summary in DSM-IV TR concedes: "Most studies of course
and outcome in schizophrenia suggest that the course may be variable, with some
individuals displaying exacerbations and remissions, whereas others remain
chronically ill. Because of variability in definition and ascertainment, an accurate
summary of the long-term outcome of schizophrenia is not possible. Complete
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remission (i.e. a return to full premorbid functioning) is probably not common in this
disorder. Of those who remain ill, some appear to have a relatively stable course,
whereas others show a progressive worsening associated with severe disability."2
The literature in relation to the therapeutic implications of a diagnosis of
schizophrenia is also characterised by variability. A pragmatic observational study
of the relationship between diagnosis and treatment in 1000 patients admitted to
psychiatric hospitals in London in 1964 (admittedly pre-dating operational diagnostic
criteria) concludes "the findings are not consistent with the notion that each
particular diagnosis leads logically, or habitually, to a particular treatment. It
suggests that variables other than diagnosis may be as, or more important than,
diagnosis in predicting choice of treatment."23 On an anecdotal level, the author
recalls a teaching method employed by the professor of clinical pharmacology at his
medical school (a physician). He would hand the students a series of medication
'kardexes' and invite us to deduce the patients' diagnoses. This task, whilst
challenging to a medical student who had rarely opened the good professor's
textbook, was theoretically achievable in the vast majority of cases. The same task
would be impossible with a substantial proportion of psychiatric 'kardexes'. Whilst
antipsychotic medication is almost universally accepted as the treatment of choice for
schizophrenia, the evidence from randomised controlled trials suggests that only a
proportion of patients (estimates range from 20-80%) benefit from such
treatment24'25'26. The efficacy of antipsychotic medication is not specific to
27 • 28 • • 29
schizophrenia as treatment trials in mania , severe depression and delirium
demonstrate. Furthermore, treatments more commonly used in affective disorders
41
such as ECT30 and lithium31 have been used successfully in patients with a diagnosis
of schizophrenia as have benzodiazepines32.
Construct Validity
In order to demonstrate the construct validity of a diagnosis, one must obtain
objective evidence that the various components of the diagnosis are present in
patients with the diagnosis but not in other patients. At its most basic level construct
validity relates to the specificity and sensitivity of diagnostic criteria. However, the
concept (or 'construct') of schizophrenia is far wider than that represented by the
necessarily reductionist operational definitions contained in ICD and DSM. The
symptoms and signs listed in these nomenclatures are considered to be
manifestations of some underlying brain pathology, the characteristics of which are
not yet fully understood. The validity of the construct ultimately depends upon
robust and plausible research findings. All research into aetiological risk factors and
biological markers (including all structural imaging work) can therefore be viewed as
either enhancing or undermining the construct validity of schizophrenia.
The first step in establishing the construct validity of schizophrenia is to demonstrate
that the characteristic, defining symptoms listed in ICD and DSM have high
specificity and sensitivity. This task is far from straightforward because specificity
and sensitivity are usually established by comparison with a gold standard (ideally a
pathognomonic biological marker). However, no gold standard exists for the
diagnosis of schizophrenia. In their comparative study of ICD-10 and DSM-IIIR
criteria, Amin and colleagues33 attempt to get around this problem by using the
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temporal stability of diagnosis at three year follow-up as the gold standard. They
report high specificity (ICD-10 89%, DSM-IIIR 93%) but low sensitivity (ICD-10
64%, DSM-IIIR 51%). Other authors have taken a different approach, examining
individual components of the diagnostic criteria such as Schneiderian first rank
symptoms. Nancy Andreasen reviewing this literature concludes "Schneider's first
rank symptoms seem to carry diagnostic weight for schizophrenia when 'massively'
present and when known organic psychoses are excluded. However, at least 10% of
affectively ill probands, especially manics, have also been shown to have at least one
first rank symptom. The main problem in their clinical application is their low
sensitivity (on average less than 50%)"34.
Andreasen's use of the phrase "massively present" reflects a problem common to all
categorisations that rely upon subjective judgements: where to draw the boundaries.
The inclusion in ICD-10 of the categories 'schizotypal disorder' and 'schizoaffective
disorders' is a tacit acknowledgement of the arbitrary nature of the diagnostic
boundaries for schizophrenia.
'Schizotypal disorder' is defined as "a disorder characterised by eccentric behaviour
and anomalies of thinking and affect which resemble those seen in schizophrenia,
although no definite and characteristic schizophrenic anomalies occur at any stage."
Its inclusion within the same group as schizophrenia is justified on the following
grounds: "there is some evidence that it is related to schizophrenia (as one of the
'schizophrenic spectrum' disorders)."35 The equivalent category in DSM-IV is
called 'schizophreniform disorder' whilst an additional category of 'schizotypal
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personality disorder' is listed elsewhere. The "evidence" to which the authors of
ICD-10 refer stems largely from genetic research, which suggests that a genetic
liability to schizophrenia may be associated with psychopathology resembling that
seen in schizophrenia only less severe (Andreasen might regard certain symptoms
as being present but not 'massively' so). Evidence from structural imaging research
suggests that these individuals, like schizophrenic patients, have reduced temporal
lobe volume37. There is additional evidence from functional imaging37 and
psychometric studies38'39 in support of the notion of a 'schizophrenic spectrum'. The
presence of a large number of 'sub-threshold' cases apparently blending into
normality undermines the validity of the construct of schizophrenia as a tightly
defined, categorical disorder with a characteristic aetiology and neuropathology. To
borrow from the language of classificatory theory, a number of the characteristic
features of schizophrenia appear to be better suited to a 'dimensional' rather than the
current 'categorical' classification.
The 'schizoaffective disorders' are defined in ICD-10 as "episodic disorders in which
both affective and schizophrenic symptoms are prominent but which do not justify a
diagnosis of either schizophrenia or depressive or manic episodes."35 The
unsatisfactory nature of this category is acknowledged in the diagnostic notes: "the
relationship of this group of disorders with both schizophrenia and the affective
disorders are uncertain. . . The diagnosis depends upon difficult clinical judgements
about the approximate 'balance' between the number, severity and duration of the
schizophrenic and the affective symptoms."35 The existence of patients with both
schizophrenic and affective symptoms is clearly a challenge to the Kraepelian view
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that these are separate disorders. Kxaepelin himself acknowledged "the difficulties
which still prevent us from distinguishing reliably between manic-depressive insanity
and dementia praecox."15 He recognised the challenge presented by this group of
patients: "No experienced psychiatrist will deny that there is an alarmingly large
number of cases in which it seems impossible, in spite ofmost careful observation, to
make a firm diagnosis."15 As Kraepelin observed, the frequency with which
affective and schizophrenic symptoms co-exist in the population is too high to be
explained by chance. Family studies demonstrate that schizophrenia and bipolar
affective disorder often co-exist within the same family40'41 and molecular linkage
studies reveal that some susceptibility loci may be common to both42. This raises the
possibility of a shared genetic susceptibility and therefore a degree of overlap
between the patho-physiological mechanisms underlying schizophrenia and bipolar
disorder, a notion that is broadly supported by the post-mortem literature43. A
number of the characteristic structural imaging findings are also common to both
schizophrenia and bipolar disorder (see overview, chapter ID).
If there is no unambiguous pathophysiological distinction between the two
conditions, one has to question whether it is justifiable to regard them as separate.
One statistical method for testing the validity of a diagnostic distinction is
'discriminant function analysis'. Kendell emphasises the potential importance of
such an approach: "a bimodal distribution of scores on a discriminant function,
obtained from an unselected population and cross validated on a second population,
should be the accepted criterion of validity for all diagnostic distinctions."44 A
number of researchers, including Kendell himself, have applied this technique to the
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functional psychoses in an attempt to demonstrate a 'point of rarity' between
schizophrenia and manic depression but none has been successful45'46. One could
interpret these results as powerful evidence against the Kraepelian division of
psychosis into schizophrenia and bipolar disorder.
Conclusions
Our contemporary concept of schizophrenia owes not only its basic structure but also
its limitations to the work of Emil Kraepelin. The problems of poor reliability and
limited content validity have been successfully tackled by the adoption of tight
operational definitions and structured psychiatric interviews. However, attempts to
demonstrate the concurrent validity of the concept using cluster analysis have been
inconclusive. The predictive validity of the diagnosis as defined by course, outcome
and treatment response remains limited. Fundamental questions relating to the
validity of Kraepelin's construct remain unanswered. His "tangible morbid process"
has not yet been found. The evidence for a 'schizophrenic spectrum' suggests that,
rather than being a "natural disease entity", schizophrenia may blend into normality.
Most worrying of all for supporters of Kraepelin is the substantial body of evidence
indicating an overlap between schizophrenia and bipolar disorder.
For contemporary schizophrenia researchers the legacy of uncertain validity remains
something of a 'Catch 22'. Nancy Andreasen and William Carpenter Jr. describe the
problem succinctly: "Although we can now define a particular construct of
schizophrenia with reasonable agreement, the construct must be recognised as
provisional and based on a need to achieve consensus about definitions rather than on
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an understanding of pathophysiology and aetiology. The major challenge
confronting the student of schizophrenia is to identify its mechanisms and causes" 1.
The 'catch' lies in the potentially self-defeating task of trying to identify the
pathophysiological mechanisms and causes of a construct whose origins owe nothing
to the science of pathophysiology. One would hope that provisional, incomplete
insights into the biological mechanisms associated with schizophrenia might lead to
an evolution of the construct into something less nebulous and more amenable to
pathophysiological investigation. Daniel Weinberger, speaking at the 10th Biennial
Winter Workshop on Schizophrenia expressed his frustration with the current
situation "being a schizophrenia researcher in the year 2000 is like being the pilot of
an aircraft circling above what you hope is an airstrip waiting for somebody to turn
the landing lights on."48
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Potential Solutions
When Kraepelin described dementia praecox, he was confident that he had identified
a "natural disease entity" attributable to a "tangible morbid process" the nature of
which would inevitably be revealed by scientific investigation. Yet more than a
century later, two of the world's leading schizophrenia researchers acknowledge that
little has changed: "The major challenge confronting the student of schizophrenia is
to identify its mechanisms and causes"47. Clearly things have not turned out the way
that Kraepelin had initially hoped. One possible reason for the relatively slow rate of
progress is the limited validity of schizophrenia as a scientific concept (as outlined
earlier in this chapter). The question of whether to work within the limitations of the
concept or to abandon it altogether is as much a philosophical as a scientific one.
The psychiatrist and philosopher Karl Jaspers commenting on the debate surrounding
Kahlbaum's concept of a 'unitary psychosis' in his text 'General Psychopathology'
writes: "The original question: are there only stages and variants of one unitary
psychosis or is there a series ofdisease-entities which we can delineate, now finds its
answer: there are neither. The latter view is right in so far that the idea of disease-
entities has become a fruitful orientation for the investigations of special psychiatry.
The former view is right in so far that no actual disease-entities exist in scientific
psychiatry."49 Of course Kahlbaum's concept has now been abandoned and certain
'actual disease-entities' have subsequently been identified within the field of
psychiatry (e.g. tri-nucleotide repeats as the underlying molecular mechanism in
Huntingdon's Chorea). However, when considered in the context of the
contemporary debate surrounding the validity of schizophrenia as a scientific
concept, Jasper's comments acquire a sobering resonance.
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The arguments put forward both by supporters and by opponents of the
contemporary concept of schizophrenia will now be examined. A compromise, or
'third way' alternative will then be presented.
'Status Quo' - Accept current concept as a useful starting point
Kraepelin's concept may be slightly over a century old but for the first three quarters
of that century scientific investigation was seriously hindered by the absence of an
agreed definition (and therefore poor reliability of diagnosis). In the twenty-five to
thirty years since the introduction of operational criteria and standardised psychiatric
interviews important scientific advances have been made. Perhaps the most
fundamental of these has been the repeated demonstration of an association between
a diagnosis of schizophrenia and structural brain abnormalities (as described in detail
in chapter ID). The central challenge of biological schizophrenia research has
shifted from proving that the syndrome of schizophrenia has biological correlates in
the brain to elucidating the precise biological mechanisms underlying the disorder50.
Supporters of the current concept would argue that to abandon it now would equate
to throwing the baby out with the bath water. To paraphrase Jaspers, the medical
concept of schizophrenia as a 'disease' has become a fruitful orientation for
researchers in biological psychiatry.
The strength of the current ICD and DSM approach lies in the periodic revision of
diagnostic criteria. This allows the criteria to evolve in line with scientific advances.
In theory this ought to enable a virtuous cycle to become established in which
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research refines and validates the criteria, which in turn facilitate future research.
Critics point to a number of problems with this approach. First the process is
inevitably slow. The significance of research findings often takes decades to become
apparent (as demonstrated by the delay between the publication of ground-breaking
studies and the award of Nobel prizes). Past experience shows that even widely
accepted research findings are not incorporated into diagnostic criteria (for example
the ICD-10 criteria for Alzheimer's dementia make no reference to structural or
functional imaging findings nor to genetic risk factors35). Second, the existence of
competing nomenclatures introduces the risk of divergence of scientific concepts
with damaging consequences. Finally, the widespread acceptance of narrow
operational definitions prevents psychiatrists from thinking in broader terms. This
inhibits the development of clinical skills and encourages premature closure on
research questions that ought to remain open51.
'Revolution' - Abandon current concept and start again
As Greisinger explained in 1867, the 'medical model' of insanity "rests principally
on the realisation that patients with so-called 'mental illnesses' are really individuals
with illnesses of the nerves and the brain"52. Alternative explanatory models have
been proposed the majority based upon sociological53, psychological54 or
psychodynamic55 theories. The 20th century saw the rise and fall of the
psychodynamic and anti-psychiatry movements. These challenges to the medical
model of insanity were ultimately unsustainable against the weight of scientific
evidence. Brain imaging provided incontrovertible evidence for abnormalities of
brain structure and function whilst randomised controlled treatment trials proved the
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efficacy of physical treatments such as psychotropic medication and electro¬
convulsive therapy. At the start of the 21st century the medical model is in an
unassailable position. Sociological and psychological theories of insanity are now
viewed as adjuncts rather than alternatives to biological theories.
Revolutionaries no longer challenge Greisinger's assertion that psychiatric symptoms
relate to biological processes in the brain. Their attention has shifted to the
conceptual framework that is currently employed to explore that relationship. A
number of geneticists, no doubt frustrated with the slow rate of progress in
psychiatric genetics, have proposed the abolition of the current classification of
psychosis and its replacement with a system based upon "behavioural subtypes"
determined by segregation data from molecular genetic studies of families56. Mary
Boyle, a clinical psychologist, dismisses 'Schizophrenia' as "a scientific delusion" .
She argues that psychotic symptoms are not 'un-understandable' as suggested by
Jaspers but are amenable to cognitive-behavioural formulation and management.
Another psychologist, Richard Bentall questions the reliability, construct validity,
predictive validity and aetiological specificity of the diagnosis concluding: "there
would seem to be little reason to feel confident about the validity of the
schizophrenia diagnosis. [The widespread acceptance of the concept as a valid
foundation for scientific research] would appear to be little more than an article of
faith, ft may be more realistic to accept that 'schizophrenia' is not a useful scientific
category and that for all these years researchers have been pursuing a ghost within
the body of psychiatry."4 Bentall and colleagues point out "the history of science is
littered with examples in which progress has been impeded by the continued use of
invalid concepts leading to persistent asking of the wrong questions". They propose
the abolition of the current classificatory system and its wholesale replacement by a
system based upon the findings of "large-scale empirical research"4. They advocate
exploration of hierarchical, dimensional and multidimensional approaches to
classification and the adoption ofmultivariate and factor analytic techniques in order
to differentiate patients on the basis of symptoms. Most critics of 'schizophrenia'
point to the fact that no pathognomonic biological marker has yet been found for the
condition despite decades of research. This assertion clearly echoes Jasper's earlier
observation that "no actual disease-entities exist in scientific psychiatry"49 (although
Jasper's original observation has subsequently been overtaken by advances in
medical science).
Whilst wiping the slate clean as Bentall and others suggest might appear to be
intellectually rigorous, it is almost certainly unachievable. It is naive to believe that
the subjective component of psychiatric diagnosis will ever be eradicated by the
adoption of empirical criteria. After all the current system is based upon (imperfect)
empirical findings. Such a revolutionary approach would inevitably cause enormous
scientific and clinical disruption. It is by no means certain that the resultant
nomenclature would be superior to that which could be achieved through the current
evolutionary approach (periodic revision of diagnostic criteria with the incorporation
of contemporary research findings and results of field trials). It must be remembered
that 'schizophrenia' is a clinical as well as a scientific concept and that any
diagnostic system brought in to replace it would have to demonstrate clinical utility
as well as scientific validity.
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As well as proposing the wholesale abolition of the current classificatory system,
Bentall et al. are amongst the advocates of a symptom-based approach to research.
They identify five potential advantages: "(i) the avoidance of problems of diagnosis
and classification; (ii) the focus on phenomena that are usually ignored; (iii) the
facilitation of theoretical development; (iv) the recognition that clinical phenomena
are related to normal behaviour; and (v) the potential improvement in classification
which might follow from a better understanding of individual symptoms."4 From
Kraepelin's original descriptions to the present day, schizophrenia has been
characterised by a wide range of symptoms and behaviours. The idea that individual
symptoms might have specific biological correlates is very attractive. With the
emergence of functional imaging techniques, symptom-based experimental design is
enjoying something of a resurgence. Unfortunately the evidence from structural
imaging research suggests that the relationship between individual schizophrenic
symptoms and specific structural brain abnormalities is a weak one57 (see chapter
ID).
'Third way' - Explore heterogeneity within current concept
As described in the previous chapter, Kraepelin's concept of 'dementia praecox'
incorporated the previously described syndromes of 'dementia paranoides',
'hebephrenia' and 'catatonia'21. Each of these syndromes survives as a 'subtype' of
schizophrenia in the DSM-IVTR classification (labelled 'Paranoid', 'Disorganised',
and 'Catatonic' respectively). 'Undifferentiated' and 'Residual' subtypes are also
listed. ICD-10 schizophrenia includes the five subtypes from DSM-IV and adds
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'Simple' and 'Post-schizophrenic depression' together with categories for 'Other'
and 'Unspecified'. The status of these subtypes within the broader context of
psychiatric classification is ambiguous. Since Kraepelin's time it has been presumed
that they are merely slightly different expressions of the same disease process. The
vast majority of structural imaging research does not attempt to differentiate between
them. Yet their endurance is testament to the symptomatic heterogeneity that
characterises schizophrenia.
A number of attempts have been made to bring order to the highly varied and
seemingly unrelated symptoms that are considered to be indicative of schizophrenia.
Hughlings-Jackson's positive and negative dichotomy58 is almost universally
accepted and is reflected in both DSM-IVTR and ICD-10. More recently, Liddle's
proposal of three core dimensions: psychomotor poverty; reality distortion; and
disorganisation59 has gained support. From the researcher's perspective, the various
methods for subdividing schizophrenic subjects according to symptoms are
potentially valuable. They offer a half-way house between accepting lock, stock and
barrel, the poorly validated Kraepelian concept of a "natural disease entity" called
'schizophrenia' and abandoning it altogether by adopting an atheoretical, symptom-
based approach.
Symptomatic diversity is only one of the many forms of heterogeneity in
schizophrenia. As noted earlier in this chapter, there is considerable variation in the
course and outcome of the illness. This is acknowledged in the ICD-10 classification
in which a fifth character may be used to classify course: continuous; episodic with
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progressive deficit; episodic with stable deficit etc. Kraepelin believed that course
and outcome offer a clearer indication of underlying pathological processes than do
symptoms. It would therefore seem logical for researchers attempting to elucidate
the aetiology of schizophrenia to group patients according to course, long-term
outcome or treatment response. In doing so they would be following the Kraepelian
tradition.
A wide range of aetiological risk factors have been identified for schizophrenia, these
include: family history; obstetric complications; maternal viral infection; cannabis
use etc. It ought to be possible to explore the role of each individual risk factor by
adopting suitable study designs (see chapter 2A). One could, for example,
differentiate patients with a strong family history of schizophrenia from patients who
are known to have no family history of psychosis. A small number of studies of this
design have been published and are reviewed in chapter ID.
Any study design that defines a sub-group of schizophrenic patients (whether on the
basis of symptoms, course, risk factors or any other heterogeneous characteristic) is a
direct challenge to the concept of schizophrenia as a "natural disease entity"
reflecting a "single tangible morbid process". In acknowledging that the
heterogeneity of the condition may be employed as a tool in the search for the
aetiology, one is accepting that there may be heterogeneity in the causative
mechanisms of schizophrenia. In recent years the Kraepelian view of schizophrenia
as a single disorder with variations in clinical presentation has been challenged by
the notion that it may be composed of multiple disorders with a common core
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clinical syndrome60 (as previously mentioned, Kraepelin himself acknowledged this
possibility towards the end of his life15). Critics of the multiple aetiology theory
argue that there is insufficient evidence to link particular symptoms or groups of
symptoms directly to particular aetiological risk factors61. Meanwhile the theory's
supporters argue that it is self-evident that the link between aetiology and symptoms
is tenuous (this is why progress has been so slow) and that recognition of different
risk factors in different cases (genetic predisposition, viral infection, obstetric
complications etc.) is proof of heterogeneity in aetiology6 . As Tsuang and Faraone
contest, the debate should no longer be "Heterogeneity: yes or no?" but
"Heterogeneity: how much?"57 The role that structural imaging has played in
informing this debate is discussed in chapter 1D.
Over the years a number of hypotheses have been proposed as candidates for
Kraepelin's tangible morbid process, (a number of the more influential hypotheses
are examined in Chapter 1C.) Although these have provided useful models for
understanding certain aspects of the condition, they fall well short of a pathological
explanation. The author shares the view of De Lisi, Tsuang, Faraone and others that
schizophrenia probably has multiple aetiologies60'62. To the author's mind, the
question of whether there is one 'schizophrenia' or several 'schizophrenias' appears
to invite the Jasperian response "there are neither"49. Although the author
acknowledges the limitations of schizophrenia as a scientific concept, he does not
share Boyle and Bentall's view that it should be abandoned3'4. He believes that
structural imaging research can continue to contribute to the understanding of the
pathophysiological processes underlying the condition(s). Furthermore, he is
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optimistic that technological advances including new imaging techniques (such as
Diffusion Tensor Imaging utilised in the study described in Chapter 2C) and new
methods of data analysis (such as Voxel Based Morphometry, illustrated by example
in Chapter 2B) will provide new insights into the biological correlates of
schizophrenia. In the author's opinion the various forms of heterogeneity that
characterise the condition offer clues to the nature of the underlying aetiological
mechanisms. Thoughtful study design, employing carefully selected sub-groups of
affected individuals (such as the 'Obligates' design adopted in the study described in
Chapter 2A) ought to be able to utilise the heterogeneity within the schizophrenic
population as a tool in the search for the pathological mechanisms underlying the
disorder. How this might be achieved is explored in Chapter IE. But first, Chapter
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1C. Role of Structural Brain Imaging in Schizophrenia Research
Historical overview of structural imaging methods
On Friday 8th November 1895, German physicist Wilhelm Roentgen exposed a
photographic plate to the rays emitted from his 'Cooke's Tube'. The developed plate
comprised the world's first radiograph1. Shortly afterwards he invited his wife
Bertha to place her left hand on a photographic plate whilst he fired 'Roentgen's
Rays' at it. The developed plate provided a clear image of the bones in her hand and
the rings on her finger (see Figure ICi). Medical imaging was born. We do not
know what Emil Kraepelin was doing on that day but it is tempting to imagine him
working on the 5th edition of his textbook2 (which was published the following year),
perhaps pondering over a new chapter entitled "dementia praecox".
Given their near simultaneous conception, one might expect developments in
medical imaging to be reflected in the evolution of Kraepelin's concept. However,
the physical characteristic of X-rays (or 'Roentgen's Rays') that enabled Wilhelm to
photograph the bones in Martha's hand is their ability to pass, virtually unhindered,
through soft-tissue. This renders X-rays unsuitable for imaging soft-tissue structures
such as the brain. The fact that the brain is surrounded by the bony structure of the
skull compounds the problem (although the challenges are not insurmountable as
subsequent developments in Computed Tomography demonstrate). Consequently,
seven or eight decades would pass before medical imaging produced any meaningful
insights into schizophrenia.
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Figure 1 Ci. Wilhelm Roentgen's 1895 radiograph of his wife's hand.
Pneumoencephalography
The first in-vivo structural imaging technique to be employed by schizophrenia
researchers was pneumoencephalography. This involves performing a lumbar
puncture, replacing a volume of cerebrospinal fluid with air, sitting the subject
upright to allow the air to pass into the ventricles, then taking radiographs of the head
in various different planes. The air shows up dark on the radiographs allowing
estimates of ventricular size and shape to be made3. Pneumoencephalogropy is a
dangerous, potentially fatal procedure. The ventriculograms produced are
incomplete and of relatively poor spatial resolution (see figure ICii). As an imaging
technique it is therefore of limited utility and was rendered obsolete by Computed
Tomography (CT).
Despite these limitations, a number of uncontrolled pneumo-encephalographic
studies demonstrating enlarged ventricles in association with schizophrenia can be
found in the literature. The earliest is a study by German psychiatrists Jacobi and
Winkler published in 1927 . Matthew Moore and colleagues in Philadelphia
published the first study in English in 19335. They employed pneumo¬
encephalography to provide in-vivo confirmation of their post-mortem work.
Pneumo-encephalographic studies of mental disorders continued through the 1930s
in Germany (with psychiatrists such as Lemke). However, its impact upon the wider
psychiatric community was limited (possibly as a consequence of its association with
the Nazi philosophy of eugenics). The technique re-emerged in the 1960s with
German, Norweigian and Japanese studies. The largest single pneumo-
encephalographic study of schizophrenia was published in 1964 by the German
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psychiatrist Gerd Huber6. He imaged 212 chronically hospitalised schizophrenic
patients aged less than 50 and found that 81.6% exhibited evidence of gross atrophy,
most commonly enlargement of the third ventricle6.




In the late 1960's, British inventor Geoffrey Hounsfield developed a method of
rotating an X-ray source and detector through 360° and using the data collected to
generate a cross-sectional image or 'slice' through the body. His original
experimental machine took nine days to acquire data and 2/4 hours to reconstruct a
single slice1. His technique was first put to clinical use in 1972 and in 1979 he was
awarded the Nobel Prize (an honour bestowed upon Wilhelm Roentgen 78 years
earlier).
Eve Johnstone and colleagues published the first X-ray CT study of schizophrenia in
1976. They compared data acquired from CT scans of 17 institutionalised
schizophrenic patients with data from 8 age-matched controls. The results showed
that schizophrenia is associated with increased ventricular size7. Robin Murray has
described the publication of this study as marking "the beginning of the modern era
of schizophrenia research"8. Daniel Weinberger has stated that reading Johnstone's
1976 Lancet paper inspired him to abandon his planned career in neurology in favour
of a lifetime in schizophrenia research9. It is notable that his first major contribution
to the schizophrenia literature was a successful replication of Johnstone's findings10.
CT technology has moved on since 1976 (compare figures ICiii and ICiv). Some
modern CT scanners acquire data in a spiral, which can be reconstructed as a slice in
any orientation or as a three-dimensional representation. The whole brain can now
be imaged in a matter of seconds and spatial resolution of the order of a millimetre
can be achieved1. Over 100 quantitative CT studies comparing the brains of
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schizophrenic subjects with those of controls have now been published". (The
cumulative findings are presented in the following section.) However, CT is an X-
ray technique and as such can not escape the physical limitations of X-rays. As a
form of ionising radiation X-rays have the potential to produce mutations in both
somatic cells and gametes. Exposing research subjects to a large number of scans is
therefore undesirable, particularly where a safer alternative is available. As noted
above, X-rays are relatively unaffected by soft-tissue hence CT does not discriminate
particularly well between different types of soft-tissue (such as white and grey
matter). It is also unreliable in parts of the brain that are close to bone such as the
mid-brain and cerebellum (because of the tendency for artefacts to arise during the
reconstruction phase). During the 1980s and '90s, Magnetic Resonance Imaging
(MRI) gradually replaced CT as the imaging method of choice for schizophrenia
research.
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Figure 1 Ciii. An X-ray CT image of the brain from an EMI 1010 machine.
The image is in the axial plane at the level of the lateral
ventricles. It is a clinical scan identifying a sub-arachnoid cyst
in the right temporal region.
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Figure 1 Civ. An image of approximately the same axial slice shown in Figure
1 Ciii but acquired using a modern X-ray CT machine. Note the
superior spatial resolution.
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The phenomenon of Nuclear Magnetic Resonance (NMR) was first identified in the
1930s by American physicist Isidor Rabi. During the 1940s two teams of scientists
working independently developed similar techniques for using NMR to examine the
chemical composition of small volume samples. Felix Bloch and Edward Purcell
were jointly awarded the Nobel Prize in Physics in 1952 for their work on Magnetic
Resonance Spectroscopy (MRS)12. By the late 1960s, MRS was established in
chemistry laboratories throughout the world as a powerful, non-destructive method
for analysing samples (see Figure lCvi). In 1973, New York chemist Paul Lauterbur
published a short paper in Nature describing the use ofMRS to establish the relative
position in space of two test-tubes containing different chemicals13. By taking NMR
techniques from the single dimension of MRS into two dimensions, Lauterbur had
laid the foundations of MRI. During the 1970s and '80s, a number of research
groups developed Lauterbur's technique. Progress was rapid, partly because
researchers were able to adapt a number of methods of data analysis that had
previously been devised for CT imaging. The first commercial MRI scanners were
installed in 198312.
MRI offers three major advantages over CT13. First it does not use ionising radiation
and is therefore less likely to be mutagenic. Second, it is highly sensitive to small
differences in soft-tissue composition hence one can readily differentiate between
white and grey matter (see figure lCv). Third, it is less affected by proximity to
bone. MRI does have certain disadvantages: it is slower than CT and is therefore
more liable to movement artefact; patients with metal in their body (aneurysm clips,
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cardiac pace-makers etc.) can not be imaged; it does not image cortical bone as well
as CT; and certain MRI techniques are prone to distortion close to air-tissue
boundaries. Also anyone who has conducted MRI-based research will know that not
everyone is able to tolerate the confined space and loud noise associated with an
MRI scanner. However, for the vast majority of structural brain imaging research
applications, MRI is now the technique of choice13.
Over the past two decades, MRI technology has advanced at pace. More powerful
and smoothly graded magnetic fields together with increased computer processing
power and new techniques such as echo planar imaging have reduced image
acquisition times and improved spatial resolution and tissue discrimination13. The
shorter scanning times and the adoption of strategies such as cardiac gating have
reduced, but not eliminated, the problems associated with movement. To date, at
least 200 case-control studies of schizophrenia employing structural MRI have been
published14 with numerous others currently in progress (this literature is discussed in
chapter ID). In recent years MRI has been employed to provide information about
regional cerebral blood flow, an indicator of local neuronal activity. Although
functional imaging is beyond the scope of this thesis, it is clear that fMRI offers a
number of important advantages over PET and SPET and the technique is already
offering valuable insights into the biological processes underlying
schizophrenia15'16'17.
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Figure 1Cvi. An example of a Magnetic Resonance Spectrum. The peaks
labelled correspond to choline (CHO), creatinine (CR) and
N-acetyl aspatrate (NAA).
Figure 1 Cvii. A T-i MRI image in the coronal plane as used for volumetric
analysis. This image is at the level of the thalamus, anterior to
the 3rd ventricle. Isotropic voxels are obtained by using a slice
thickness of only 1,8mm.
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New structural MRI techniques such as Diffusion Tensor Imaging (DTI) (see chapter
2C for an example) and the development of new methods for analysing structural
MRI data such as Voxel Based Morphometry (VBM) (see chapter 2B for an
example) are discussed in Chapter IE. But first, Chapter ID described the
contribution that structural imaging research has made to our understanding of
schizophrenia.
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Contribution of structural imaging findings to major patho-physiological hypotheses
Since the inception of Kraepelin's concept of dementia praecox, a variety of
explanatory models have been proposed as candidates for the underlying "tangible
.10
morbid process" . As discussed in chapter 1 A, Kraepelin himself suggested that the
pathology may be "either metabolic or possibly endocrinological in nature"18. In
recent decades, during what might be called "the modern era of schizophrenia
o
research" , three theories have been notable for the support they have attracted: the
'Dopamine Hypothesis'; the 'Neurodevelopmental Hypothesis'; and the
'Disconnection Hypothesis'. In this chapter the author addresses each of these
theories from the perspective of structural brain imaging before describing an
interesting recent attempt at unification: the 'Dysplastic Net Hypothesis'.
Of course not all of the models proposed for schizophrenia are rooted in
neuropathology. There is a huge body of work examining schizophrenia from a less
overtly 'biological' viewpoint. Sociological, psychological and even psychodynamic
theories have been offered. Whilst none of these models could be considered
germane to a thesis about structural brain imaging, their collective contribution to our
understanding of schizophrenia is undeniably important. Furthermore the powerful
'biological/non-biological' dichotomy against which many of these theories arose
has now been replaced by an acceptance that biological, psychological and
sociological factors interact in a reciprocal fashion. Theories that were originally
presented as explanatory are now considered contributory. The author will now
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present a necessarily brief overview of some of the 'non-biological' theories that he
feels are most relevant to contemporary structural imaging research.
Non-Biological Hypotheses
Childhood environment
Psychodynamic theory is based upon the principle that difficulties in adulthood are a
consequence of early childhood experience, in particular early perceptions of the
mother-child relationship. Although none of the psychodynamic formulations of
psychosis (anger turned against the self, breakdown of the defence mechanisms in
the face of overwhelming inner conflict etc.) would withstand scientific scrutiny, the
notion that the relationship with one's parents may be important is evident in many
of the early sociological theories. Bateson and colleagues suggested that
schizophrenia results from "double bind" communication between parent and child
[Bateson et al., 1956]. Lidz and colleagues observed that parent's of schizophrenic
children display "schism" and "skew" in their marriages and described their
personalities as dominated by "narcissistic egocentricity" [Lidz et al., 1957]. Wynne
and Singer also focussed upon relationships within families and characterised the
parenting styles of parents with schizophrenic children as "fragmented" and
"amorphous" [Wynne & Singer, 1963 & 1965]. These theories lent credence to the
once popular notion of the "schizophrenogenic mother", a term first coined in 1948
by Frieda Fromm-Reichmann.
One of the major criticisms of this body of work is that it fails to establish the
direction of causality. It is perhaps hardly surprising that relationships within a
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family are unusual when one of the family members is suffering from a severe
mental disorder. More recent studies have tried to circumvent this problem by
adopting a retrospective design. For example, retrospective analysis of a cohort of
over 5,000 children born in the UK in a single week in March 1946 reveals a
statistically significant deficit in the parenting experience of those individuals who
subsequently develop schizophrenia. Health visitors' assessments conducted when
the children were four years old were examined. Ratings of parenting skills of
mothers of children who went on to develop schizophrenia were six times more
likely to be "poor" than were those of other children [Jones et al., 1994]. Whilst few
would now argue that the development of schizophrenia in late adolescence or early
adulthood is directly attributable to inconsistent early parenting, studies such as that
described above suggest that the early family environment may be a contributory
factor in some cases.
The current view that early family environment may contribute to the development
of schizophrenia through a complex interaction with biological vulnerability factors
is supported by evidence from adoption studies. For example, a Finnish study of
over 140 children adopted away from their schizophrenic biological mother finds that
those children reared in "disturbed" adoptive families are significantly more likely to
develop severe mental illness in adulthood than those children reared in "healthy"
adoptive families [Tienari, 1991].
Stress
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Another aspect of the psychodynamic model reflected in sociological and
psychological theories is the notion that symptoms arise as a consequence of external
pressures. There are two major strands to this work: life events; and expressed
emotion.
The study of life-events in schizophrenia was pioneered by George Brown and Jim
Birley in the 1960s. They observed a two-fold increase in a wide range of life events
experienced by 50 schizophrenic patients in the three weeks prior to admission to
hospital [Brown & Birley, 1968], Brown argues that life events may "trigger"
psychotic breakdown in people with a strong pre-existing tendency to schizophrenia
rather than having a "formative" role in the causation of the disorder [Brown et al.,
1973]. The initial findings have been largely supported by subsequent studies
including a large multicentre trial conducted by the WHO incorporating almost 400
subjects [Day et al., 1987]. However, the issue of direction of causality remains
largely unresolved.
The notion of 'environmental stress' incorporates not only what happens to us (life
events) but also how others interact with us (whether supportive or undermining
etc.). Within the schizophrenia literature this issue has been addressed primarily
through the concept of 'expressed emotion'. The level of expressed emotion within a
relationship reflects the the number of critical comments that are made and the
degree of hostility and emotional over-involvement that are displayed. Perhaps the
most influential studies to employ this concept were those conducted in the 1970s by
Julian Leff and Christine Vaughn. They analysed the results of studies involving 128
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schizophrenic out-patients and found that patients who lived in a high expressed
emotion environment were four times more likely to relapse than patients who lived
in a low expressed emotion environment [Vaughn & Leff, 1976], Furthermore, the
time spent within the high expressed emotion environment had a significant impact
upon relapse rates such that those patients who spent more than 35 hours per week
exposed to high expressed emotions were more than twice as likely to relapse as
those exposed for less than 35 hours. Subsequent studies not only support Leff and
Vaughn's findings but suggest that interventions that reduce expressed emotion
within families can be successful in reducing relapse rates in schizophrenia [Tarrier
et al., 1988].
Social Isolation
That people who suffer from schizophrenia are less likely to be married or to have a
large social network than the general population is well established. It is easy to see
how both the positive and negative symptoms of the disorder might contribute to this
social isolation. A number of recent studies suggest that social isolation pre-dates
the onset of symptoms and may in itself represent a risk factor for the disorder. For
example van Os and colleagues found that not only were single people more likely to
develop schizophrenia than were married people but that the risk increased still
further if the single person lived in a neighbourhood where most people were living
in partnerships [van Os et al., 2000], The authors suggest that being single in a
predominantly 'couples' environment leads to increased social isolation (actual
and/or perceived). Coming from the opposite direction, Jablensky and Cole found
that marriage is protective against schizophrenia, particular for men, and that this
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effect could not be fully accounted for by better-adjusted males being more likely to
marry [Jablensky & Cole, 1997], The 1946 cohort study described above also
touches on the issue of social isolation with a preference for solitary play at the age
of 4 or 6 conveying a two-fold increase in lifetime risk of schizophrenia [Jones et al.,
1994], Of course the direction of causality is again difficult to establish, particularly
if one accepts the concept of the 'schizophreniform spectrum' (see Chapter ID).
Social isolation has also been implicated in the now well-establihed relationship
between schizophrenia and migration [Harrison et al., 1988; Sugarman & Craufurd
1994; Hutchison et al., 1996], Certainly the complex nature of the relationship
suggests that powerful sociological factors, of which social isolation is likely to be
one, are at work [Boydell et al., 2001].
Substance Misuse
A large cohort study of over 45,000 Swedish army conscripts found that cannabis use
before the age of eighteen was associated with a two-to-three-fold risk of subsequent
schizophrenia [Andreasson et al., 1987]. Moreover the effect appeared to be dose-
related with heavy users at six times the risk of non-users. However, as with most
studies involving recreational drug users the findings are complicated by multiple
substance misuse (for example half of the cannabis users also used amphetamines)
and skewed socio-demographic distribution. Some of the criticisms of the original
paper have been addressed in more detailed follow-ups of the same cohort
[Andreasson et al., 1989; Zammit et al., 2002], Furthermore, a number of recent
studies from various groups around the world have successfully replicated the main
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finding [Arseneault et al., 2002; Patton et al., 2002; Fergusson et al., 2003; Verdoux
et al., 2003],
The Dopamine Hypothesis
The phrase "The Dopamine Hypothesis" was probably first coined by Snyder in
197519'20. However, Carlsson & Lindqvist21 and Randrup & Munkvad22 had
proposed the central tenant of the theory - that the symptoms of schizophrenia are
caused by an increase in dopaminergic transmission in the brain, a decade earlier.
The dopamine hypothesis therefore pre-dates the introduction of CT and MRI and its
conception owes nothing to structural imaging findings.
The dopamine hypothesis was born out of neuropharmacology research, which
demonstrated that schizophrenia-like symptoms can be induced by dopamine
agonists22 and that most antipsychotic agents share a common denominator of
dopamine blockade23'24. Although there is no direct role for structural imaging in
this type of research, parallels between structural imaging and neuro-
pharmacological findings could potentially lend indirect support to the hypothesis.
However, the most robust structural imaging findings in schizophrenia relate to
increases in ventricular volume (see chapter ID). Clearly such widespread
alterations in macroscopic brain structure are not readily accounted for by alterations
in a neurotransmitter system that has very few projections to the cerebral cortex.
This is not to say that the two areas of research share no common ground
whatsoever. Receptor binding studies demonstrate that the basal ganglia contain by
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far the highest concentration of dopamine (D2) receptors of any brain region25. This
is reflected by the structural imaging finding of increased basal ganglia volume in
first episode schizophrenic patients receiving antipsychotic medication (D2
antagonists)26. Furthermore, knowledge of the major dopaminergic pathways
(mesolimbic and mesocortical in particular) gleaned from neuro-pharmacology has,
to some extent, informed the decision by many contemporary structural (and
functional) imaging groups to focus attention upon limbic structures and prefrontal
regions of the brain.
A series of functional brain imaging studies conducted in the early 1990s appeared to
undermine the dopamine hypothesis. For example, in 1992, a group from the
Institute of Psychiatry published a SPET study comparing six schizophrenic patients
treated with conventional antipsychotics with ten patients treated with the atypical
antipsychotic Clozapine. They found that Clozapine had greater efficacy in relieving
psychotic symptoms despite very low D2 occupancy [Pilowsky et al., 1992], The
following year the same group published another SPET study of 18 schizophrenic
patients receiving typical antipsychotic medication, 10 of whom had shown a good
clinical response and eight of whom had shown a poor response. They found that
"clinical improvement appears to occur in the responsive group, even at relatively
low D2 occupancy, whereas non-responders do not improve as maximal D2
blockade." [Pilowsky et al., 1993], The notion of a simple relationship between D2
occupancy and antipsychotic efficacy was no longer tenable.
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In recent years dopamine has proved something of a "comeback kid" in
schizophrenia research [Jones & Pilowsky 2002], Functional imaging studies
adopting dynamic challenge paradigms suggest that endogenous dopamine release
may be hyper-sensitive and exaggerated in psychotic patients. For example, Laruelle
and colleagues measured occupancy of striatal D2 receptors following administration
of amphetamine and found it to be doubled in schizophrenics compared with
controls. Furthermore the increase in endogenous dopamine release was greatest in
the most acutely ill patients [Laruelle et al., 1996]. The growing body of research
using PET and SPET to measure alterations in occupancy rates at specific receptors
in response to various drugs has led to an updating of the dopamine hypothesis. The
contemporary dopamine hypothesis states that overactive phasic dopamine
transmission in limbic regions may be responsible for positive symptoms, whilst
underactive tonic dopamine transmission in frontal and prefrontal regions may be
responsible for negative symptoms [Moore et al., 1999], Kapur states it eloquently
as follows: "somewhere in their late teens patients develop an abnormality of the
dopamine system such that there is an exaggerated release of dopamine, out of
synchrony with the stimuli that usually induce them. This state does not lead to any
physical feelings, but, leads to the assignment of inappropriate salience and
motivational significance to external and internal stimuli." [Kapur, 2003],
Although functional imaging is beyond the scope of this thesis, the revised dopamine
hypothesis is important as it offers a possible link between neurodevelopmental
insult and later onset of acute psychosis. There is some evidence from lesion studies
in animals [Lipska et al., 1993] and from SPET studies of infants with hypoxic-
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ischaemic brain damage [Kapucu et al., 1998] to support the notion that early
developmental insult might lead to "dopamine sensitisation" in later life through a
mechanism of reverse tolerance [Murray et al., 2002],
The Neurodevelopmental Hypothesis
Medical historians might argue that the neurodevelopmental hypothesis of
schizophrenia can be traced back to Thomas Clouston's proposal of 'adolescent
insanity' expounded in his 1888 lecture entitled "The Neuroses of Development"27.
However, the earliest coherent formulations of the hypothesis in the modern
literature were written almost one hundred years later. Two papers published in
1987 outline the arguments for the role of neurodevelopmental factors in the
aetiology of schizophrenia. Daniel Weinberger28, writing in Archives of General
Psychiatry, suggests that the epidemiological and histopathological data "are
consistent with a neurodevelopmental model in which a fixed 'lesion' from early in
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life interacts with normal brain maturational events that occur much later" .
Although Weinberger cites evidence from CT studies, structural imaging findings are
not central to his proposal. Meanwhile, in a short article in the British Medical
Journal, Robin Murray and Shon Lewis argue "a model that regards early
neurodevelopmental deviance as one of several risk factors provides a unifying
explanation for what until now have been regarded as curious epiphenomena of
schizophrenia."29 The first piece of evidence they cite stems directly from structural
brain imaging: "cerebral ventricles are enlarged in many schizophrenics . . . such
• 9Q
changes are present at the earliest stage of schizophrenia and are not progressive."
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Murray and Lewis also cite epidemiological findings such as excess winter births
amongst schizophrenic patients and increased incidence of obstetric complications,
left-handedness, soft neurological signs and cognitive impairment. They draw
parallels between schizophrenia and conditions such as epilepsy and dyskinesias,
which are recognised as being neurodevelopmental in origin. The putative
pathological mechanism they advance is one of "interference with neuronal fallout"
during the early development of the nervous system resulting in "impairment of the
organisation of axonal connections, which leads to immature patterns of cells and
their projections persisting ... the lesion lies dormant until the brain matures
sufficiently to call into operation the damaged systems."29 They demonstrate the
feasibility of a prolonged latent period between brain insult and subsequent
disturbance of brain function by citing evidence from lesion studies in animals.
Since 1987, the collective evidence from over 100 structural brain imaging studies of
first episode schizophrenic subjects30 has provided considerable support for Murray
and Lewis' assertion that cerebral ventricular enlargement is present "at the earliest
stage of schizophrenia" (see chapter ID). However, whilst these data demonstrate
that the more substantial structural brain abnormalities associated with schizophrenia
are not attributable to chronicity of illness nor to treatment, they do not prove that the
abnormalities are neurodevelopmental in origin. Abnormalities identified in first
episode patients could, theoretically, arise immediately prior to (or in conjunction
with) the onset of symptoms. These possibilities, however unlikely, can not be
entirely discounted until prospective data relating to healthy individuals who
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subsequently develop schizophrenia become available. This is one of the aims of the
Edinburgh High-Risk Study31 (described in chapter ID).
Murray and Lewis' second assertion, that the abnormalities "are not progressive" has
not received unanimous support from subsequent CT and structural MRI findings.
Whilst some follow-up imaging studies of schizophrenic cohorts report no evidence
of progression32'33, others suggest that certain structural brain abnormalities may
show a degree of progression during the first few years of illness30'34'35'36.
Other findings from structural brain imaging provide indirect support for the
neurodevelopmental hypothesis. The cerebral asymmetry (or torque), which is a
normal feature of brain morphology and is thought to arise as a result of normal
development during the second trimester of intra-uterine life, appears to be reduced
in schizophrenic subjects37'38. Similarly, the gyri of the cerebral cortex may be less
convoluted in schizophrenic subjects39. Furthermore, cerebral ventricular
enlargement has been found to correlate with premorbid events such as childhood
social and educational adjustment and history of obstetric complications40, albeit
rather inconsistently.
The epidemiological evidence employed by Murray and Lewis in support of their
hypothesis has, by-and-large, stood the test of time. The associations between
schizophrenia and excess winter births, obstetric complications, left-handedness, soft
neurological signs and cognitive impairment have all been replicated. Whilst some
of the correlations may be weak, they appear to be robust40. There are also some
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relatively new, though less robust41, epidemiological data linking increased incidence
of schizophrenia with maternal starvation42 and influenza infection43, both of which
are recognised disruptors of intra-uterine development.
At the centre of the neurodevelopmental hypothesis is the notion that evidence of
disrupted brain development will be found somewhere within the cytoarchitecture of
the adult schizophrenic brain. Schizophrenia has long been regarded as "the
graveyard of neuropathology"44 on account of the historical failure to identify any
consistent pathological findings in the disorder. However, in one sense the lack of
readily identifiable neuropathology is supportive ofMurray and Lewis' theory. If the
macroscopic abnormalities of brain structure were due to neurodegeneration, one
would expect to find evidence of gliosis. Absence of gliosis is perhaps the single
most consistent neuropathological 'finding' in schizophrenia.
In recent years a small number of studies of the allocortex in and around the medial
temporal lobe (hippocampus45, parahippocampus46, entorhinal cortex47 and cingulate
& prefrontal cortices48) have produced promising results consistent with disruption
of early neurodevelopment. Each of these studies has identified abnormal
cytoarchitecture associated with schizophrenia such that certain populations of
cortical neurons are displaced inwards (located within a deeper than usual layer of
the cortex). In the normal course of brain development these neurons migrate
outwards, from deeper to more superficial layers of the cortex. This migration
occurs during the second trimester of pregnancy. The discovery of these inwardly
displaced neurons suggests disruption of the normal process of migration. The data
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from these histopathological studies must be considered preliminary, however they
are suggestive of neurodevelopmental insult during the second trimester. Indeed the
findings are difficult to explain in any other way. Whilst this handful of small
studies may not amount to indisputable evidence of Murray and Lewis' "persistence
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of immature patterns of cells and their projections" (and are certainly not
suggestive of "interference with neuronal fallout"29), they do at least illustrate the
plausibility of the neurodevelopmental hypothesis. Critics argue that none of these
neuropathological findings has been successfully replicated, that the phenotype of the
affected neuronal populations is uncertain and that the relationship between
neurochemical findings (see dopamine hypothesis above) and the neuropathology of
schizophrenia remains unclear [Harrison 1999],
Murray and Lewis' hypothesis has survived fifteen years of scrutiny by brain
imaging, epidemiology and neuropathology but unambiguous neuropathological
evidence of abnormal neurodevelopment has not been found [Harrison, 1999], The
precise nature of the neurodevelopmental insult (or insults) remains the subject of
open debate. Furthermore, the mechanism by which disrupted brain development
gives rise to the signs and symptoms of schizophrenia also remains unclear,
(although recent evidence is consistent with "dopamine sensitisation" [Murray et ah,
2002]).
Whilst few schizophrenia researchers would now challenge the assertion that early
developmental 'deviance' is one of several risk factors for schizophrenia, many
would argue that there is also a neurodegenerative component to the disorder.
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Proponents of the neurodegenerative hypotheseis cite evidence from treatment
studies suggesting that treatment resistance is relatively uncommon in first-episode
patients but becomes more likely wirth each successive psychotic relapse [Lieberman
et ah, 1993]. They also cite evidence from structural imaging studies suggesting
progressive ventricular enlargement in association with poor outcome [Lieberman et
ah, 1996 & 1997, DeLisi et ah, 1995, Gur et ah, 1997 & Rapoport et al 1997] (this
literature is discussed in greater detail in Chapter ID). The questions raised by the
neurodevelopmental/neurodegenerative debate continue to dictate the agenda of
contemporary schizophrenia research, particularly in the field of structural imaging.
The Disconnection Hypothesis
Eugen Bleuler coined the term "schizo phrenia" ("split mind") to reflect what he saw
as the disintegration, or 'disconnection', of psychic processes in certain patients49.
Murray and Lewis suggested "an impairment of the organisation of axonal
connections"29 as a possible pathological mechanism for the disorder. The
disconnection hypothesis represents a unification of these two ideas. It was first
coherently formulated in detail in 1995 by the impressive pairing of eminent
neuropsychologist Chris Frith and psychiatrist/ground-breaking functional brain
imager Karl Friston50. The hypothesis states that schizophrenia can be understood in
cognitive terms, and in terms of pathophysiology, as a failure of functional
integration within the brain. The authors present an explanatory model for
schizophrenia based upon functional disconnectivity between the prefrontal and
temporal regions. The evidence cited in support of the theory reflects the two
authors' areas of expertise - cognitive neuropsychology51 and functional brain
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imaging, particularly PET . Only fleeting reference is made to structural imaging
findings in the original paper.
The basis of Frith's argument is that the signs and symptoms of schizophrenia do not
generally represent a single deficit, but can be seen as resulting from the abnormal
integration of two or more processes (for example, auditory hallucinations result
from "a failure to integrate 'inner speech' and 'attribution of agency'"51). Friston's
argument is that 'functional segregation' models of the brain, which attribute certain
functions to specific cortical regions are unlikely to be able to explain the signs and
symptoms of schizophrenia. He believes that one must view the brain from the
perspective of'functional integration' if one is to understand the pathophysiology of
schizophrenia. In terms of functional brain imaging he emphasises the distinction
between studies of 'first order effects' (such as hypofrontality) and studies of
'functional connectivity' that look for evidence of temporal correlations between
neuronal activity in different regions of the brain. He subjects PET data (and other
neurophysiological measures) to a mathematical analysis to produce 'eigenimages',
which illustrate the extent of functional connectivity between different regions of the
brain. The main finding from this analysis is of increased prefronto-temporal
functional connectivity. Friston attributes this somewhat counterintuitive result to a
failure of normal inhibition of temporal activity by prefrontal or vice-versa.
Frith and Friston are at pains to point out that the disconnection hypothesis refers to
functional and not to anatomical connectivity. However, the identification of
structural correlates of prefronto-temporal dysconnectivity is unlikely to do their
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hypothesis any harm. The most obvious support from structural imaging data is the
fact that the medial temporal lobes and prefrontal cortex are arguably the two most
macroscopically abnormal regions of the brain in schizophrenic subjects53'54 (see
chapter ID). Since the publication of the disconnection hypothesis a number of
groups have examined structural imaging data sets from the perspective of
correlations between frontal and temporal lobe volumes. The majority of these
analyses find reduced correlations between the volumes of these two brain regions in
schizophrenics, a result which is interpreted as indicative of a lack of mutually
trophic influences between the frontal and temporal regions during brain
development55'56'57. Another potential strategy for examining connectivity using
structural MRI is presented by the recently developed technique of Diffusion Tensor
Imaging (DTI). This allows estimation of the directional 'purity' of white matter
tracts. However, results from DTI studies of fronto-temporal tracts are, to date,
inconclusive58'59,60'61 (see chapter 2C).
The disconnection hypothesis is a relatively recent proposal. Frith and Friston would
probably argue that, as a functional hypothesis, it makes no testable predictions about
macroscopic brain structure. Its impact upon structural imaging research may
therefore be limited. However, it will almost certainly play a central role in
determining the direction of functional magnetic resonance imaging research in
schizophrenia.
Towards a Unitary Theory: The Dysplastic Net Hypothesis
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There is nothing inherently contradictory in the theories described above. Each of
the 'biological' models is consistent with a range of 'environmental' modifying
factors. Furthermore, it is perfectly possible to accept all three biological hypotheses
simultaneously. This produces a model of schizophrenia in which disruptions to
early neurodevelopment result in functional dysconnectivity between prefrontal and
temporal regions of the adult brain, one consequence ofwhich is increased sensitivity
in mesolimbic dopaminergic pathways. This is the essence of the 'dysplastic net'
hypothesis proposed by Ed Bullmore, Sophia Frangou and Robin Murray in 199762.
The 'net' in the title refers to the neuronal networks that are established during the
second and third trimesters of pregnancy as axonal projections invade the cortical
plate and establish early synaptic connections. As the authors point out, these
neuronal networks are both anatomical and physiological (functional). Given that
the development of cerebral cortex is dependent upon the trophic effects of afferent
impulses, one would predict that the greater the functional connectivity between
cortical regions during periods of neuronal proliferation and pruning, the greater the
correlation between the volumes of those regions in the adult brain. The dysplastic
net hypothesis therefore predicts that correlations between volumes of the temporal
and pre-ffontal regions will be reduced in schizophrenia. As described above, a
number of studies have confirmed this prediction55'5 '57.
The dysplastic net hypothesis provides an elegant explanation for the complex, and at
times ethereal phenomenon that is schizophrenia. Who knows, it might even be true!
However intellectually appealing it may be, this proposal remains highly speculative.
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As with any theoretical model, the ultimate determinant of its impact and longevity
will be its credibility in the face of hard research data. With this in mind, an
overview of the main findings to date from structural brain imaging studies of
schizophrenia will now be presented.
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ID. Current State of Knowledge
Introduction
Kraepelin and his contemporaries were confident that the symptoms of schizophrenia
reflected underlying brain pathology but they were unable to prove the association.
Over the ensuing decades neuropathological explanations for symptoms were
supplanted by psychodynamic theories to the detriment of biological research. As
Ron and Harvey have pointed out "to have forgotten that schizophrenia is a brain
disease will go down as one of the great aberrations of 20th century medicine."1
A number of factors probably contributed to the temporary decline in the biological
view of schizophrenia. First, the flood of neuropathological discoveries that
characterised late nineteenth and early twentieth century medicine (see Chapter 1A)
slowed to a trickle. Second, a number of influential negative studies were published,
for example in 1924 Dunlap published a paper in the American Journal of Psychiatry
in which he stated "there are no abnormalities in the brains of schizophrenic patients
that can not also be found in the brains of healthy subjects."2 Third, Freud and the
other psychoanalysts provided a fashionable and intellectually appealing alternative
explanation for the peculiarities of thought and behaviour that characterise the
disorder.
Whilst the Kraepelian argument (that schizophrenia is a disease of the brain) was
undoubtedly drowned out by the clamour of psychoanalytic conjecture, it was never
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completely silenced. For example, the highly successful and independent-thinking
neuropathologists Oskar and Cecile Vogt (husband and wife) remained persistent and
vocal champions of the biological theory of schizophrenia. With the arrival of safe
and practical in-vivo brain imaging techniques, biological psychiatry finally had the
means to regain lost intellectual ground.
The first task faced by brain imaging researchers was to demonstrate that the clinical
syndrome of schizophrenia is indeed associated with abnormalities of brain structure.
This was achieved with early studies, such as that by Johnstone and colleagues3,
which established the relationship between chronic schizophrenia and ventricular
enlargement (thereby triggering a resurgence of interest in biological correlates of
schizophrenia). However, these initial findings were challenged by critics who
argued that ventricular enlargement was more likely to be a consequence of
treatment than of illness per se. This debate continued until a large, well-conducted
study by David Owens and colleagues demonstrated that "ventricular enlargement is
unrelated to past physical treatment (neuroleptics, insulin coma and
electroconvulsive therapy)."4
Subsequent advances in imaging technology, together with adroit study design, have
enabled researchers to explore the relationship between schizophrenia and
macroscopic brain structure in greater detail. Following the best scientific tradition,
the field has advanced from question to question - each prompted by the last. The
principal questions that schizophrenia poses to structural imaging researchers will
now be addressed.
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Is the brain abnormal in schizophrenia?
As described above, the first brain abnormality to be identified by in-vivo structural
imaging in schizophrenia was ventricular enlargement3. This remains the most
robust and consistently replicated finding in the field5. Even early X-ray CT
machines (such as the original EMI 1010) provide good discrimination between
ventricular spaces and brain substance, particularly at the level of the lateral
ventricles (as demonstrated in figure ICiii). Although ventricular size can be
reported in a variety ofways, the most widely used method in the CT literature is the
Ventricle-Brain Ratio (VBR)6. The area of the ventricles is conventionally expressed
as a percentage of the total area of the brain scan, at the level on the scan at which
the ventricles appear largest (a method first described by Synek and Reuben in
19767).
The most comprehensive review of this literature is the multivariate meta-analysis by
Van Horn and McManus published in 1992. The analysis incorporates 39 studies of
ventricular size in schizophrenia employing the VBR method. The authors conclude
"there is a difference in VBR between schizophrenics and controls which would
seem to be an indisputable characteristic of schizophrenia."6
Whilst increased VBR may be "an indisputable characteristic of schizophrenia", it
falls short of being a pathognomonic biological marker for the disorder for a number
of reasons:
113
(1) The difference between schizophrenics and controls is too small to be of
practical significance in diagnosis6. In another quantitative review of the CT
literature, Raz and Raz, estimate the effect size (d) to be between 0.57 and
0.70 standard deviation units8 (and classified as 'medium' on the Cohen
criteria9). This effect size corresponds to a 'non-overlap' of only 43%
between schizophrenic and control groups of the same size.
(2) The finding is not specific to schizophrenia. Raz and Raz incorporate data
from subjects with mood disorders into their analysis and conclude that the
affective psychoses are also associated with increased VBR (effect size
o
<7=0.49 to 0.55, not significantly different from effect size in schizophrenia ).
Siever and colleagues report increased VBR in patients with schizotypal
personality disorder10. Other conditions such as hydrocephalus and various
forms of dementia1 ''12 are also known to be associated with increased VBR as
is normal ageing7 and closed head injury13.
(3) The magnitude of the increase in VBR associated with a diagnosis of
schizophrenia varies considerably from individual to individual and from
study to study. There is evidence that the degree of ventricular enlargement
may be related to certain clinical and demographic characteristics of the
patient.
(4) The reliability and validity of VBR as a measure are open to question14'15.
The model of scanner, the precise scanning protocol used to obtain the image
and the method used to extract measurements from that image all influence
the resultant VBR. It is therefore not possible to compute absolute values for
VBR using in-vivo imaging techniques14. (Various methods have been
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proposed for quantifying loss of brain tissue. Whilst VBR is the most widely
used, alternatives may offer superior reliability and validity. As a ratio, VBR
inevitably conflates any increase in lateral ventricular size with any
reductions in whole brain volume. This problem can be avoided by adopting
a statistical approach that either regresses lateral ventricular volume against
volumes of brain structures or treats ventricular volume as a covariate16.)
In their meta-analysis, Van Horn and McManus find that studies of VBR in
schizophrenia report a wide range of effect sizes5. This is not at all surprising
because many of the studies are small (n = 6 to 95) and therefore random sampling
error would be expected to produce a spread of results. The rationale behind meta¬
analysis is that, by pooling data from many small studies, the true effect size can be
determined with a greater degree of certainty. However, whilst much of the apparent
discrepancy between the results of different studies may be accounted for by chance,
a well-conducted systematic review will also examine the pooled data for evidence
of 'moderator variables'17.
Structural imaging studies of schizophrenia have identified correlations between
2 18 19 • 20 21 22ventricular enlargement and: cognitive impairment ' ' ; negative symptoms ' ' ;
21 22 22reduced frequency of positive symptoms ' ; unemployment ; poor premorbid
20 23 20 23 V 24social adjustment ' ; poor prognosis ' ; and male sex ' . These are all therefore
potential moderator variables in a multivariate meta-analysis. Inevitably, most of the
39 studies examined by Van Horn and McManus did not collect data relating to all of
these variables. In this sense the data set is incomplete. However, this is a universal
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feature of meta-analyses in medical research. The solution is to examine those
potential moderators for which data are available. In the case of the Van Horn and
McManus analysis, these include: method of ascertainment of VBR; diagnostic
criteria employed to determine caseness; type of control subjects; age of subjects;
age of onset of schizophrenia; duration of illness; proportion of males among
subjects; number of subjects in study; and year of publication of study. Of these nine
'candidate' variables, three (diagnostic criteria, duration of illness and year of
publication) are found to have a moderating effect.
Van Horn and McManus' analysis reveals that studies employing DSM-III criteria
for schizophrenia report a significantly larger increase in VBR than those employing
RDC. Given that the DSM-III criteria are 'tighter' than the RDC (see chapter 1A)
this finding suggests that ventricular enlargement may be related to severity of
illness. However, Van Horn and McManus find that studies employing the even
tighter inclusion criteria of simultaneous fulfilment of both DSM-III and RDC report
the smallest increase in VBR. The authors offer an explanation based upon inclusion
of patients with alcohol and other problems into the 'single criteria' studies.
However, the 'both criteria' result is based upon a sample of only five small studies
and may be misleading. What is clear from the meta-analysis is that the magnitude
of increase in VBR is remarkably sensitive to small variations in the diagnostic
criteria employed. The fact that even the most robust and consistent finding in
structural imaging research is tarnished by unresolved issues relating to the definition
of the disorder demonstrates the extent of the challenge faced by researchers in this
field. (These issues are discussed in Chapter IB.)
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The second significant association identified by the meta-analysis is between
magnitude of increase in VBR and duration of illness. Although this finding invites
the conclusion that the pathological process underlying schizophrenia is progressive,
there are a number of alternative explanations. First, duration of illness may be a
proxy for severity. Second, and more controversially, the underlying pathological
process may not be the same in all cases of schizophrenia. The evidence for and
against these competing hypotheses is discussed later in this chapter.
The third moderator variable identified by Van Horn and McManus' meta-analysis is
year of publication. The authors note a gradual reduction in effect size over time
(recent studies reporting a smaller increase in VBR). Whilst there is no trend in the
mean VBR reported for the schizophrenic subjects, VBR in controls increases with
time (thereby narrowing the gap). The explanation offered is that this reflects an
increasing awareness amongst clinical researchers of the importance of careful
selection of controls for studies of this type. There is a small literature relating to the
choice of control subjects in this type of research25. This may have informed a move
away from the recruitment of 'super' controls such as medical patients previously
identified as having normal brain scans.
In conclusion, the short answer to the question "is the brain abnormal in
schizophrenia?" is "yes, it is indisputable that the ventricles are enlarged." However,
this finding is not specific to schizophrenia and is not present in all cases. The
117
magnitude of the finding appears to correlate with indices of poor prognosis but is
susceptible to variations in diagnostic criteria.
Ventricular enlargement is a somewhat 'general' finding, which presumably reflects
a loss of surrounding brain tissue. The list of recognised causes incorporates a highly
varied range of pathological processes. As a tool for differentiating between various
proposed pathological mechanisms, any measurement of ventricular enlargement is
therefore likely to be of limited value. Furthermore, whilst collapsing the
information contained in a brain scan to a single number such as VBR may facilitate
the demonstration of 'a difference' between schizophrenic subjects and controls, it
does not allow the pathology to be localised. It is evident that a number of important
questions relating to the brain pathology underlying schizophrenia can not be
answered solely by measurements of ventricular size.
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Is the whole brain affected or are the abnormalities localised?
The majority of CT studies of schizophrenia report lateral ventricular size (often
expressed as VBR). However, in their comprehensive review of the literature, Raz
and Raz include 23 studies that also report findings relating to the 3rd ventricle. They
conclude: "increases in the volumes of the lateral and the third ventricles in
schizophrenic subjects were linked [correlated], . . When measurement method was
taken into account, however, dilation of the third ventricle was found to be more
pronounced than lateral ventricular enlargement."7 This finding suggests that the
pathological process underlying schizophrenia may not affect all regions of the brain
equally. However, the poor soft-tissue discrimination ofCT limits its utility as a tool
for accurate measurement of specific regions within the brain, particularly regions as
small as the 3rd ventricle where a slight absolute enlargement might produce a large
relative enlargement.
Unlike CT, MRI provides excellent discrimination between white and grey matter. It
is also capable spatial resolution comparable to the best X-ray CT scan26. With MRI
it is possible to identify anatomically discrete regions within the brain. MRI
therefore offers researchers the technological capability to examine grey and white
matter in different parts of the brain for evidence of the pathological process
responsible for the ventricular enlargement associated with schizophrenia. Two
quantitative overviews of this literature have been published to date. The first, in
1998, by Lawrie and Abukmeil is described as a "systematic and quantitative
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review" and incorporates 40 studies27. The second, in 2000, by Wright et ah, is a
more conventional meta-analysis of data from 53 studies4.
Lawrie and Abukmeil argue that the limited amount of available data precludes the
adoption of a conventional meta-analysis approach, (i.e. combining data from
different studies into one large pool and then subjecting this to statistical analysis).
Rather they calculate the median increase or decrease in volume of each particular
brain region. They construct 'funnel plots' as a means of identifying publication bias
and find little or none. By avoiding tests of statistical significance, their approach
reduces the risk of reporting false negative findings where the available data are
limited ('Type II' error). Lawrie and Abukmeil circumvent the potential problems
associated with differences in diagnostic criteria by including only those studies that
employ DSM IIIR criteria.
The principal finding of the review is that the volumetric MRI literature provides
powerful support for the association between schizophrenia and ventricular
enlargement. The average (median) increase in cerebral ventricular volume is 18%.
Furthermore, this finding does not appear to be affected by differences in
methodology and is not explained by publication bias. A few of the studies report
data from sub-regions of the ventricles and, although the authors acknowledge
potential inconsistencies in the definition of anatomical boundaries and possible
publication bias, there is some evidence for differential enlargement of the body
(median increase 50% left, 47% right) and occipital horns (31% left, 28% right) of
the lateral ventricles. The suggestion within the CT literature of possible
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disproportionate enlargement of the third ventricle7 is not supported by this review of
the MRI literature. However, the authors report a gender difference in this
component of the ventricular system with a more prominent increase in male subjects
(median 21%) than in females (median 5%).
One might expect ventricular enlargement to be associated with a corresponding
reduction in brain substance. Lawrie and Abukmeil identify consistent reductions in
whole brain volume of about 3%. These reductions are evident bilaterally and in
both sexes. The data suggest that the temporal lobes may be affected to a greater
extent than are other regions of the brain, (median reductions 6% left, 9.5% right).
However, the authors note that this finding is not apparent in more recent studies that
analyse data from male and female subjects separately. They argue that it may be a
false positive attributable to examining only (severely affected) male subjects in
early studies. The idea that results of structural imaging studies in schizophrenia
may be affected by the gender of the subjects is supported by closer examination of
findings relating to specific medial temporal lobe structures. It is in this region of the
brain that Lawrie and Abukmeil find the largest reductions in volume. However, the
literature is rather difficult to review because different studies sub-divide this part of
the brain in slightly different ways. Ten studies report volumes for the 'amygdala-
hippocampal complex' (median volume reduction 6.5%), although the two studies
that report data from female subjects find a small increase in the volume of this
region (0.5 & 3.5%). Seven studies report volumes for the hippocampus separately.
The findings from male subjects suggest a differential volume reduction in this
region (7% left, 8.5% right), whilst the two studies reporting data from female
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subjects find volume reductions of 2.5 and 3%, comparable to overall reductions in
brain volume. The five studies reporting volumes of the amygdala (10% bilaterally)
and the three reporting volumes of the parahippocampal gyrus (14% left, 9% right)
do not include any female subjects.
Of the 40 studies reviewed by Lawrie and Abukmeil, eight employ techniques that
allow white and grey matter to be measured separately (so-called 'segmentation').
The results from these studies suggest that, whilst volumes of grey matter are
reduced, white matter volume may actually be increased.
The meta-analysis conducted by Wright and colleagues incorporates 1,588 subjects
with schizophrenia from 53 separate studies (including most of the 40 studies in the
previous review). The methodology is more orthodox than that employed by Lawrie
and Akumbeil. Data from individual studies are converted into a common form
(ratio of volume in schizophrenics to corresponding volume in controls) before being
combined into one large data pool for multi-variate analysis, using a random effects
model. The findings are reassuringly similar to those of the previous review. Wright
and colleagues report an increase in ventricular volume (mean 26%) with differential
increases in the volume of the body of the lateral ventricle (mean 42%). They report
no differential increase in the volume of the third ventricle (mean 26%). Whole
brain volume is reduced by approximately 2-3% with no right-left or male-female
differences. There is no clear evidence for a differential reduction in temporal lobe
volume. However, medial temporal lobe structures including amygdala (9%
bilaterally), hippocampus (7% left, 6% right) and para-hippocampal gyrus (11% left,
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8% right) are subject to greater reductions in volume than would be expected were
the whole brain affected equally. With respect to gender, Wright and colleagues
replicate Lawrie and AbukmeiPs finding that the magnitude of the schizophrenic-
control differences is smaller in the five female only studies than in the eleven male
only studies. However, when the pooled data from all 1,588 subjects are analysed,
there is little evidence for a major gender effect. Wright et al. also examine data
relating to white-grey segmentation. They conclude that reductions in grey matter
volume are greater than reductions in white matter volume. They do not confirm
Lawrie and Akumbeil's suggestion that white matter volume may be increased.
Given the current state of knowledge, the best available answer to the question "is
the whole brain affected or are the abnormalities localised?" is a rather unsatisfactory
"probably both!" Schizophrenia is associated with general reductions in brain
volume (and with corresponding increases in ventricular volume) and localised
reductions in volume ofmedial temporal lobe structures. It is intriguing to speculate
that these may represent relatively distinct disease processes (a possibility that is
explored later in this chapter).
Although the structural imaging literature relating to female schizophrenics is far
from extensive, there is some evidence to suggest that certain localised macroscopic
brain abnormalities identified in male subjects may not be present in female subjects.
Whilst this apparent difference may be attributable to differential selection bias, the
possibility remains that the underlying pathological process may be different in the
two sexes (a notion supported by gender differences in age of onset ). As described
123
earlier, certain other findings from structural imaging studies (such as the association
between chronicity of illness and ventricular size) can also be construed as providing
evidence for more than one pathological process in schizophrenia. (The 'single'
versus 'multiple' pathology debate in presented later in this chapter.) Of course the
association between chronicity and ventricular size can also be interpreted as
evidence for a progressive, neurodegenerative process in schizophrenia. Structural
brain imaging has been employed to explore the temporal relationship between brain
abnormalities and symptoms. The main findings from this literature will now be
reviewed.
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When do the abnormalities arise?
The definitive experiment to establish the temporal relationship between the
development ofmacroscopic structural brain abnormalities and the clinical course of
schizophrenia would be a large, longitudinal, cohort study. Subjects would be
recruited before the emergence of any clinical symptoms. Detailed structural
imaging examinations would be performed prior to the onset of illness, during the
prodromal phase, the first psychotic episode, the first remission, and then at regular
intervals for the duration of the illness and beyond. To borrow from the language of
epidemiology, such an experiment would yield information relating to predisposing,
precipitating and perpetuating factors in the aetiology of schizophrenia. It would
address the following questions:
1. Do structural brain abnormalities pre-date the onset of symptoms?
2. Does the macroscopic appearance of the brain change in any way as the
sufferer becomes unwell?
3. Do the structural brain abnormalities progress as the illness progresses?
Obviously such an experiment would be a massive undertaking, not least because of
the difficulties inherent in the identification of pre-symptomatic schizophrenic
subjects. This experiment has not and probably never will be conducted. However,
the ambitious 'Edinburgh High-Risk Study' (EHRS) adopts a design that is as close
to the ideal as is practicable. This is a cohort study of individuals who are at
increased risk of developing schizophrenia by virtue of a strong family history of the
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disorder (at least two affected first or second degree relatives). By selecting
individuals who have 10-20 times the 'population-risk', the size of cohort required to
generate adequate statistical power is reduced from over 2000 to around 15029.
Unfortunately, the designs' greatest strength is also its greatest weakness. Inevitably
the relative contribution of genetic factors to the genesis of schizophrenic symptoms
in the EHRS cohort will be unusually high. The extent to which findings from this
necessarily unrepresentative group can be generalised to the wider population of
schizophrenic patients is unclear. The structural imaging literature contains some
evidence for differences between familial and non-familial schizophrenia30.
Recruitment for the EHRS began in 1994. To date, baseline assessments have been
completed for over 160 high-risk subjects between the ages of 16 and 25. The
assessment includes a comprehensive battery of psychometric tests and a volumetric
MRI scan, which is analysed on a region of interest basis. Baseline assessments have
also been completed for approximately 80 matched control subjects from two groups:
first episode patients with schizophrenia; and 'normal' subjects with no known
family history of psychotic disorder31. The baseline structural imaging findings
suggest that high familial risk for schizophrenia is associated with reductions in the
volume of the amygdalo-hippocampal complex and the thalamus. These regional
reductions in volume resemble those observed in schizophrenic subjects but are of a
lesser magnitude32. Although the study is in its early stages, preliminary findings
from the first two-year follow-up assessments are starting to emerge. These appear
to suggest that the development of psychotic symptoms is associated with a reduction
in right temporal lobe volume33.
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As the study proceeds, comparisons of brain imaging data from those subjects who
develop schizophrenia with data from those who do not will hopefully lead to the
identification of features of macroscopic brain structure that pre-date (and may
therefore predict) the onset of symptoms. It is also hoped that the study will reveal
specific macroscopic changes in brain structure occurring during the early stages of
the illness and thereby provide clues as to the nature of the pathological process
responsible for the onset of symptoms. Finally, provided the cohort is followed-up
over a sufficiently long period, it could provide information relating to the
progression of structural brain changes over time.
The EHRS and other cohort studies may eventually provide definitive answers to the
question: "When do the structural brain abnormalities associated with schizophrenia
arise?" In the meantime, the only option available to researchers is to use the best
evidence from cross-sectional studies to build up a longitudinal picture. With respect
to the question "do structural brain abnormalities pre-date the onset of symptoms?",
the best evidence comes from studies of patients during their first episode of
schizophrenia. Shenton and colleagues review 124 MRI studies of first episode
subjects. They conclude that the structural brain abnormalities consistently reported
in chronic schizophrenia (enlarged ventricles and reduced whole brain volume) are
present at the first episode of illness34. Furthermore, although the data relating to
specific regions of the brain are less consistent, the authors conclude: "the brain
regions involved [during the first episode of illness] are the same brain regions
observed in more chronic patients."34
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The question: "Does the macroscopic appearance of the brain change in any way as
the sufferer becomes unwell?" is extremely difficult to answer without 'before',
'during' and 'after' data from individual cases. Even with unmedicated first episode
cases it is impossible to exclude the possibility that structural brain changes
occurring at the very earliest stages of the illness have been missed. The provisional
finding from the EHRS of reductions in right temporal lobe volume33 relates to 19
subjects with transient or isolated psychotic symptoms rather than schizophrenia per
se and 12 of the subjects reported these symptoms at baseline.
Comparison of data from chronic patients with those from first episode subjects
ought to provide information pertaining to the progression of structural brain
abnormalities in schizophrenia. However, our ignorance of the effects of normal
ageing upon brain morphology makes interpretation of findings from such
comparisons rather difficult. Fortunately data are available from a small number of
cohort studies. The largest of these is the Stony Brook First Episode Study
conducted by Lynn DeLisi and colleagues35. 50 first episode subjects were reviewed
at 4 year follow-up together with 20 matched controls. Both schizophrenics and
controls showed general reductions in volumes of the right and left cerebral
hemispheres and increases in the volumes of the lateral ventricles over time.
However, the changes were more marked in the patient group. When results from
specific brain regions were examined, the only areas showing statistically significant
differential volume reductions in the patient group were the right cerebellum and the
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isthmus of the corpus callosum. The authors interpret their findings as suggestive of
a "subtle active brain process continuing through the first few years of the illness"35.
A recently published ten year follow-up study from Japan reports significantly
greater increases in lateral ventricular volume in schizophrenic subjects than in
controls (23% v 5%)36. However, a number of other follow-up studies report no
17 lO
evidence of progression of structural brain abnormalities in schizophrenia ' .
Shenton and colleagues review 15 published studies relating to 5 cohorts of
schizophrenic patients. They acknowledge the inconsistency ofmany of the findings
and comment that further research is required. However, they conclude "there
appear to be progressive changes in the frontal lobes and possibly in the parietal
lobes, superior temporal gyrus, and lateral ventricles. Amygdala-hippocampal
volume appears not to change over time."
In conclusion, given the current state of knowledge, it is not possible confidently to
answer the question "when do the structural brain abnormalities associated with
schizophrenia arise?" A considerable body of evidence from studies of patients
during their first psychotic episode suggests that most of the abnormalities are
already evident at this stage. A small number of follow-up studies suggest that some
of the brain changes may progress during the first few years of illness. However, the
question of what happens to brain structure as someone becomes unwell remains a
mystery. The Edinburgh High-Risk Study will hopefully provide more satisfactory
answers to these questions within the next few years.
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Is there more than one pathological process at work?
Our current concept of schizophrenia has its roots in the 'medical model' of the late
nineteenth century (as outlined in Chapter 1A). This states that signs and symptoms
reflect 'disease entities', each of which results from a single necessary and sufficient
causative agent. However, the clinical picture in schizophrenia is characterised by a
wide range of signs and symptoms, none of which is unique to the disorder.
Furthermore, the course and outcome of the disorder are highly variable. The
question of whether 'schizophrenia' reflects a single 'disease entity' has been the
subject of open debate since the inception of the concept (see Chapters 1A and IB).
The identification of macroscopic structural brain abnormalities associated with the
diagnosis provides powerful support for the presence of underlying brain pathology
and supports the notion of 'schizophrenia' as a 'disease' of the brain. However, the
picture is complicated by the fact that a substantial proportion of subjects with
schizophrenia have no identifiable macroscopic brain abnormalities. This finding
invites three rival explanations or theoretical models, each of which makes specific
predictions that can be tested against research evidence.
1. Schizophrenia is a single disease entity of varying severity.
This model proposes a single, common pathological process underlying all cases of
schizophrenia, reflected in changes in brain structure. However, the changes are only
recognisable at a macroscopic level if they exceed a particular threshold of severity.
This model predicts that the magnitude of structural brain changes will be
proportional to indices of illness severity such as scores on symptoms rating scales,
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poor treatment response and poor functional outcome. It also predicts that, (for a
given severity of illness), the nature and extent of structural brain changes will be
independent of risk factors and of gender. Finally, it predicts that structural brain
changes evident in schizophrenic subjects will follow a unimodal distribution.
Nancy Andreasen and colleagues conducted one of the earliest CT studies examining
the relationship between structural brain abnormalities and severity of clinical
symptoms. They compared 16 patients with marked ventricular enlargement with 16
patients with normal ventricular volumes. The main finding was that increased VBR
is associated with a preponderance of negative symptoms, whilst normal ventricular
21size is associated with an increased incidence of positive symptoms . A more recent
MRI study of 59 schizophrenic subjects identifies no clear relationship between brain
imaging findings and symptom severity39. Marsh and colleagues in Stanford address
the problem from the opposite direction. 56 'severely ill' patients are compared with
44 'moderately ill' patients and 52 healthy controls. Whilst increased clinical
severity is associated with larger increases in CSF volume and greater reductions in
ffonto-parietal grey matter volume, reductions in temporal lobe grey matter volume
are smaller in the more severely affected subjects than in the moderately affected
group40. None of these results suggests a straightforward relationship between
structural brain changes and a single dimension of 'severity'.
Poor symptomatic response to antipsychotic medication is an indirect indicator of
illness severity in schizophrenia. Lee Friedman and colleagues review the VBR
literature relating to treatment response and conclude that there is no statistically
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significant association between treatment resistance and raised VBR41, (although
their analysis does identify a non-significant trend suggestive of a small positive
correlation; effect size = +0.11). Lawrie and colleagues use both structural MRI and
SPET to compare 20 treatment-responsive and 20 treatment-resistant patients
matched for sex, age and duration of illness. They find no significant association
between treatment resistance and any brain-imaging variable42. However,
'qualitative re-analysis' of the scans (by which the authors mean clinical ratings by
an experienced neuro-radiologist blind to group) reveals a trend towards greater
cerebral atrophy in the treatment-resistant subjects that is not identified by
volumetric analysis43. On balance, the research evidence can probably be interpreted
as indicating a weak association between treatment resistance and structural brain
changes.
The literature relating structural brain changes to indicators of poor functional
outcome (such as unemployment, loss of relationships, chronicity of in-patient care
etc.) in schizophrenia is equally indeterminate. The first CT study to examine this
relationship (Pearlson et al. 1984) identified a strong association between persistent
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unemployment and increased VBR in 46 psychotic patients . A more recent review
of the literature by Staal and colleagues (incorporating 15 CT and 6 MRI studies)
highlights the wide range of outcome measures used by different groups and
acknowledges that this hinders the review process. The authors tentatively conclude
that ventricular enlargement is probably associated with global measures of poor
outcome44. The same research group recently published their own MRI study
comparing 20 'poor outcome' patients with 25 'favourable outcome' patients and 23
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healthy controls. They conclude that poor outcome is associated with loss of frontal
grey matter and increase in lateral and third ventricle volume45. These studies
provide some support for the idea that patients with macroscopic structural brain
abnormalities have a poorer functional outcome than patients with macroscopically
normal brains. However, all of these studies share the intrinsic limitation of a cross-
sectional design. The only longditudinal study published to date (Wassink,
Andreasen et al. 1999) reports that the only structural brain abnormality to predict
psychosocial impairment at seven year follow up is reduced cerebellar volume46.
Another prediction of the 'single disease entity' model that can be tested against
research evidence is that brain changes will be independent of specific risk factors.
If macroscopic structural abnormalities reflect underlying brain pathology and the
pathological process is the same in all cases of schizophrenia, then in-vivo structural
imaging findings should be the same in all cases, irrespective of the aetiological risk
factors that contributed to that pathological process. Most of the studies in this area
examine the role of family history of psychosis as a risk factor for schizophrenia.
The most recent meta-analysis of this literature concludes that patients with no
known genetic predisposition for schizophrenia have lateral ventricles that are 20%
->A
larger than those with a recognised genetic predisposition . However, the
magnitude of this result is, at best, counter-intuitive. If correct, the degree of
ventricular enlargement attributable to non-genetic determinants of schizophrenia is
greater than the total ventricular enlargement associated with the disorder (estimated
at 18%27). One has to wonder whether the literature relating to family history is
subject to some form of selection bias (e.g. familial studies containing fewer chronic
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or severe cases) although it seems improbable that the difference is entirely
attributable to bias. One interesting aspect of this literature is that the familial/non-
familial difference is not found in studies of female subjects. This suggests a
significant sex by family history interaction. Finally, there is considerable evidence
to suggest that a genetic predisposition for schizophrenia may be associated with
particular structural brain abnormalities even in the absence of symptoms32'47'48'49'50'51
(this literature is discussed in greater detail in Chapter 2A). This undermines the
view that there is a simple, one-to-one, relationship between macroscopic structural
brain changes associated with schizophrenia and the pathological process underlying
the signs and symptoms of the disorder.
The argument relating to risk factors (outlined above) is equally applicable to gender
- the single process theory predicts that the abnormalities should be the same in both
sexes. As discussed in the previous section, the structural imaging literature relating
to schizophrenia in women is limited. However, the available data indicate
significant differences between male and female schizophrenics in terms of both the
magnitude and the location of structural brain abnormalities.
The final prediction of the 'single process' model that lends itself to hypothesis
testing relates to the statistical distribution of structural imaging data. If
schizophrenia is a single disease entity of varying severity, one might reasonably
expect indices of severity to follow a unimodal (probably Gaussian) distribution. If
structural brain abnormalities reflect the underlying pathological process,
quantitative measurements of brain changes ought to correspond to severity and
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therefore ought to be distributed in a unimodal fashion within the schizophrenic
population. David Daniel and colleagues test this hypothesis by examining the
distribution of VBR amongst 691 schizophrenic subjects from 20 imaging studies.
The results demonstrate a unimodal distribution of VBR. The authors conclude "the
neuropathological process, which is obvious in patients with extreme VBR values,
also exists but to a lesser degree in patients with 'normal'-sized ventricles."52
The concept of a single dimension of severity is also supported by imaging studies of
subjects from either end of the severity spectrum. Studies of 'schizotypal' patients
report structural brain changes resembling those found in schizophrenia but of a
lesser magnitude9,53. Meanwhile a recent MRI study of patients with co-morbid
schizophrenia and mild learning disabilities, which the authors consider to be a
severe form of schizophrenia, reports structural brain abnormalities similar to those
found in schizophrenia but of a greater magnitude54. However, as discussed in the
previous chapter, the notion of a 'schizophreniform spectrum' does not sit
comfortably with the 'single disease entity' view of schizophrenia.
2. Schizophrenia is a disease with a complex, multi-process pathology.
This model proposes a common pathological mechanism underlying all cases of
schizophrenia. However, the mechanism is complex, incorporating more than one
process. Not all of the processes produce the same macroscopic changes in brain
structure. The appearance of the brain on in-vivo imaging reflects the relative impact
of each of the different processes upon brain structure at the time the scan is
conducted. Within this model, discrete structural brain changes are attributed to
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particular neuro-pathological processes, each process making its own unique
contribution to the clinical picture of schizophrenia. The model therefore predicts
the presence of reliable correlations between specific structural imaging findings and
identifiable clinical characteristics.
The theory that most clearly illustrates this view of schizophrenia is Crow's 'Two
Process' proposal55. In this model, one pathological process ('Type I') involves
biochemical imbalance and is reflected in positive symptoms, which tend to occur in
acute episodes; meanwhile, a separate process ('Type II') involves loss of cerebral
tissue and is reflected in negative symptoms, which tend to be persistent and
progressive. The central prediction of Crow's theory is that ventricular enlargement
will correlate strongly with negative symptoms. Data from early CT studies
appeared to support this idea21, however, subsequent CT and MRI studies have
demonstrated that the association between ventricular enlargement and negative
symptoms is less powerful than was first thought7'56. Furthermore, the experimental
finding of a correlation between ventricular enlargement and measures related to
brain dopamine activity (such as raised homovanillic acid and dopamine beta
hydroxylase)57 suggests that biochemical imbalance and loss of cerebral tissue are
closely related phenomena and are therefore unlikely to reflect separate processes.
Although this early attempt to synthesise structural imaging findings into a complex,
yet coherent pathological model for schizophrenia was unsuccessful, the primary aim
of the majority of brain imaging studies in schizophrenia remains unchanged.
Almost all studies are designed to identify correlations between specific
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abnormalities of brain structure and particular clinical characteristics of the illness.
The rationale behind this design is that with the aid of such correlations, one ought to
be able to elucidate the nature of the individual processes that comprise the complex
pathological mechanism underlying schizophrenia. In other words correlations will
help to identify pieces of the schizophrenia jigsaw. Hundreds of such studies have
been published. Numerous correlations have been identified, however, very few
have been consistently replicated27'34. As previously discussed, the generalised
findings of ventricular enlargement and reduced whole brain volume appear to be
consistently correlated with cognitive impairment and also with negative symptoms,
chronic hospitalisation, male sex and non-familiality (although these latter
associations are relatively weak). Associations between regional brain changes and
specific clinical characteristics are less reliable. The more frequently cited
58correlations include: increased basal ganglia volume with antipsychotic medication ;
increased lateral ventricle (temporal horn) and third ventricle volume with severity of
both positive and negative symptoms59; reduced volume of the left superior temporal
gyrus (anterior portion) with auditory hallucinations60; reduced volume of the left
superior temporal gyrus (posterior portion) with thought disorder61,62; reduced left
hippocampal volume with severe obstetric complications63; and reduced right
hippocampal volume with chronicity of illness64.
Whilst these associations may be unreliable, there is no denying their attractiveness
to schizophrenia researchers. A number of speculative aetiological theories have
been advanced partly on the basis of preliminary structural imaging findings. A
common theme amongst many of these proposals is the 'two hit hypothesis'65'66.
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This model, which stems primarily from epidemiological findings, states that both a
pre-existing 'vulnerability' and exposure to a 'trigger' are necessary for the
development of schizophrenia. Associations between structural imaging findings
and known aetiological risk factors (e.g. left hippocampal volume reduction and
obstetric complications) are interpreted as evidence for the neuro-pathology of
vulnerability. Associations between brain abnormalities and symptoms (e.g.
increased lateral ventricle volume and cognitive impairment) are viewed as
expressions of the environmentally triggered neuro-pathological process. The appeal
of the two hit model for structural imaging researchers is that it facilitates the
construction of testable hypotheses (an example of a study designed to test a two hit
hypothesis is given in chapter 2A). However, cynics might argue that the
adaptability of the model encourages the over-interpretation ofmodest data.
3. Schizophrenia comprises a number of different disease entities.
Supporters of this model argue that the signs and symptoms that we call
'schizophrenia' can be produced by a number of unrelated pathological processes.
For each patient, the nature and magnitude of macroscopic structural brain
abnormalities is a reflection of the particular disease from which they are suffering.
This model is the antithesis of the Kraepelian view of schizophrenia. It suggests that
instead of searching for Kraepelin's "tangible morbid process", researchers ought to
be looking for a range of different pathological mechanisms. Within this model,
those patients with macroscopic brain abnormalities are viewed as suffering from a
different disease (or group of diseases) from those with grossly normal brains. The
model therefore predicts that these two (or more) groups of patients will differ on a
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range of clinical indicators including treatment response, outcome, and symptom
profde and that such disparities will not be accounted for simply by differences in
illness severity. It also predicts that the two groups will differ in terms of
aetiological risk factors and gender.
A number of early structural imaging studies were designed specifically to test this
hypothesis. For example, in 1980, Weinberger and colleagues compared response to
neuroleptic treatment in ten schizophrenic patients with enlarged cerebral ventricles
with that in ten patients with normal ventricles matched for age, serum drug levels
and various indices of severity. The principal finding was that patients with enlarged
ventricles showed a poorer clinical response. This was interpreted, by the authors, as
demonstrating that these patients were suffering from a "biologically different
illness"67. Although this finding has not been consistently replicated42, a recent
review of outcome variables in schizophrenia, including treatment response,
concludes that ventricular enlargement is a (weak) independent predictor of poor
outcome44. Interestingly, attempted suicide (which is one of the more extreme
outcomes in schizophrenia) has been found to be more common in patients with
z o
ventricular enlargement .
Andreasen and colleagues adopted an 'enlargement versus no enlargement' design in
their 1982 study of clinical correlates of structural brain abnormalities. They
reported poorer cognitive performance, greater incidence of negative symptoms and
lower frequency of positive symptoms in the patients with ventricular enlargement21.
These findings have subsequently been replicated on a number of occassions19,69,70.
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The association between ventricular enlargement and impaired cognitive
performance was, of course, first identified by Johnstone and colleagues2 and is
arguably the single most robust finding in the field18'34. However, correlations
between accepted clinical sub-types and specific structural brain changes have not
been forthcoming. For example, an early CT study suggesting that schizophrenic
patients with ventricular enlargement are more likely to show the paranoid subtype
and less likely to show the hebephrenic subtype than are patients with normal
ventricles has not been replicated71.
If schizophrenic patients with significant ventricular enlargement are indeed
suffering from a biologically distinct illness from those with normal ventricles, one
would expect this to be reflected in differences in the risk factor and gender profiles
of the two groups72. As discussed previously, there is considerable evidence to
support the notion that ventricular enlargement is a more common finding amongst
male schizophrenics than amongst females7'24. There is also evidence to suggest that
schizophrenic patients with no family history of psychosis have larger cerebral
ventricles than patients with a known genetic predisposition for the disorder30. If one
accepts this finding, then one might expect ventricular enlargement to be positively
73associated with recognised non-genetic risk factors such as winter birth . The
available research evidence does indeed support the notion that ventricular
enlargement is more common amongst schizophrenics born in winter74.
Potentially the most powerful source of evidence in support of the 'different
diseases' theory is molecular genetics. The ultimate aim of this type of research is
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the identification of a single gene mutation that is responsible for several cases of
schizophrenia within one extended family. This could, hypothetically, lead to the
construction of a comprehensive explanatory model of the precise molecular
mechanism responsible for the signs and symptoms of schizophrenia in those
individuals. Strictly speaking any person with schizophrenia who did not share the
mutation could be viewed as suffering from a different disease (in the sense that the
pathological process is likely to be different at the molecular level). A variety of
research strategies have been employed in the attempt to narrow down the search for
a 'schizophrenia gene'. These include genetic linkage studies, association studies
and 'candidate gene' approaches. Although this extensive field of research is beyond
the scope of this thesis, it is probably not unreasonable to say that molecular genetic
studies in psychosis have proved disappointing to date. Despite many promising
preliminary findings, no positive linkage or association result has been satisfactorily
replicated. This has not prevented researchers from exploring relationships between
apparent linkage markers and structural imaging findings. For example Shihabuddin
and colleagues in New York report that a linkage marker they identified on the short
arm of chromosome 5 (5p 14.1-13.1) is associated with increased VBR and increased
fronto-parietal atrophy even in the absence of symptoms75 (at least within the
pedigree under study).
One 'fly in the ointment' for supporters of the 'different diseases' model is the
finding that abnormalities of macroscopic brain structure in schizophrenia follow a
unimodal distribution. The aforementioned analysis of VBR by David Daniel and
colleagues52 has recently been replicated in the form of a 'distribution analysis'
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conducted by an Italian group76. These analyses demonstrate that any division of
schizophrenic subjects into those with ventricular enlargement and those without is
arbitrary. However, whilst a unimodal distribution may not be consistent with a 'two
different diseases' model, it is consistent with a 'several different diseases' model
provided one assumes considerable overlap between the different processes in terms
of associated structural brain changes.
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Conclusions
In this chapter the author has attempted to provide an overview of the current state of
knowledge in the field of structural brain imaging in schizophrenia. He has also
attempted to illustrate how findings from structural imaging research have informed
the debate about the nature of the pathological process underlying schizophrenia.
The most important conclusion to be drawn from the structural imaging literature is
that schizophrenia is associated with structural brain abnormalities. It is indisputable
that the ventricles are enlarged and that brain volume is reduced. However, these
finding are not specific to schizophrenia and are not present in all cases. As a group,
schizophrenic women may show lesser structural brain abnormalities than do
schizophrenic men. The magnitude of the abnormalities is, to some extent,
dependent upon how one defines schizophrenia. The reductions in brain volume are
probably attributable to reductions in grey more than white matter and certain
regions of the brain (e.g. medial temporal lobe structures) appear to be
disproportionately affected. Most of the structural abnormalities are apparent by the
time the diagnosis is made (during the first psychotic episode) but some may then
progress. Precisely what happens to brain structure as the patient is becoming unwell
remains a mystery.
All of the findings outlined above relate to group differences between populations of
patients with schizophrenia and 'normal' control populations. Just as there is
considerable individual variation in the symptoms and course of schizophrenia, so
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there is considerable individual variation in structural imaging findings. Structural
imaging research has contributed to but has not resolved the debate surrounding the
construct validity of Kraepelin's concept (see chapter IB).
It seems increasingly unlikely that a "single necessary and sufficient causative
agent"77 will be found that will allow schizophrenia to sit comfortably within the
nineteenth century 'medical model' concept of a 'disease entity'. However, the
concept of 'disease' has evolved since Virkow's time. The nineteenth century view
of 'disease entities' defined by specific pathological lesions has been superseded by
the concept of diseases as "states incurring biological disadvantage"78.
Pathognomonic disease markers are no longer required to justify a diagnostic
category. Evidence of statistical difference from the norm is sufficient to lend
validity to a diagnostic concept. The clinical validity of a concept is therefore not
dependent upon the demonstration of a common underlying pathology shared by all
patients with the diagnosis. Viewed from this perspective, the current diagnostic
category of'schizophrenia' has convincing clinical validity.
However, from the perspective of biological researchers working within the medical
model, the limited scientific validity of the concept remains an important issue.
Within the scientific community, the debate about whether all schizophrenic patients
share a common underlying pathology continues. Lynn DeLisi refers to the
"splitters" and the "lumpers"79. Although the arguments on either side of this debate
have been explored in the previous section, in practice many of the differences boil
down to semantics. For example, it is impossible to determine at what point "a
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complex and varied pathological mechanism incorporating a number of different
processes" becomes "a number of different pathologies". This debate, which has
been running more or less continuously since at least 1920 when Kraepelin
acknowledged "other illnesses may assume schizophrenic forms"80, is unlikely to be
resolved in the immediate future. For contemporary schizophrenia researchers, the
most productive way forward is likely to involve acknowledging the limitations of
schizophrenia as a scientific construct and working within those limitations.
Whilst the argument about whether schizophrenia is a single, heterogeneous disease
or a collection of different diseases is intellectually stimulating, the practical issue of
how best to advance our understanding of the condition should remain pre-eminent.
Three strategies available to structural imaging researchers employed on this task are
described in the next chapter. In section 2 of this thesis the author present three
studies illustrating each of these strategies in turn.
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IE. Methodological Considerations in Structural Brain Imaging
Introduction
In the previous chapter the structural brain imaging literature relating to
schizophrenia was reviewed and the current state of knowledge summarised. In this
chapter various strategies available to structural brain imaging researchers hoping to
advance our understanding of the disorder are discussed. The approaches presented
by the author fall into three broad categories:
(1) Imaginative clinical study design employing carefully selected sub-groups from
within the schizophrenic population
(2) Adoption of newly developed approaches to MRI data analysis
(3) Utilisation of novel structural imaging techniques
Some of the techniques discussed in this chapter represent the 'cutting edge' of
structural imaging methodology. However, it is important to resist the temptation to
employ novel techniques simply for the sake of it, (the so-called 'fallacy of facility').
Technological advances are only useful if they address a weakness in existing
methods. As the previous chapter demonstrates, a number of fundamental questions
relating to macroscopic brain structure in schizophrenia remain unanswered. Whilst
there is probably no harm in schizophrenia researchers familiarising themselves with
new imaging methods, this should not be at the expense of conventional imaging
studies. We must not try to run before we can walk. The field is crying out for large,
robustly designed and meticulously conducted studies aimed at answering
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fundamental questions (such as the Edinburgh High Risk Study, described in chapter
ID). However, there is also room for small studies addressing specific research
questions through imaginative design. This approach will be discussed first.
158
Imaginative clinical study designs
In chapter IB, the clinical and aetiological heterogeneity that characterise
schizophrenia are discussed. In chapter ID, the apparent inconsistencies amongst
structural brain imaging findings associated with the disorder are described. The
high degree of disparity shown by individual patients presents a challenge to those
wishing to develop an explanatory model applicable in all cases of schizophrenia.
Indeed, it represents a challenge to anyone wishing to conduct research into the
disorder. When adopting a straightforward 'schizophrenic cases versus controls'
design, the within-group variability can reduce the between-group differences.
However, individual differences may also provide clues about the complex pathology
underlying schizophrenia. The key is to employ imaginative study design that may
shed light upon the mechanisms underlying the clinical and aetiological
heterogeneity. In chapter 2A the author illustrates this approach through the
presentation of one of his own studies, which aims to identify those aspects of brain
structure that represent endophenotypic markers for schizophrenia.
Exploring Clinical Heterogeneity
Symptoms
The most obvious form of clinical heterogeneity in schizophrenia occurs at the level
of symptoms. Kraepelin combined a number of different clinical syndromes to
produce 'dementia praecox'1. Bleuler talked not of 'schizophrenia' but of 'the group
of schizophrenias'2. Modern classifications subdivide schizophrenia in accordance
with the predominant symptoms3'4. However, attempts to identify reliable
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associations between specific symptoms (or symptom clusters) and specific structural
imaging findings have, to date, proved unsuccessful (see chapter ID). It could be
argued that this reflects the problem at the heart of schizophrenia research - that
symptoms are too far removed from the underlying cause to allow pathological
conclusions to be drawn from clinical observations.
Measures ofbrain function
One possible strategy for overcoming this problem would involve the identification
of reliable phenotypic variants within the schizophrenic population, which are
'closer' to the underlying brain pathology than are symptoms. Electrophysiological
research has been moderately successful in this regard. Reduced amplitude and
increased latency of P300 auditory evoked potentials5 and deficit of inhibition of
involuntary saccadic eye movements6 are neurophysiological markers with a
reasonable degree of specificity for schizophrenia, although neither is present in all
cases. To date, there is a small but fairly consistent body of evidence linking
abnormalities of event-related potentials to structural abnormalities of the medial
temporal lobe7. However, electrophysiology is likely to be superseded in this regard
by functional magnetic resonance imaging (fMRI)8 and magnetoencephalography
(MEG)9 both of which offer superior spatial and temporal resolution and greater
flexibility.
Although functional imaging is beyond the scope of this thesis, it is inevitable that
findings from fMRI and MEG will inform future structural imaging research. One
possible route is through the sub-division of the schizophrenic population according
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to phenotypes determined by neurophysiological measures. For example, the
disconnection hypothesis (see chapter 1C) could be examined by comparing volumes
of medial temporal lobe structures in schizophrenics with and without
'hypofrontality'. Daniel Weinberger and colleagues report a high degree of
correlation between reduced hippocampal volume and reduced cerebral blood flow
(measured using PET) in the dorsolateral prefrontal cortex in schizophrenic twins
from discordant monozygotic twin pairs10 (a result interpreted as being powerfully
supportive of the disconnection hypothesis). This finding demonstrates a clear link
between structural and functional brain abnormalities in schizophrenia. However, it
also invites questions about the nature of the relationship. For example, do the
volume reductions arise as a result of 'disuse atrophy' or is the abnormal function a
consequence of pre-existing structural abnormality? The potential for combining
structural imaging with measures of brain function is enormous and is likely to be
facilitated by the development of voxel-based methods of analysis of structural
imaging data (as described below). As with any productive area of research, studies
of this design are likely to generate as many questions as answers.
Relapse and remission
As discussed above, the relationship between macroscopic changes in brain structure,
abnormalities of brain function and symptoms is poorly understood. Given that in a
substantial proportion of cases, schizophrenia is a relapsing and remitting illness, it
would seem logical to design a study around the changes that presumably occur
during the relapse-recovery cycle. For example, one might conduct a cohort study in
which patients were scanned when they were well, during an episode of illness and
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again once they had recovered. By using a patient's own scans as the comparator,
many of the problems associated with individual variation would be circumvented.
Such a design could be seen as taking full advantage of the safe repeatability that
differentiates MRI from X-ray based imaging techniques.
Course
The modern operational definitions of schizophrenia3'4, designed to maximise
reliability of diagnosis, adopt an essentially Schneiderian approach with a relatively
narrow focus upon psychotic phenomenology rather than taking into account the
"total clinical picture"1 as Kraepelin advocated (see Chapter IB). Kraepelin believed
that course was at least as important as symptoms. However, the clinical
heterogeneity that characterises the symptoms of schizophrenia is echoed in the
variability apparent in the course of the illness11. A number of structural imaging
studies have (inadvertently) explored this heterogeneity by comparing chronic cases
with first episode cases (see chapter ID). However, the primary aim of these studies
has been to look for evidence of progression through a cross-sectional study design.
The fact that first episode cases differ significantly from chronic cases in terms of
course (in that many will ultimately recover or follow a relapsing/remitting rather
than a chronic course) is seen as a confounder. It would surely be more constructive
to view variation in course as an interesting clinical feature worthy of study in its
own right. The optimal study design would involve a large cohort of subjects
recruited during the first episode and followed-up at regular intervals for several
years (or even decades). The null hypothesis would be that differences in course are
not reflected in differences in macroscopic brain structure at presentation. The Stony
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Brook First Episode Study12 (see chapter ID) is arguably the closest to this design in
the current literature. However, with only 50 subjects followed-up for only 4 years it
lacks the statistical power required to draw meaningful conclusions about structural
correlates of variations in clinical course.
One facet of the variable course of schizophrenia that has been examined by
structural imaging is age of onset. Late onset schizophrenia ('paraphrenia') presents
a challenge to neurodevelopmental theories of the disorder, which explain the latency
between presumed neurodevelopmental insult and onset of symptoms in terms of
brain maturation (see chapter 1C). To date, surprisingly few structural imaging
studies of this interesting sub-group of patients have been published and findings are
inconsistent13'14. Far more studies of early onset schizophrenia have been published
and there is some evidence of progression of structural brain abnormalities in
children and adolescents15.
Treatment response
The final component of clinical heterogeneity that merits consideration is variability
of response to treatment. As discussed in chapter ID, the research examining the
relationship between response to conventional antipsychotic drugs and abnormalities
of brain structure is inconclusive. The only meta-analysis in the field finds a weak
positive correlation between increased ventricular size and treatment resistance16.
However, most of the studies use CT and it is possible that MRI would reveal
regional effects not detected by CT (particularly if analysed using VBM, see below).
There is currently only a small amount of (conflicting) evidence relating to
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Clozapine ' . It is possible that the differences between clozapine responders and
non-responders may reveal information about the pathological process(es) that lead
to symptoms. Also, changes in brain structure in response to medication (such as the
increase in basal ganglia volume associated with conventional antipsychotics, see
chapter 1D) may be informative. As new treatments are developed, so new research
opportunities of this type will arise. In return, structural imaging findings may
ultimately have a role to play in informing future prescribing decisions.
Exploring Heterogeneity ofRisk Factors
One of the most striking features of schizophrenia is the variety of factors that have
been identified as conveying an increased risk for the disorder (see chapters IB and
1C). The strength of the 'neurodevelopmental hypothesis' (see chapter 1C) stems
partly from its compatibility with these "curious epiphenomena"19. An appreciation
of the mechanisms through which particular risk factors convey increased
susceptibility for the condition would contribute directly to our understanding of the
pathological process(es) within the schizophrenic brain.
Perhaps the most direct approach to this question is the comparison of patients with a
particular risk factor against those without. Studies of this design, relating to family
history of psychosis, winter birth and obstetric complications (including prematurity,
intra-uterine growth retardation, prolonged labour etc.) have all been published (see
chapter 1D). Whilst this is undoubtedly a hypothetically powerful design, in practice
it can be difficult to establish the presence or absence of a given risk factor with the
required degree of certainty (this is particularly true of family history where verbal
164
accounts are notoriously unreliable). It is also impossible to control perfectly for all
other relevant variables. One way around this problem is to quantify each subject's
exposure to every potential risk factor and then analyse the entire data-set with a
statistical technique such as 'regression analysis'. This produces an estimate of the
proportion of variance in a particular measurement (e.g. the volume of a particular
brain structure) that is accounted for by differences in the level of exposure to a
particular risk factor (e.g. family history of psychosis). Depending upon the
statistical model employed, it may also be possible to identify interactions between
different risk factors. This type of statistical approach relies upon large data sets
(e.g. regression analysis requires a minimum of ten subjects per variable). For
reliable conclusions to be drawn about interactions between risk factors, the numbers
required can be enormous. Schizophrenia research, and imaging research in
particular, is not renowned for large studies. There is a powerful argument for the
introduction of large multi-centre studies to address fundamental aetiological
questions relating to the disorder.
The role of risk factors can also be investigated from the opposite direction. Cases
and controls matched precisely for the risk factor are compared, any differences are
presumed not to be attributable to the risk factor. The archetype for this design is the
study of discordant monozygotic twin pairs. However, monozygotic twins
discordant for schizophrenia are rare. Recruiting sufficient numbers to allow
meaningful interpretation of results is a monumental task. To date, only a handful of
such cohorts have been assembled. The first structural brain imaging study of this
type (Reveley et al. 1982) involved 7 twin pairs and revealed increased lateral
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ventricular size in the affected twin20. In the 1980s, Fuller Torrey recruited 15 sets of
twins from across North America. On structural MRI, the affected individuals were
found to have larger ventricles and sulcii (12/15) and smaller hippocampii (14/15)
than their unaffected twins21. These findings have recently been replicated by a
Dutch group22. A further 7 twin pairs have subsequently been added to the Fuller
Torrey cohort and analysis of the imaging and obstetric-history data suggests an
association between structural brain abnormalities and birth complications
(prolonged or traumatic labour)23. (This body of research is discussed in greater
detail in Chapter 2A.)
Another research design that is particularly pertinent to conditions, such as
schizophrenia, in which gene-environment interactions are implicated involves the
study of 'obligate carriers'. This design (discussed and illustrated in chapter 2A)
allows the effects attributable to high genetic risk to be separated from those
attributable to illness per-se. As with studies involving monozygotic twins, the rarity
of obligate carriers represents a significant obstacle to researchers wishing to adopt
this design.
Exploring Co-Morbidity
A small group of individuals have the misfortune to suffer from both schizophrenia
and some other brain disorder. A number of studies have focussed upon such
patients in the hope that knowledge of the pathological processes responsible for the
co-morbid condition can in some way be extrapolated to schizophrenia.
Unfortunately there are a number of problems with this approach. First, the number
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of subjects is often small (reflected by the preponderance of single case reports in
this literature). Second, there is often as much ignorance surrounding the pathology
of the co-morbid condition (e.g. 'socio-culturar learning disability) as there is
surrounding the pathology of schizophrenia. Third, the clinical diagnosis of
schizophrenia can be very difficult in the presence of another disorder characterised
by abnormalities of behaviour and cognition (e.g. pervasive developmental disorders
such as autism).
However, these problems may not be insurmountable. For example, velo-cardio-
facial syndrome (VCFS) is a complex congenital condition strongly associated with
early onset schizophrenia24. The pathology is understood to result from a
microdeletion in the qll band of chromosome 22. Recent structural brain imaging
studies of VCFS reveal reductions in whole brain volume with differential reductions
in the hippocampus and superior temporal gyrus . Work on VCFS has already
informed genetic research into schizophrenia. It is not inconceivable that knowledge
acquired from studies of this carefully selected (and in many ways unrepresentative)
sub-group of patients will be of value to other schizophrenia researchers including
those involved in structural imaging. On a similar theme, studies of schizophrenic
subjects with gross structural brain abnormalities of developmental origin (thalamic
adhesions, hippocampal fissures, lateral ventricular septae etc.) may be generally
informative to structural imaging researchers.
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New approaches to MRI data analysis
The development of structural brain imaging from pneumoencephalography through
early X-ray CT scanning to modern MRI is described in Chapter 1C. As with any
technology-based field, advances have been both evolutionary (the gradual
refinement of existing methods) and revolutionary (the introduction of new, radically
different techniques). In this section the author considers a number of recently
developed approaches to MRI data analysis that may have an impact upon structural
brain imaging research in the near future. In chapter 2B the author presents one of
his own studies employing voxel-based morphometry (VBM).
Advances in the technical specification ofMRI scanners appear with each successive
generation. For example, whilst early scanners generated a magnetic field strength
of around 0.5Tesla, the typical modem scanner is rated at 1.5T with strengths of 3T
and above available (although very high field strengths introduce technical problems
that need to be overcome e.g. high specific absorbtion rates due to induced fields).
The quality of the raw imaging data available to researchers continues to improve in
terms of tissue discrimination and spatial resolution. Meanwhile the time taken to
acquire images is being steadily reduced. However, the main advances pertinent to
schizophrenia research relate as much to how the data are analysed as to the quality
of the data.
The methods of analysis traditionally used in structural MRI (such as VBR and ROI)
are essentially evolutions of those used in CT and conventional X-ray radiography.
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They rely upon information obtained from individual brain slices (or a series of
slices) to calculate the length, area, or volume of particular brain structures.
However, the ability of MRI systems to reassemble thin slices into a three-
dimensional representation of the brain is now being exploited. For example, the
notion of quantifying gyrification, traditionally associated with phylogenetics, has
recently been introduced into in-vivo imaging. The 'gyrification index' (GI) is
calculated by measuring the total length of the gyri within the cerebral cortex and
dividing this by the total cortical surface area. The resultant number gives an
indication of the extent of convolution of the gyri. Schizophrenia has been found to
be associated with reductions in GI26. Given that gyrification is primarily an in-utero
neurodevelopmental process, this finding is interpreted as supportive of the
neurodevelopmental hypothesis. Another method that uses the three-dimensional
information obtained by MRI is 'shape analysis'. This is a collective term embracing
a number of techniques based upon comparisons of the curvature or asymmetry of
various brain structures. For example, the shape of the corpus callosum has been
demonstrated to be abnormal in schizophenia27.
In contrast to structural MRI, the methods of analysis used in functional MRI are
evolutions of those used in PET and nuclear medicine. They therefore tend to be
computational and based upon comparisons between individual data points (as
opposed to measurements obtained from two-dimensional representations). In recent
years this type of data analysis has been introduced into structural imaging. Three
different computational methods are currently available: voxel-based morphometry
28 29
(VBM) ; deformation-based morphometry (DBM) ; and tensor-based morphometry
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(TBM)30. VBM is the most widely used and is described and illustrated in chapter
2B. VBM uses statistical parametric mapping (SPM) (widely used in functional
imaging research) to build up brain maps of statistical probabilities. In the case of
VBM, the probabilities relate to differences in grey matter density either between
two groups or between the study group and a 'normal' template. The process
involves comparison of neuroanatomical differences on a voxel-by-voxel basis (this
is discussed in greater detail in Chapter 2B). DBM provides information about
global differences in brain shape, whilst TBM provides information about local
shape differences. One of the main advantages of VBM over the other
computational techniques is that it requires less computer-processing power. It can
be performed reasonably quickly on conventional workstations.
Whilst computational methods may potentially revolutionise the way in which
structural imaging data is analysed for research purposes, there remains considerable
scope for evolutionary improvement of the conventional ROI approach. In the
review of the literature presented in chapter ID, the author argues that variations in
the way in which ROI results are presented make it difficult to compare different
studies directly. This is especially true of the medial temporal lobe structures that are
of particular interest to schizophrenia researchers. These problems arise partly
through the difficulties inherent in reliably identifying anatomical boundaries
between relatively small, contiguous structures with complex three-dimensional
shapes. There is a powerful argument for standardisation of ROI methodology in
schizophrenia research and a number of groups have presented semi or fully
automated parcellation methods designed to overcome these difficulties31'32.
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Novel structural imaging techniques
X-rays are X-rays. Whilst radiographers can alter the exposure time, the strength of
the beam, the direction of the beam, the spread of the beam and even the means of
detection, they can not alter the physical characteristics of the individual photons that
constitute X-rays. By contrast, the production (and subsequent detection) of
variations in the phase and frequency of radio waves that forms the basis ofmagnetic
resonance imaging is an active and pliable process. In the hands of a skilled and
ingenious operator, an MRI scanner can perform an impressively diverse array of
imaging tasks. In chapter 2C the author illustrates the challenges inherent in
adopting novel imaging techniques through the presentation of a proton magnetic
resonance spectroscopy ('H-MRS) and diffusion tensor imaging (DTI) study that he
conducted with considerable help from colleagues at the Department of Medical
Physics, University ofEdinburgh.
As discussed in chapter 1C, magnetic resonance spectroscopy (MRS) predates
magnetic resonance imaging (MRI) by some 30 years but it is only in the past decade
that MRS has been commonly used as a tool in schizophrenia research. MRS allows
the direct measurement of concentrations of particular chemicals in the brain in-vivo
(see chapter 2C). Generally it is used in conjunction with other structural or
functional imaging techniques (in the study described in chapter 2C it is used in
conjunction with DTI). Early MRS studies used Phosphorus-31 (or occasionally
Lithium-7 or Fluorine-19), however, the vast majority of recent studies relate to
Hydrogen-133. The most consistent finding is of a focal reduction in N-Acetyl
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Aspartate (NAA) in the frontal and temporal lobes34 and in the dorsolateral prefrontal
cortex in particular35.
Diffusion tensor imaging (DTI) is a relatively new MRI technique. It relies upon the
measurement of the rate of diffusion of water molecules in different directions to
produce a 'tensor' containing three-dimensional information. The deviation from
isotropic diffusion ('anisotropy') described by this tensor reflects local
cytoarchitechture (see chapter 2C). DTI is potentially valuable to schizophrenia
researchers as it allows quantitative analysis of intra-cerebral white matter tracts and
hence provides a means for examining structural correlates of functional connectivity
within the brain. It therefore allows structural imaging researchers to contribute to
the debate surrounding the 'disconnection hypothesis' (see chapter 1C). Only a
handful ofDTI studies in schizophrenia have been published to date and the findings
are inconsistent36. However, there is some evidence for reduced anisotropy in the
corpus callosum37 and the arcuate fasiculus38.
Arguably the most important new MRI techniques for schizophrenia research are
those that examine brain function rather than brain structure. Although functional
imaging is beyond the scope of this thesis, the author has alluded to it on a number of
occasions. The primary goal of functional neuroimaging is to provide a clear map of
neuronal activation or deactivation in the brain associated with a given mental
operation. A number of techniques achieve this goal, however, the vast majority of
fMRI studies in schizophrenia employ 'blood oxygen level dependent contrast'
(BOLD). This technique relies upon the relative concentration of oxygenated and
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de-oxygenated haemoglobin (although the signal is also influenced by changes in
blood flow and blood volume). Neuronal activity within a particular brain region
results in an increase in regional cerebral metabolism, which in turn produces an
increase in perfusion. Over-compensation results in a decrease in the ratio of
deoxyhaemoglobin to oxyhaemoglibin, which is reflected in an increase in the
BOLD signal . The author will not attempt to review the fMRI literature in
schizophrenia. Suffice to say this technique has provided powerful evidence for
abnormalities in neuronal activation in schizophrenia in response to a wide range of
cognitive39 and motor40 tasks (usually in association with poor performance). It has
also helped to identify biological correlates of specific psychotic symptoms41'4 and
demonstrated changes in patterns of neuronal activation attributable to antipsychotic
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Structural Magnetic Resonance Imaging (MRI) in Obligate Carriers
of Genes for Schizophrenia, their Affected and Unaffected Siblings
This study illustrates the use of imaginative study design employing a carefully
selected sub-group from within the schizophrenic population.
2B. Study 2
Voxel Based Morphometry (VBM) and Region of Interest (ROI) Analysis
of the Genotypic and Phenotypic Neuroanatomy of Schizophrenia
This study illustrates and explores the likely impact of a recenly developed
computational approach to MRI data analysis.
2C. Study 3
Diffusion Tensor Imaging (DTI) and Proton Magnetic Resonance
Spectroscopy ('H-MRS) in Schizophrenics and Normal Controls
This study illustrates the challenges inherent in the adoption of novel structural
imaging techniques in schizophrenia research.
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2A: Study 1
Structural Magnetic Resonance Imaging (MRI) of the Brain in Presumed
Carriers of Gene(s) for Schizophrenia, their Affected and Unaffected Siblings
N.B. The study described in this chapter has been published. A reprint of the
following paper is enclosed in a pocket attached to the inside of the back
cover of this thesis.
Steel R.M., Whalley H.C., Miller P., Best J.J.K., Johnstone E.C. &
Lawrie S.M. 2002. "Structural MRI of the brain in presumed carriers of
genes for schizophrenia, their affected and unaffected siblings."
Journal of Neurology, Neurosurgery and Psychiatry 72(4):455-458.
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Background, Aim & Hypothesis
As discussed in chapter ID, there is overwhelming evidence indicating that
schizophrenia is associated with macroscopic structural brain abnormalities. The
most consistently identified abnormalities include reduced whole brain volume and
increased lateral ventricle volume. The balance of evidence supports the notion of
differential volume reductions of the temporal lobes and, in particular, medial
temporal lobe structures such as the amygdala, hippocampus and parahippocampus.
It is not known for certain when these abnormalities arise: however, they have been
consistently identified in patients during their first episode of illness. The pre¬
eminent contemporary theory, the 'neurodevelopmental hypothesis' proposes that
they arise as a result of abnormal brain development (see chapter 1C).
A substantial minority of cases of schizophrenia are familial. First degree relatives
of schizophrenic patients have a morbid risk of developing schizophrenia which is
6 7
approximately ten times higher than in the general population ' . The
epidemiological evidence from adoption studies suggests that this familiality is
O Q
primarily attributable to genetic rather than environmental factors ' . The results of
twin studies provide incontrovertible evidence for the role of both genetic and non-
genetic ('environmental') factors in the aetiology of schizophrenia. The role of
genetic factors is demonstrated by the substantially higher proband-wise concordance
13
rates between monozygotic twins than between dizygotic twins (46% versus 14%) .
Meanwhile, the role of environmental factors is evident in the far from absolute
concordance within monozygotic twin pairs - the monozygotic twin of a patient with
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schizophrenia is more likely to be well (54%) than to suffer from the condition
(46%)13.
The aim of this study is to examine the relationship between genetic risk for
schizophrenia and the abnormalities of brain structure associated with the condition.
Central to the study design are individuals who have apparently transmitted
schizophrenia from an affected parent to one or more affected children whilst
remaining well themselves (see figure 2Ai). These individuals are considered to
represent an unexpressed ('non-penetrant') genotype akin to unaffected monozygotic
twins from discordant twin pairs. (Studies of the offspring of discordant
monozygotic twin pairs reveal that children of both the affected and the unaffected
twin share the same increased risk of developing schizophrenia14 indicating that the
genetic risk is present but not expressed in the unaffected twin). The authors have
followed the example set by the Maudsley Family Study [Sharma et al. 1997] in
using the term 'obligate carrier' to describe these individuals. The term 'obligate
carrier' comes from Mendelian genetics where it is defined as "an individual who
may be clinically unaffected but who must carry a gene mutation based on analysis
of the family history" [NIH, 2003], Although the term 'obligate' is borrowed from
Mendelian genetics, the study design is not dependent upon a simple Mendelian
single gene 'all-or-none' pattern of inheritance. Even if one assumes a complex,
polygenic mode of inheritance (as the literature relating to genetics of schizophrenia
suggests), the 'obligates' design remains valid because collectively 'obligates' carry
a greater proportion of the genetic burden for the condition than do their unaffected
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siblings with unaffected adult children (termed 'non-affected non-carriers' in this
study).
The traditional methods of genetic research are 'linkage' and 'association'. Genetic
linkage assesses the proximity between a given locus and a disease gene by
estimating the frequency of separation between them at meiosis (termed
'independent segregation'). This method requires DNA samples from many affected
and unaffected members of a multiply affected family. The precise polymorphisms
in the linked locus can be different for each family (i.e. there may be linkage to a
locus but no association with any particular allele - this is true of many linkage
studies in schizophrenia [McGuffin et al., 2003]). For association, it is necessary to
demonstrate that a specific allele at a polymorphic 'marker' locus segregates with the
disease in many different families. This method requires DNA samples from a large
number of affected individuals (from many different families) and from
representatives of the general population from which the affected individuals are
drawn. These methods have proved highly effective in identifying the genetic basis
of rare inherited disorders caused by major single gene effects. However, the genes
responsible for familial cases of schizophrenia have proved difficult to locate and
identify10'1 ''12. Single genes conveying major risk for the disorder appear to be either
rare or nonexistent [Tsuang et al., 1999], Patterns of inheritance within multiply
affected families are not easily explained by the single major gene model, the data
have been shown to fit a multi-factorial, polygenic model far better [Gottesman
1991], The consensus of opinion amongst contemporary genetic researchers is that
genetic liability for schizophrenia almost certainly results from the combined effects
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of multiple susceptibility loci interacting with environmental factors [Tsuang et al.,
2001; McGuffin et al., 2003].
Despite relatively small effect sizes, many positive family based linkage studies have
been published with reasonably consistent findings emerging on chromosomes 1, 6,
8, 11, 13, 15 and 22 [Seidman & Wencel, 2003]. A recent meta-analysis of the
literature highlights statistically robust linkage with loci at 8p, 13q and 22q [Badner
& Gershon, 2002],
Whilst the effect of each susceptibility gene may be too small to facilitate estimation
of risk at either the population or individual level, an understanding of the
biochemical pathways through which a gene conveys increased risk may provide
insights into the molecular mechanisms underlying the illness. Experience from
research into Alzheimer's disease provides an encouraging precedent: The
identification of mutations in the P-amyloid precursor and presenilin genes in
families at increased risk of Alzheimer's disease together with the discovery of a
more general genetic susceptibility variant, Apo E4, has led to an understanding of
the central role played by aberrant P-amyloid metabolism in the neuropathology of
this relatively common disorder and serious attempts to link these susceptibility
factors in common biochemical pathways [Sisodia & St George-Hyslop, 2002;
Morishima-Kawashima & Ihara, 2001]. A number of recent studies have hinted at
possible links between susceptibility loci and neuropathology in schizophrenia.
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The Icelandic deCODE Genetics group refined the previously identified region of
linkage within the short arm of chromosome 8 to a number of single nucleotide
polymorphisms (SNPs) within the neuroregulin 1 (NRG1) gene, the core haplotype
conveying a two fold risk for schizophrenia [Stefansson et ah, 2002], The same
group has subsequently replicated this finding in a separate (Scottish) population
[Stefansson et ah, 2003]. The suggested association between variations in NRG1 and
schizophrenia carries an attractive neurobiological plausibility - neuroregulin is
understood to play an important role in neurodevelopment, promoting neuronal
migration and cellular differentiation [Buonanno & Fischbach, 2001].
The susceptibility locus on the long arm of chromosome 22 has attracted the interest
of a number of research groups not least because of the established association
between microdeletions in this region and velocardiofacialsyndrome (see chapter
IE). Liu and colleagues reported associations between SMPs in the proline
dehydrogenase (PRODH) gene and schizophrenia [Liu et ah, 2002], Shifinan and
colleagues found associations between SMPs in the gene coding for catechol-O-
methyltransferase (COMT) and schizophrenia [Shifman et ah, 2002], This finding is
particularly exciting as COMT is known to act directly upon monoaminergic
neurotransmission and a polymorphism within the gene (Val 108/158 Met) has been
found to have an effect upon prefrontal cognitive function [Egan et ah, 2001].
Daniel Weinberger has described the COMT story as "describing the first plausible
mechanism of genetic susceptibility for a mental illness" [Weinberger, 2002],
However, a recent meta-analysis of the COMT literature published by a group from
Harvard suggests that the evidence for linkage is "modest" and that the evidence
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from association studies is weak and may apply only to European populations [Glatt
et al., 2003],
Whilst the role of polymorphisms in the COMT gene in the genesis of schizophrenia
requires further clarification, the COMT literature provides an illustration of the way
in which intermediate biological phenotypes may help to bridge the gap between
genes and symptoms. As Daniel Weinberger observes, "biological effects at the
level of cell and neural system function are far removed in biological space and time
from the clinical psychopharmacology of schizophrenia and from phenotype at the
level of clinical diagnosis" [Weinberger, 2002]. The reasonably reliable biological
markers of impaired prefrontal cognition and reduced prefrontal dopaminergic
transmission provide an endophenotype linking the COMT val allele to
schizophrenia. The study in this chapter should be seen within this context. By
exploring the link between macroscopic brain structure and genetic risk for
schizophrenia, one ought to be able to identify those features of brain morphology
which represent an endophenotypic marker for the genes conveying susceptibility for
the disorder.
In this study volumetric data collected from obligate carriers are compared with data
from both their affected and non-affected non-carrier siblings: The hypothesis being
that structural brain abnormalities reflecting non-genetic factors will be apparent
only in the schizophrenic subjects, whilst those resulting from genetically-mediated
aetiological mechanisms (and therefore representing endophenotypic markers) will
be found in both the schizophrenic subjects and in their obligate siblings.
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Figure 2Ai. The study design can separate the effects of gene(s) from the
effects of illness.
INHERITED HIGH SHOWS SYMPTOMS
GENETIC RISK OF SCHIZOPHRENIA
AFFECTED SIBLING Yes Yes
OBLIGATE Yes No
UNAFFECTED SIBLING No No

















As described above, the study was designed to separate out the genetic risk for
schizophrenia from the illness itself. This involved recruiting specific sib-ships from
multiply affected families. Each sib-ship consisted of an obligate carrier, an affected
sibling, and a non-affected sibling with adult children without the disorder (and
therefore presumed to be a 'non-carrier'). Volumetric data from these three groups
was then compared (analysis described below). An anonymised example of an ideal
obligate family tree is shown above (see figure 2Aii).
Exclusion criteria reflected known risk factors for altered brain volume: age>65
years; alcohol dependence (past or present); dementia or other "organic" brain
disease; and any space-occupying intra-cranial lesion.
Families showing the ideal pattern of inheritance described in figure 2Aii are
obviously rare. Family trees relating to 255 multiply affected Scottish families
(originally identified for the Edinburgh High Risk Study15) were examined. Sixty
obligates were identified, 14 of whom had both an affected sibling and a non-
affected, non-carrier sibling. All fourteen families were contacted. Five families
were unsuitable as one or more of the siblings met the exclusion criteria listed above
(the majority of exclusions were due to age). Of the remaining nine families, three
did not wish or were unable to participate. Data were therefore obtained from six
sibling 'triples'. Five of the sib-ships were of the same sex (3 female, 2 male); the
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remaining family included a female patient and obligate and male non-carrier (who
was a twin with the patient).
Diagnosis
All subjects were interviewed using the Present State Examination (PSE)16 and the
Schedule for Affective Disorders and Schizophrenia - Life-Time version (SADS-
L)17. This allowed diagnoses obtained through reference to psychiatric records or
discussions with general practitioners to be confirmed or refuted. All six
schizophrenic siblings fulfilled DSM-IV criteria for schizophrenia. Three of the
obligates and three of the non-affected, non-carrier siblings fulfilled criteria for non-
psychotic psychiatric disorders (all were either depressive disorder or brief
depressive reaction, none was on psychotropic medication at the time of the scan).
Psychiatric hospital case notes were examined to confirm duration of illness and
current dose of antipsychotic medication. Diagnoses of schizophrenia in first degree
relatives were confirmed through reference to psychiatric records.
Personal Data
The interview incorporated questions relating to relationships, education,
employment, alcohol consumption, drug use, obstetric complications and childhood
illnesses (see Table 2Ai for details). Pre-morbid IQ was estimated using the National
Adult Reading Test (NART)18. There were no significant demographic differences
between the groups although the obligates were slightly older than their siblings. As
one might expect, the schizophrenic subjects were less likely to be in employment or
a relationship than their well siblings. Two of the schizophrenic subjects reported
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being told of complications surrounding their birth ("cord around my neck" and
"coma after delivery") as did two of the obligates (both forceps deliveries) and one
of the non-affected siblings ("unexpected twin, didn't breathe"). The only report of
significant childhood illness was of scarlet fever in one of the obligates.
Interestingly the obligates' IQs were on average 10-12 points higher than both their
schizophrenic and non-affected, non-carrier siblings' (although the difference was
not statistically significant: F=0.84, p=0.45).
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46.2 (7.4) 49.0 (4.8) 45.2 (7.7)
NART IQ
mean (sd)
95.6 (15.4) 107.4 (12.9) 97.3 (17.8)
Years in Education
mean (sd)
11.0 (0.9) 11.2 (2.4) 10.8 (1.6)
Current Employment:
no / part-time / full-time
3/2/1 0/1/5 1/1/4
Marital Status:




2/4 2/4 1 15
Childhood Illness:
yes / no




Duration of Illness in Years
mean (sd)
20.8 (9.9) N / A N/A
Antipsychotic Dose (mg/day
Chlorpromazine equivalent)
342 (256) None None
Current Symptoms:




The MRI examinations included a dual spin echo sequence to exclude any significant
brain lesions and a rapid volume acquisition sequence for volumetric data analysis.
Any coil inhomogeneities were corrected for by scanning a flood phantom
immediately after image acquisition and normalising to this prior to analysis.
Unfortunately, it was not possible to examine all the subjects on the same machine.
The first three sibling triples were scanned at the MRI Unit, City Hospital, Edinburgh
(before the Unit closed) on a 1 tesla Magnetom scanner (Siemens, Erlanger,
Germany) using a MPRAGE sequence , FOV 250mm, Flip angle 12°, TR=10 ms,
TE= 4 ms, TI = 200 ms, and relaxation delay 500 ms, giving 128 partitions 1.88 mm
thick. The remaining three triples were scanned at the Royal Infirmary, Edinburgh,
using a 1 tesla Signa scanner (General Electric Company, Milwaukee, USA) using a
SPGR sequence, FOV 250 mm, Flip angle 30°, TR = 16.4 ms, TE = 3.3 ms, RBW
8.93 KHz, giving 124 partitions 1.5 mm thick. Regions of interest were traced on a
slice-by-slice basis according to well-established criteria using the semi-automated
computer programme "ANALYZE" (Mayo Foundation, Rochester, MN). All data
were analysed by the same experienced rater (Heather Whalley, Department of
Psychiatry, University of Edinburgh) who was blind to group and has previously
demonstrated high inter- and intra-rater reliability15. Boundaries between brain
regions were determined by naturalistic boundaries in accordance with standard
19 20 21criteria ' ' . Volumetric data for the following brain regions was collected: whole
brain, third ventricle, fourth ventricle, right and left lateral ventricles, pre-frontal
lobes, temporal lobes, caudate nuclei, lentiform nuclei, thalamic nuclei and
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amygdalo-hippocampal complexes. Examples of the images used for volumetric
analysis are shown in figure 2Aiii.
Figure 2Aiii. Coronal MRI scans as used for volumetric analysis.
These images are from three siblings who participated in the






For the purposes of this thesis, the author felt it would be helpful to present two
distinct statistical analyses. The first is a reproduction of the intentionally
conservative and uncomplicated, 'original' analysis that was conducted for the
purposes of publication. The second is a more ambitious, 'exploratory' analysis
conducted primarily to facilitate comparison with the voxel-based morphometry
(VBM) analysis described in chapter 2B (see Figure 2Bi) but also to satisfy the
author's curiosity.
Original analysis
In order to reduce the number of statistical tests and thereby reduce the chance of
false positive findings, brain regions and sides were collapsed into the following
regions: cortical structures (incorporating pre-frontal and temporal lobes on both
right and left); sub-cortical structures (caudate, lentiform and thalamic nuclei);
amygdalo-hippocampal complexes; and intra-cerebral ventricular system (lateral,
third and fourth ventricles). The null hypothesis was that there would be no
difference between the three groups in terms of regional brain volumes. This was
tested by straightforward repeated measures analysis of variance with the volumes of
each collapsed region and whole brain volume entered as within-subjects factors. All
tests were two-tailed with a threshold ofp < 0.05 adopted for statistical significance.
Because each between-subjects factor within a repeated measures analysis of
variance removes one degree of freedom (and therefore reduces statistical power),
careful consideration was given to each potential confounder. It was felt that both
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'family' and 'scanner' could potentially produce significant effects that would
confound the main analysis. Both of these were therefore incorporated as between-
subjects factors. Age and sex were also considered, however the groups were so well
balanced for these variables that they were deemed unlikely to act as significant
confounders. Finally, consideration was given to the issue of correction for whole
brain volume. Because the central hypothesis was that reduced amygdalo-
hippocampal volume per se may represent an endophenotypic marker for
schizophrenia (rather than relative reduction of amygdalo-hippocampal volume), it
was decided not to correct for whole brain volume. The authors acknowledge that
this issue is open to debate - indeed both sides of the debate are evident in the
structural imaging literature.
Exploratory analysis
The second analysis was designed to resemble as closely as possible the voxel-by-
voxel comparisons that constitute VBM (see chapter 2B). Analysis of co-variance
(ANCOVA) was conducted on data from the four 'collapsed' regions and all 16
regions of interest. All potential confounders - age, sex, family, scanner and whole
brain volume were entered as co-variates. Three comparisons were carried out,
testing for differences in regional brain volumes: schizophrenic siblings versus
obligates (SZ v Obi); schizophrenic siblings versus non-affected non-carrier siblings
(SZ v NA); and obligates versus non-affected non-carrier siblings (Obi v NA). In
order to mimic the voxel-by-voxel probability map produced by VBM, the p-value of
each between-group comparison for each individual region of interest was noted (see
Table 2Aiii). A two-tailed threshold for statistical differences of /?<().05 was
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adopted. Because the primary aim of the analysis was to ape VBM using ANCOVA,
a number of statistical assumptions were made that would ordinarily be avoided. For
example, correction for multiple-comparison (e.g. by Bonferroni) was considered
over-conservative on the grounds that the confirmatory VBM analysis dealt with
uncorrected p values (see Chapter 2B). The results from this exploratory analysis
should therefore be treated with caution.
Power
The power of any study design is dependent upon sample size and the magnitude of
any predicted effect. The unique design of this study renders accurate prediction of
effect size problematic. There are no directly comparable data in the published
literature. The only previously published study comparing obligate carriers with
schizophrenic subjects and non-obligate relatives (the Maudsley Family Study
[Sharma et ah, 1998]) quotes effect sizes of 0.5-0.6 for differences in whole brain
and cortical grey matter volume. However, these effect sizes relate to data collected
from unmatched groups of relatives from sixteen different families rather than from
sibling triples. A number of small MRI studies have been published suggesting that
genetic factors account of over 70% of the individual variance in brain volumes
[Bartley et al., 1997; Pennington et ah, 2000], A recently published volumetric MRI
study of over 100 healthy twin pairs from the Netherlands found the heritability of
whole brain volume to be comparable to that of height (90% cf. 89%) [Baare et al.,
2001]. One would therefore expect the sibling triples design to markedly reduce
non-specific variation in regional brain volumes thereby increasing the predicted
effect size. The Maudsley Family Study does not quote data relating to the
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amygdalo-hippocampal complex (the region of greatest interest in this study).
Evidence from the literature suggests differential volume reductions in this region
associated with schizophrenia (approximately 6.5% cf. 3% for whole brain volume
[Lawrie & Abukmeil, 1998]). One might therefore anticipate a larger effect size for
comparisons relating to this region. Finally, in the original analysis (see above) data
from sixteen discrete brain structures are collapsed into four larger composite
regions. This is likely to further increase the predicted effect size. (In the event an
effect size of 3.3 for the reductions in amygdalo-hippocampal volumes in
schizophrenic subjects compared with non-affected non-carrier siblings was the
largest found in this study.)
With so many factors potentially influencing the effect size, any power calculation
would inevitably rest upon many assumptions. The authors felt that it would be
impossible to reduce subjectivity to the level where an accurate estimation of power
could be made. For this reason no formal power calculation was included in the




The mean volumes of each region of interest (and of the collapsed regions) for each
group are shown in Table 2Aii. The statistically significant differences identified by
this conservative analysis are also shown in Table 2Aii (the right hand column).
There were no statistically significant group by scanner interactions.
Differences between schizophrenic subjects and their non-affected, non-carrier
siblings were largely consistent with the existing literature (see Chapter ID). Whole
brain volume was significantly smaller in the schizophrenic subjects (by
approximately 5%), with a disproportionate reduction in the volume of the
amygdalo-hippocampal complexes (12%). The expected increase in ventricular
volume was, however, not found (see Table 2Aii).
In terms ofwhole brain volume and volumes of cortical structures, the obligates were
indistinguishable from their non-carrier siblings (and significantly larger than their
schizophrenic siblings). They also had significantly smaller ventricles than their
schizophrenic siblings. However, with respect to the amygdalo-hippocampal
complex, the obligates' brains did not differ significantly from their schizophrenic
siblings' (both groups showing a significant reduction in volume compared with the
non-affected, non-carriers).
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Table 2Aii. Volumes of Brain Regions by Group (expressed in cm3).
The collapsed regions used for the 'original' analysis
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Results of Exploratory Analysis
Comparing each region of interest individually whilst controlling for age, sex,
family, scanner and perhaps most notably, whole brain volume, produces some
interesting findings (see Table 2Aiii, which in essence equates to a VBM probability
map).
Schizophrenic siblings have significantly smaller temporal lobes and thalami than
their non-affected siblings but significantly larger lentiform nuclei (this last finding is
probably attributable to medication22). Obligates have larger right temporal lobes but
smaller thalami and smaller amygdalo-hippocampal complexes, particularly on the
left than their non-affected siblings. Obligates also have larger cortical structures,
especially the right temporal lobe, larger amygdalo-hippocampal complexes and
smaller sub-cortical structures than their schizophrenic siblings.
These findings can be summarised as follows:
SZ < Obi < NA Amygdalo-Hippocampal Complexes
Obi < SZ < NA Thalamus
NA, Obi < SZ Lentiform Nucleii
SZ < NA < Obi Right Temporal Lobe
(Although it is perhaps worth noting that the SZ v NA comparison of amygdalo-
hippocampal volumes actually has a />value of/? = 0.08 and therefore does not reach
statistical significance when a threshold of p < 0.05 is adopted. This is partly
explained by correction for whole brain volume (see below)).
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Table 2Aiii. Results of 'exploratory' analysis.
Three between group analyses of covariance (as described in
text) are shown. Results quoted as p values (probability of result
arising if there is no between group difference). Results attaining







Amygdalo-Hippocampal Cmpl. 0.03 0.08 0.01
Left 0.04 0.22 0.01
Right 0.04 0.14 0.22
Sub-Cortical Structures 0.01 0.02 0.10
Thalamus L 0.05 0.01 0.01
Thalamus R 0.09 0.01 0.01
Caudate L 0.07 0.33 0.93
Caudate R 0.05 0.49 0.86
Lentiform Nucleus L 0.05 0.01 0.23
Lentiform Nucleus R 0.03 0.02 0.18
Cortical Structures 0.01 0.11 0.33
Pre-frontal Region L 0.33 0.13 0.87
Pre-frontal Region R 0.30 0.07 0.71
Temporal Lobe L 0.18 0.003 0.11
Temporal Lobe R 0.03 0.03 0.01
Intra-Cerebral Ventr. System 0.23 0.08 0.20
Lateral Ventricle L 0.61 0.16 0.16
Lateral Ventricle R 0.15 0.06 0.25
3rd Ventricle 0.19 0.38 0.21
4th Ventricle 0.38 0.41 0.60
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Influence of Covariates
Age, sex and whole brain volume were entered into the exploratory analysis as
covariates despite not being corrected for in the original analysis (see above). It is
possible that this may account for some of the differences between the two sets of
results. Table 2Aiv (below) shows the strength of correlations between each of these
covariates and volumes of each brain region. It is clear that neither age nor sex is
likely to have had a major effect upon the results (the correlations are weak and the
groups are well balanced for these variables). However, the powerful and
statistically significant correlations between whole brain volume and regional brain
volumes merit closer scrutiny.
The main finding of this study relate to volumes of the amygdalo-hippocampal
complexes (AHC). The original analysis found reduced AHC volumes in
schizophrenics and a statistically indistinguishable reduction in obligates (SZ, Obi <
NA) whilst the exploratory analysis found obligates to be intermediate between their
affected and unaffected siblings (SZ < Obi < NA). This difference can not be
explained by the fact that whole brain volume was controlled for in the exploratory
analysis because schizophrenics have smaller brains than the other two groups (hence
when WBV is controlled for the relative AHC volume would increase rather than
decrease).
The finding of reduced volumes of cortical structures in schizophrenics in the
original analysis may simply reflect an overall reduction in brain volume. Similarly,
the apparently larger lentiform nuclei of schizophrenics found on the exploratory
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analysis may be a relative effect. However, the temporal lobe volume findings on
the exploratory analysis (SZ < NA < Obi) are, if anything strengthened by the fact
that they are robust in the face of whole brain volume correction. Finally, the
somewhat counterintuitive thalamus finding on the exploratory analysis (Obi < SZ <
NA) may be attributable to correction forWBV (the raw data suggests Obi, SZ < NA
indicating that reduced thalamic volume may be an endophenotypic marker for
schizophrenia).
Table 2Aiv. Correlations between covariates and regional brain volumes for
all 18 subjects. Values quoted are partial correlation coefficients
(controlling for other covariables) results attaining statistical
significance (p < 0.05) are shown in bold type.
Age Sex WBV p value
Amygdalo-Hippocampal Cmpl. -0.32 0.14 0.80 p=0.01
Sub-Cortical Structures -0.36 0.32 0.90 p<0.01
Cortical Structures 0.04 0.20 0.79 p=0.01




In this study, the original analysis of the data reveals that presumed carriers of the
gene(s) for schizophrenia ('obligates') share a significant reduction in amygdalo-
hippocampal volume with their schizophrenic siblings (i.e. for amygdala-
hippocampus: SZ & Obi < NA). However, in contrast to their affected siblings, they
do not show reduced frontal or temporal lobe volumes (nor reduced whole brain
volumes), and they do not have large ventricles (i.e. for cortical structures: SZ < Obi
& NA). These results are most readily interpreted as suggesting that the reductions
in amygdalo-hippocampal volume associated with schizophrenia reflect genetic risk
for the disorder and may therefore represent an endophenotypic marker for
schizophrenia. Meanwhile, ventricular enlargement and reductions in cortical
volume reflect the schizophrenic phenotype and are presumably a consequence of
environmental factors.
The second analysis puts a slightly different slant on the data. However, for the
reasons explained above, it must be viewed as exploratory. The results are probably
best regarded as interesting hypotheses worthy of further investigation rather than as
definitive and robust research findings. On this analysis, whilst the obligates are
found to have significant reductions in amygdalo-hippocampal volumes compared
with their non-affected siblings, the schizophrenics' amygdalo-hippocampus are
smaller again (i.e. for amygdala-hippocampus: SZ < Obi < NA). This suggests that
reductions in amygdalo-hippocampal volumes (particularly on the left) reflect both
genetic and environmental risk factors. Meanwhile the cortical region that reveals
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the most significant between-group differences is the right temporal lobe. On this
analysis the obligates' right temporal lobes are even larger than those of their non-
affected siblings (i.e. for right temporal lobe: SZ < NA < Obi). One speculative
interpretation of this finding is that larger temporal lobes may be in some way
protective against schizophrenia. Interestingly the sub-cortical structures of thalamus
and basal ganglia (which were collapsed into one large region for the first analysis)
appear to show opposite effects. The schizophrenics have significantly larger
lentiform nuclei than their siblings (i.e. for lentiform nuclei: NA & Obi < SZ). This
presumably reflects the increase in basal ganglia volume associated with
22
antipsychotic medication . In contrast, the schizophrenics have smaller thalami than
their non-affected siblings, however, the obligates have the smallest thalami of all
(i.e. for thalami: Obi < SZ < NA). This suggests that reduced thalamic volume
reflects genetic risk for schizophrenia even in the absence of disease. It would
appear that on the original analysis this finding was masked by the increases in
lentiform volume.
In chapter 2B, the two analyses described above are compared with a VBM analysis
(see Figure 2Bi). The impact of different methods of statistical analysis upon the
conclusions drawn from brain imaging data is an important issue for structural
imaging research. This is discussed in chapter 2B.
One interesting and unexpected finding of this study was the relatively high IQ of the
obligates (as shown in Table 2Ai their average NART score of 107 was 10 points
higher than either their schizophrenic or non-affected siblings). This finding invites
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a number of different explanations. One interesting possibility is that, amongst
individuals at high genetic risk of schizophrenia, intelligence may be (or may reflect)
a protective factor.
Limitations
The use of two separate MRI scanners in this study is an obvious and potentially
serious limitation. However, the risk of bias was minimised by scanning all
members of any given family on the same machine and by entering the scanner as a
between-subjects factor in the first statistical analysis and as a co-variate in the
second. As no significant scanner interactions were found, this study provides some
evidence that regional volumetric analyses are reliable across scanners (although
obviously this comparison has low power). The notion that results of brain imaging
studies may be 'scanner-dependent' is a potentially serious problem for researchers
in this field. The issue is discussed further in chapter 2B.
In any condition with apparently familial and non-familial cases, it can be argued
that highly familial cases are unrepresentative of the condition as a whole23. This
study involved subjects from families in which schizophrenia was not only unusually
prevalent but also inherited in a pattern resembling that seen in autosomal dominant
conditions. The genetic mechanisms involved in these families may therefore be
different from those acting in families with a different pattern of inheritance and may
be of little relevance to non-familial cases of schizophrenia. However, as discussed
in chapter IE, the heterogeneous nature of schizophrenia invites a research strategy
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that employs carefully selected sub-groups from within the affected population to
address specific aetiological questions. Hence this 'limitation' is also a strength.
The most obvious limitation of this study is its small size. For this reason the
original analysis described above was designed to maximise power whilst
minimising the risk of false positive findings. The study's relatively small size is a
direct and perhaps inevitable consequence of the design, which relies upon the
recruitment of carefully selected (and therefore rare) sibling groups. However, the
use of siblings as controls carries the advantage of eliminating a number of potential
sources of bias reducing in particular non-specific variation in regional brain
volumes, thereby increasing the power of the study (see power calculations above).
Comparisons with Previous Research
Various research strategies have been employed to investigate the relationship
between structural brain abnormalities and genetic risk for schizophrenia. These
include twin studies, comparisons of familial versus sporadic cases and studies
involving unaffected relatives of schizophrenic subjects. Some studies of unaffected
relatives identify 'obligates' as a group of particular interest24'25. However, the
author is not aware of any published study that shares the 'sibling triples' design
employed in this study.
Twin studies
Because monozygotic twins share a genotype, differences between such twins can be
assumed to be of environmental (non-genetic) origin. A small number of structural
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brain imaging studies of monozygotic twin pairs discordant for schizophrenia have
been published. The first such study, employing X-ray CT (Reveley et al. 1982)26,
reports increased ventricular size in affected twins when compared with their
unaffected co-twins. However, both groups of twins had larger ventricles than
healthy controls. Together, these findings suggest that ventricular enlargement may
be related to both environmental and genetic factors. The first study to employ MRI
(Suddath et al. 1990)19 does not include a separate control group. The authors
compare affected with non-affected twins and report increases in lateral and third
ventricle volumes with small reductions in whole brain volume in the affected twins.
They also report differential reductions in hippocampal volume, which they conclude
are environmentally mediated. This conclusion is further supported by the
subsequent finding of an association between reduced hippocampal volume and
obstetric complications in the same (but extended) cohort27. A recent ambitious MRI
study (Baare et al. 2001)28 compares four groups: discordant monozygotic twin pairs;
discordant same-sex dizygotic twin pairs; healthy monozygotic twin pairs; and
healthy dizygotic twin pairs. The control ('healthy') groups are matched to the
discordant groups for zygosity, sex, age and birth order. With respect to whole brain
volume, subjects with schizophrenia show reductions. However, whilst the
unaffected dizygotic twins from discordant pairs have normal sized brains, the
unaffected monozygotic twins of schizophrenic subjects show significant reductions
in brain volume (although their brains are not as small as their schizophrenic
siblings'). These findings suggest that reductions in whole brain volume reflect both
genetic and environmental factors. The results with respect to frontal lobe volume
are very similar, inviting a similar conclusion. However, with respect to
210
hippocampal volume in discordant monozygotic twin pairs, there is almost no
difference between affected and unaffected twins (both show considerable reductions
in hippocampal volume when compared with healthy monozygotic twin pairs). This
contrasts sharply with discordant dizygotic twins in which only the affected twin
shows reduced hippocampal volume. These findings strongly suggest a
predominantly genetic mechanism for the reductions in hippocampal volume
associated with schizophrenia and support the main conclusion of this study - that
reduced amygdalo-hippocampal volume may be an endophenotypic marker for
schizophrenia.
Familial versus sporadic
A number of studies have compared schizophrenic patients with a known family
history of schizophrenia with schizophrenic patients with no known family history.
The most consistent finding in this literature (as discussed in chapter ID) is of an
inverse relationship between ventricular enlargement and familiality29'30'31'32. Jones
33and colleagues report a similar finding in relation to cortical sulcal widening . This
suggests that the ventricular enlargement associated with schizophrenia is of
predominantly environmental origin. An interesting study from the Institute of
Psychiatry adopted this design to explore the association between structural brain
abnormalities and both genetic risk and obstetric complications (a recognised
'environmental' risk factor, see chapter ID) in schizophrenia. 27 patients with no
known family history but with a history of severe pregnancy and birth complications
were compared with 21 patients with uncomplicated obstetric histories from multiply
affected families34. The results suggest that reductions in right hippocampal volume
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may be genetically mediated, whilst reductions in left hippocampal volume are
related to birth trauma.
Studies ofunaffected relatives
A number of previous studies report volumetric data from brain imaging in relatives
of schizophrenics. A study of a Finnish cohort finds reductions in cerebral grey
matter, particularly in the frontal and temporal regions (with corresponding sulcal
widening) in both schizophrenic subjects and their unaffected siblings, however, the
siblings do not show the ventricular enlargement associated with schizophrenia35. A
Dutch study finds that, for a range of brain abnormalities, including whole brain
volume, frontal grey matter, lateral and third ventricle size, siblings fall midway
between schizophrenics and normal controls36. Data from the Edinburgh High Risk
Study support the notion that, in terms of volumes of certain brain structures,
asymptomatic individuals with a genetic risk for schizophrenia may lie somewhere
between schizophrenics and 'population-risk' controls37. This appears to be
particularly true of the prefrontal region, the thalamus and the amygdalo-
hippocampal complex. Other studies support these region-specific findings. An
American study comparing non-psychotic, non-schizotypal first degree relatives of
schizophrenics with carefully matched controls reports reductions in thalamic and
amygdalo-hippocampal volumes38. A Canadian study finds reduced amygdalo-
hippocampal volumes in first degree relatives of schizophrenics in association with
impaired delayed verbal memory39. Finally, a very recent study from Harvard finds
that non-psychotic relatives from multiply affected families share left hippocampal
volume reductions with their schizophrenic relatives, whereas non-psychotic
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relatives of patients in whom the condition is sporadic do not show reduced left
hippocampal volume reductions40. As with the Canadian study, left hippocampal
volume reductions are found to correlate with impairment of verbal memory.
Obligate studies
Most of the studies of unaffected relatives described above adopt a straightforward
'schizophrenics versus relatives versus controls' design. By-and-large, relatives are
not sub-divided according to the likelihood of their carrying the gene(s) for
schizophrenia (although in the EHRS a computed estimate of genetic risk is treated
as a continuous variable37). In the Maudsley Family Study, Tomnoy Sharma and
colleagues separate first degree relatives into 'presumed obligate carriers' and
'presumed non-obligate carriers'. They find that, in terms of structural brain
abnormalities, obligates more closely resemble their schizophrenic relatives than do
non-obligates. This is particularly true of left lateral ventricle enlargement24 and loss
of normal prefrontal asymmetry (in normal, right-handed controls the right prefrontal
region is typically larger than the left)25. Unfortunately, Sharma and colleagues do
not report amygdalo-hippocampal volumes. The differences in brain structure
between obligates and non-obligates highlight the potential value of research
involving this particular group of individuals. However, the design adopted by the
Maudsley Family Study does not allow such a clear separation of genetic and
environmental factors as the 'sibling triples' design used in this study.
The data from this study suggest that reduced volume of the amygdalo-hippocampal
complex (and also possibly the thalamus) in schizophrenia is predominantly
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genetically determined. Meanwhile, increased ventricular volume and reductions in
cortical volume (especially the right temporal lobe) are not. These findings are
broadly compatible with previous research. There are, inevitably, a number of areas
of disagreement. For example, the twin study by Suddath et al.19 comes to the
opposite conclusion (that hippocampal reductions are environmentally mediated,
attributable to obstetric complications27). However, that study did not include a
group without genetic risk for schizophrenia (equivalent to the 'unaffected, non-
carrier sibling' group in this study). The genetic versus obstetric risk study by
Stefanis and colleagues found that right hippocampal reductions were genetically
mediated34, whereas in this study (and in the recent study from Harvard40) the genetic
effect was, if anything, greater on the left (although this was a speculative finding
from the exploratory analysis). A number of studies including the EHRS found
associations between genetic risk and reductions in prefrontal volumes37 that were
not replicated in this study. It is possible that this reflects a relative lack of power in
this small study.
Implications
The data from this and other studies suggest that genes may play a central role in the
development of certain structural brain changes associated with schizophrenia.
Whilst the evidence is far from conclusive, a reasonable case can be made for
predominantly genetic aetiology of volume reductions in the amygdalo-hippocampal
complex (particularly on the left), thalamus and prefrontal cortex. Meanwhile other
structural brain abnormalities associated with the disorder appear to be either
partially genetically mediated (e.g. ventricular enlargement) or independent of
genetic factors (e.g. right temporal lobe reduction).
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It is highly probable that, even in families with an apparently dominant pattern of
inheritance the development of psychosis is a consequence of highly complex gene-
environment interactions. Studies that separate out the genetic risk for schizophrenia
from the illness itself offer a valuable perspective upon the interplay between genes
and environment in the aetiology of this multifaceted disorder. It is possible that the
localised structural brain changes identified in this and other studies may prove to be
a useful endophenotypic marker offering a bridge between genes and symptoms.
More research will clearly be required before definitive conclusions can be drawn.
The author would suggest that there is a role for studies of the 'obligate' design
outlined in this chapter. This potentially valuable group has been under-utilised in
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A Voxel Based Morphometry (VBM) and Region of Interest (ROI) Analysis of
the Genotypic and Phenotypic Neuroanatomy of Schizophrenia.
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Background, Aim & Hypothesis
Statistical Parametric Mapping (SPM)1 was originally developed as a tool for use in
functional brain imaging research. It was first employed to detect patterns of
regional cerebral activation in positron emission tomography (PET) imaging and has
been adopted as the standard method of analysis in functional Magnetic Resonance
Imaging (fMRI). It involves fitting scans to a standard anatomical atlas and then
applying statistical techniques to detect clusters of activation and assess the
significance of change. In recent years SPM has been adapted for use in structural
imaging research. It now represents an alternative to conventional Region of Interest
(ROI) analysis. One new procedure, designed to allow comparison of local
concentration of grey matter between two groups of subjects, is referred to as Voxel
Based Morphometry (VBM)2. As with other SPM techniques, the raw data are
subjected to a series of mathematical transformations prior to analysis. In VBM, the
pre-processing sequence consists of 'spatial normalisation' followed by
'segmentation' (into grey matter, white matter and CSF), and finally 'smoothing'.
Although a number of different statistical techniques such as TBM and DBM (see
chapter IE) are now available for use by brain imaging researchers, VBM was
chosen for this study because it is the 'front runner' in structural imaging and also
because it is in a format that is easily available and firmly supported through an
internet discussion list.
Computational techniques such as VBM offer a number of hypothetical benefits over
conventional ROI analysis. First, the results ought to be reproducible because the
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methodology does not depend on operator input (although there is a degree of
subjectivity at the pre-processing stage). Second, because such techniques rely upon
voxel-wise statistical tests performed on the whole brain, differences ought to be
detected wherever they occur in the brain. This removes the focus from specific
brain regions and avoids the need for (regional) hypothesis-driven design. However,
results obtained by this type of analysis may prove rather difficult to interpret
precisely because the technique need not test regional hypotheses. One approach
designed to allow a specific regional hypothesis to be tested by VBM is 'small
volume correction' (SVC). This entails performing detailed analysis on a small sub-
region of the brain incorporating a particular region of interest. In this study an SVC
centered upon the amygdala is described.
The extent to which the adoption of computational methods of data analysis such as
VBM will influence future structural brain imaging research is not clear. The aim of
this study is to identify inconsistencies and areas of commonality between the results
obtained and conclusions drawn from a single, robust data set when analysed with a
traditional method and with a computational approach. The structural MRI data set
from the study described in chapter 2A3 is reanalysed using VBM. The results
obtained by VBM are then compared with those obtained by ROI.
This particular data set was chosen for a number of reasons: First, the scanning
sequences used were conventional and there were no technical problems with the
collection of the imaging data. Second, rather than a simple 'case-control' design
which would offer only one between-group comparison, there are three study groups
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and hence three between-group contrasts. Third, the original ROI analysis of the data
revealed a number of region-specific between group differences. This data set
therefore ought to lend itself to a voxel-based, whole brain analysis such as VBM.
A total of three analyses are presented in this chapter (see Table 2Bi): the 'optimised'
VBM analysis; the 'original', conservative ROI analysis (see Chapter 2A); and the
'exploratory' ROI analysis designed to mimic the voxel-by-voxel comparisons that
constitute VBM (see Chapter 2A). The primary ROI versus VBM contrast is that
comparing results as they would appear in press (i.e. the 'original' ROI versus the
'optimised' VBM).
Hypothesis
The main hypothesis of this study is that the new computational technique, VBM,
will not substantially alter the results obtained or conclusions drawn from the data
but that it will offer certain advantages over traditional ROI analysis (such as more
precise anatomical localisation of between-group differences). The rationale behind
the 'exploratory' ROI analysis is that it will help to elucidate any discrepancies
between the reults obtained through VBM and those obtained through conventional
ROI.
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Table 2Bi. The different statistical analyses facilitate exploration of the origins
of discrepancies between results obtained from the same data
set when analysed using VBM rather than ROI.
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The subjects comprised six sib-ships each consisting of an obligate carrier, an
affected sibling and a non-affected sibling (as described in Chapter 2A).
Scanning Protocol
The scanning protocol is described in Chapter 2A.
ROI: methodology & statistical analyses
The regions of interest methodology is described in Chapter 2A. Two distinct
statistical analyses were conducted: 'original' and 'exploratory' (as described in
Chapter 2A and illustrated in Table 2Bi).
VBM: pre-processing methodology
Initially the images were converted to 'ANALYZE' format as for the ROI analysis
(see Chapter 2A). The anterior commisure was then located manually in all the
images within SPM (in order to assist spatial normalisation).
Spatial normalisation
This involves aligning the T1 images to a T1 template constructed by the Montreal
Neurological Institute (MNI)4. The images need to be in the same stereotactic space
to ensure that the comparisons that follow are carried out between anatomically
corresponding voxels. The image alignment was carried out using a 12 point linear
affine transformation. Nonlinear (or 'warping') transformations were avoided as
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these have been shown to cause unwanted deformations where structural brain
abnormalities are present5. The purpose of the alignment process is not to produce
brains that are exactly matched to the template but to correct for global differences so
that local changes across grey matter density are comparable for equivalent brain
regions2.
Segmentation
Following spatial normalisation, the grey matter probability maps were extracted
with the segmentation procedure included in SPM1. This also involved correction for
the non-uniformity of image intensity that is sometimes apparent in MR images
(although this may not be strictly necessary - Ashburner and Friston have shown
that the non-uniformity correction makes little difference to the tissue classification
of images without non-uniformity artifacts). The segmentation process works by
comparing the images to probability images representing the likelihood that each
voxel belongs to a tissue class (i.e. grey, white, CSF or other). The end result is a
grey matter probability map.
Smoothing
The smoothing process ensures data are more normally distributed thereby increasing
the validity of the statistical tests that follow. The process takes account of
differences in local structure. Smoothing is equivalent to a convolution operator
effectively converting voxel values into a measure of the local tissue composition6.
The Gaussian kernel size adopted for smoothing determines the scale at which the
subsequent statistical analysis will be most sensitive. In this study a Gaussian kernel
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of 12mm FWHM was chosen as this is greater than the thickness of the cerebral
cortex yet sufficiently small to allow gyrus-by-gyrus assignment of significant results
7 8within the Talairach space.
VBM: statistical analyses
VBM comprises a voxel-by-voxel between-group comparison of the density (or
concentration) of grey matter. Although it is a highly computational technique, it is
not a 'one-size-fits-all' method. A degree of judgment is required at the pre¬
processing stage (as described above). Decisions also need to be made at the
analysis stage. For example, which confounding variables should be entered as
covariates in the analysis and what threshold will be adopted for statistical
significance.
'Optimised' analysis
Potential sources of bias were addressed by entering all known confounders as co¬
variates (hence the 'optimised' appellation). These were: sex9, age10, total number of
grey matter voxels11 (GM) (this ensures that any positive results reflect regionally
specific rather than generalised differences in brain morphology) and scanner (the
data used in this study were obtained using two different machines, as described in
Chapter 2A). The final covariate entered into the optimal analysis was family group
(the rationale behind using siblings as controls is that this reduces non-specific
variability in brain morphology).
Three one sided comparisons were carried out, non-affected non-carrier siblings >
schizophrenic siblings (NA > SZ); non-affected non-carrier siblings > obligates (NA
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> Obi); and obligates > schizophrenic siblings (Obi > SZ). A threshold ofp > 0.005
uncorrected for multiple comparisons was considered significant (although
probability peaks at the lower threshold ofp > 0.01 were also examined). Correction
for multiple comparisons was not carried out because it is considered to be overly
strict when applied to the analysis of structural data with VBM in general (as
Ashburner and Fritson observe "analyses based upon uncorrected peak height appear
to be valid"7) and for confirmatory analyses in particular. Finally, because SPM
produces results coordinates in MNI space4, the results were converted to Talairach
7 # 12
space (with a nonlinear transform first described by Brett ).
SVC in the amygdala region
The rationale behind the small volume correction (SVC) technique is that it allows a
specific regional hypothesis to be tested by facilitating a detailed analysis of the
candidate region. The same procedure of pre-processing followed by voxel-by-voxel
analysis is followed, however, the statistical parameters are optimised for the specific
region under scrutiny. In this study an SVC analysis was conducted within the
amygdalo-hippocampal complex (as there is more evidence implicating genetic
factors in the genesis ofmorphological changes in this region than in any other, see
Chapter 2A). The analysis incorporated voxels within a sphere of radius 10mm




The mean volumes of each ROI by group are shown in Table 2Aii.
Results oforiginal ROI analysis
These are shown in Table 2Aii and discussed in Chapter 2A. A summary of the
statistically significant findings is shown below:
SZ < Obi, NA Whole Brain Volume
SZ, Obi < NA Amygdalo-Hippocampal Complexes
SZ < Obi, NA Temporal & Prefrontal Lobes
Obi < SZ Intra-Cerebral Ventricular System
These results suggest that reduced AHC volume may be a genetic effect, whilst
reduced temporal and prefrontal lobe volume may be phenotypic (see Chapter 2A).
Results ofexploratory ROI analysis
These are shown in Table 2Aiii and discussed in Chapter 2A. A summary of the
main statistically significant findings is shown below:
SZ < Obi < NA Amygdalo-Hippocampal Complexes
Obi < SZ < NA Thalamus
NA, Obi < SZ Lentiform Nucleii
SZ < NA < Obi Right Temporal Lobe
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These results suggest that reduced AHC volume may be both a genetic and a
phenotypic effect, whilst reduced thalamic volume may be a predominantly
genetic effect and increased lentiform volume a phenotypic effect (possibly
attributable to medication). Increased temporal lobe volume in obligates may
reflect a protective factor (see Chapter 2A).
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VBM: results
Results of 'optimised' VBM analyses
Results from the three VBM analyses: Obi > SZ; NA > SZ; and NA > Obi are
presented in pictorial form in Figures 2Bi, 2Bii, and 2Biii respectively.
A summary of the main findings from all three analyses presented in the form of
Talairich co-ordinates is shown in Table 2Bii.
The most striking feature of the Obi > SZ analysis is the large probability peak in the
right medial temporal lobe region (centred upon Talairich co-ordinates 29, 2,-15
corresponding to the parahippocampal gyrus). This appears to correspond to similar
medial temporal probability peaks bilaterally on the NA > SZ analysis (-12, -1, -18
and 29, 2, -15). The striking right-left asymmetry in the results from the medial
temporal region (NA & Obi > SZ on the right, NA > Obi & SZ on the left) suggests
lateralisation of the effects of risk factors. Genetic effects appear to predominate on
the left. However on the right, reduced grey matter density in the medial temporal
lobe appears to be an endophenotypic marker in that it is found in association with
the schizophrenic phenotype but not with genetic risk for the disorder. (For the sake
of brevity the term 'phenotypic' will be used to describe this type of effect.)
Examination of Figure 2Bii reveals a number of significant differences in cortical
grey matter density between the schizophrenic subjects and their non-affected
siblings. On visual inspection these appear to be scattered around the frontal,
temporal, parietal and occipital cortices. The Talairach co-ordinates listed in Table
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2Bii describe the precise location of these probability peaks (predominantly left
middle frontal gyrus and right superior frontal gyrus). Comparison of the frontal and
temporal regions of the brain in Figures 2Bi & 2Biii demonstrates far more
differences in these regions between obligates and schizophrenics (Figure 2Bi) than
between obligates and their non-affected siblings (Figure 2Biii). These findings
suggest that the reduced grey matter density in these regions of the schizophrenic
brain is unlikely to be attributable to differences in genetic predisposition for
schizophrenia.
Interestingly, the VBM analysis also identifies a number of probability peaks in the
occipital region (particularly the cuneus and pre-cuneus) and the cerebellum.
Examination of these suggests largely mixed phenotypic/genotypic effects.
The VBM analysis identifies almost no localised differences in sub-cortical grey
matter densities. It may be that pre-processing parameters designed to maximise the
sensitivity of cortical comparisons render the data relatively insensitive to sub¬
cortical differences.
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Figure 2Bi. Results of Optimised VBM analysis Obi > SZ at p < 0.005
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Figure 2Bii. Results of Optimised VBM analysis NA > SZ at p < 0.005
238
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Results ofSVC in amygdala region
The greatest between-group differences on both the ROI and the VBM analyses
relate to medial temporal lobe structures. It was therefore decided to perform an
specific (and presumably confirmatory) SVC analysis in this region. The shape of
the hippocampus renders it an unsuitable location for an SVC (the defined volume
for an SVC in SPM must be spherical). It was therefore decided to centre the SVC in
the amygdala.
The highest probability peaks identified on the SVC were as follows:
Result Anatomical Talairach Peak Significance
Location Co-ordinates Height Level
X Y Z (corrected)
SZ, Obi < NA Left Amygdala -19 0 -22 7=2.8 0.05 < p < 0.01
SZ < Obi, NA Right Amygdala 29 2 -15 7= 5.6 p < 0.01
/ Uncus
This suggests a phenotypic effect on the right and a genetic effect on the left,
consistent with the main VBM analysis.
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Comparison of results: VBM v ROI
The VBM analyses conducted for this study deal with grey matter voxels only (VBM
was designed for use with grey matter and the validity of findings relating to white
matter and CSF is open to question). The regions of interest data do not incorporate
every possible brain region (only those regions that are widely believed to be
implicated in schizophrenia are included). Therefore the only direct ROI v VBM
comparisons that it is possible to make relate to grey matter in the prefrontal
(corresponding to frontal lobe voxels with Talairach Y > 35) and temporal cortices,
the thalamic, caudate and lentiform nuclei, and the allocortex of the amygdalo-
hippocampal complexes. These comparisons are displayed in Tables 2Biv and 2Bv.
VBM versus original ROI
Direct comparison of results from the optimised VBM and original ROI analyses (for
the regions listed above) reveals a remarkable degree of overlap. (This is illustrated
in Table 2Biv, which shows the probability peaks on VBM that lie within the
boundaries of the ROI data set - overlap is indicated by bold type.)
As discussed previously, the most striking features of the VBM analyses are the large
probability peaks in the medial temporal lobe regions. These appear to correspond
very well with the disproportionate reduction in the volumes of the amygdalo-
hippocampal complexes identified on the original ROI analysis. However, the
conclusion of the original ROI analysis was that, in terms of amygdalo-hippocampal
volumes, the obligates resembled their schizophrenic siblings. The identification by
VBM of differences between obligates and schizophrenics in the right
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parahippocampal gyrus (29, 2, -15) and right insula (45, 5, -5) appears to contradict
this conclusion. One of the acknowledged weaknesses of the original ROI analysis
was that by collapsing the right and left amygdalo-hipocampii into one gross region,
it became blinded to any right-left differences. This was one of the reasons for
performing the 'exploratory' ROI analysis.
The original ROI analysis found no difference between obligates and non-affected,
non-carriers in terms of prefrontal and temporal lobe volumes (both being
significantly larger than schizophrenics). A glance at the almost empty right hand
column ofTable 2Biv shows that this is entirely in keeping with VBM.
Finally, neither analysis identified differences in sub-cortical structures (with the
exception of an isolated voxel cluster in the left lentiform nucleus on VBM, -19, 13,
5/9). As proposed in Chapter 2A, it is possible that the original ROI failed to
identify differences because reductions in thalamic volume were cancelled out by
increases in lentiform volume when the regions were combined. Meanwhile, the
VBM analysis would not be able to identify any increases in grey matter density in
the lentiform nuclei as it tested only for reductions in density. Such an explanation
does not, however, account for the absence of probability peaks in the thalamus.
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VBM versus exploratory ROI
The 'exploratory' ROI analysis was designed and conducted primarily to facilitate
comparison with the optimised VBM analyses. Indeed the methodology adopted
consciously mimics the VBM approach with probabilities of between-group
differences being calculated for each individual region of interest. It is perhaps
surprising therefore that the degree of overlap between the results of this analysis and
VBM is considerably less than between the original ROI analysis and VBM. (This is
illustrated visually by the relative sparsity of bold type in Table 2Bv compared with
Table 2Biv.)
With respect to amygdalo-hippocampal volumes, the exploratory ROI findings are in
broad agreement with the VBM findings - predominantly genetic effect on the left
with predominantly phenotypic effect on the right.
The single sub-cortical probability peak identified by VBM (in the left lentiform
nucleus: -19, 13, 5/9) is in agreement with the findings of the exploratory ROI
analysis. However, it is notable that the VBM failed to detect the other basal ganglia
differences and the thalamic differences identified by the exploratory ROI analysis.
One possible explanation is that the VBM parameters (in particular the Gaussian
kernal of 12mm employed for smoothing) were designed to maximise the chance of
detecting differences in cortical grey matter. This may have rendered the analysis
relatively insensitive to differences in sub-cortical grey matter.
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With respect to cortical grey matter, the VBM analysis suggests a phenotypic effect
(SZ < Obi, NA) in right and left prefrontal and right and left temporal lobes,
whereas the exploratory ROI only identifies a statistically significant effect in the
right temporal lobe.
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The aim of this study was to identify inconsistencies and areas of commonality between
the results obtained and conclusions drawn from a single, robust data set when analysed
with a traditional method and with a computational approach. The findings indicate
considerable areas of commonality with relatively few inconsistencies allowing very
similar conclusions to be drawn from the two analyses. Furthermore, the overlap is
maximal when the two analyses are compared 'as they would appear in press'.
Both analyses identify abnormalities of limbic and cortical structures in association with
a diagnosis of schizophrenia. The results from both analyses support the conclusion that
there is an association between genetic risk for schizophrenia and limbic, but not
cortical, abnormalities. The greatest difference between the two approaches is reflected
in the extent to which the findings can be localised. The ROI analysis deals with
relatively large anatomical structures (this is particularly true of the analysis described in
this study which deals with conglomerated, 'gross' regions of up to 300cm3), whilst the
VBM deals with voxels of the order of a millimetre across. The VBM analysis is
therefore able to identify precisely where the between-group differences are at their
greatest.
Limitations
The limitations of the original study are discussed in Chapter 2A. However, the
limitations of the ROI versus VBM comparison and of VBM in general merit further
discussion.
The most obvious limitation of this comparison is that it does not incorporate all regions
of the brain. As the name suggests, the original 'Regions of Interest' data relate only to
specific regions implicated in the pathophysiology of schizophrenia. In this respect it is
typical of ROI studies, which are usually designed to test a specific regional hypothesis
(in this case the amygdalo-hippocampal complex). Collecting ROI data from every
brain region is not only time consuming but also leads to problems with multiple
statistical tests. Meanwhile, the VBM analysis was restricted to grey matter. Although
VBM has been used to identify differences in white matter and even CSF density, it was
primarily designed to examine grey matter and the validity of VBM findings from other
tissue types is questionable.
In the course of comparing two methods of data analysis, the original null hypothesis
(that there would be no between group differences in amygdalo-hippocampal structure)
is subjected to a total of four statistical tests: the original ROI; the 'exploratory' ROI; the
optimised VBM; and the SVC. In the normal course of events this would be
indefensible. However, the optimised VBM is essentially a confirmatory test, whilst the
'exploratory' ROI and SVC analyses are both exploratory tests. The subtle differences
between the various results are informative. The original ROI collapses both sides into
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one and finds SZ & Obi < NA (suggestive of a genetic effect). The exploratory ROI,
optimised VBM and SVC all find SZ & Obi < NA on the left (suggestive of a genetic
effect) and SZ < Obi & NA on the right (suggestive of a phenotypic effect). If one
returns to the original volumetric data, one finds a similar trend (SZ < Obi < NA) on
right and left, suggesting a mixed genetic and phenotypic effect on both sides (albeit
non-significant). The apparent right-left differences may be an artefact of arbitrary
statistical thresholds, which result in the intermediate (obligate) group being identified
as statistically indistinguishable from one extreme or the other depending on how the
data are treated. The arbitrary nature of statistical thresholds is an issue common to all
forms of data analysis but appears to be particularly pertinent to structural brain imaging
and perhaps especially VBM.
What statistical threshold to choose is not the only subjective judgement required in
VBM. As mentioned previously, there is scope for adjusting the parameters at both the
pre-processing and the analysis stages. The optimal protocol for detecting differences in
cortical grey matter is not necessarily the best protocol for identifying differences
elsewhere in the brain. Most of the major pre-processing parameters have now been
standardised , however, the methods devised by Ashburner and Friston inevitably
represent a compromise. In this study VBM appears to be relatively poor at detecting
differences in the grey matter of the thalamic and caudate nuclei. Also the small volume
correction facility, which offers the opportunity to test specific regional hypotheses, is
limited by the fact that it can only examine spherical regions of interest rather than
regions defined by anatomical boundaries. Other limitations of VBM include the
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tendency for probability peaks to be located at anatomical boundaries (the so-called
'edge effect'16) and its inability to examine generalised, whole brain effects (an issue
which may be pertinent to schizophrenia research, see Chapter ID).
One issue of particular relevance to this study is the extent to which structural imaging
findings, in particular those obtained through computational methods of analysis, may be
'scanner-dependent'. The apparent benefits of computational methods of analysis
(reproducibility and removal of subjective judgements) would be undermined if
systematic differences were identified between results obtained from different machines.
The data analysed in this study were obtained using two different MRI scanners: a 1
tesla Siemens Magnetom model; and a 1 tesla General Eelectric Signa model (see
Chapter 2A). The potential risk of this confounding the results was minimised by
ensuring that all three members of a sibling 'triple' were scanned on the same machine
and by entering 'scanner' as a between-subjects factor in the ROI analysis and as a
covariate in the VBM analysis. No statistically significant scanner effect was identified
in either analysis. However, one would not expect to identify subtle effects with such a
limited number of subjects. Researchers conducting longditudinal studies, where scans
are conducted years apart, often have no option other than to use different machines.
The electron-magnets in MRI scanners have a limited life-span and, even if they lasted
forever, technological advances would render an old model obsolete within years.
Colleagues from within the author's department working on the Edinburgh High Risk
Study (Hodges et al. 1999) have begun examining the very large data set (over 500 scans
obtained from over 200 individuals) for evidence of between-scanner effects. They
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believe that they have identified systematic yet unpredictable differences attributable to
different machines. Their initial impression is that the effects are greatest when
comparing machines of different field strength (in this case 1 tesla versus 1.5 tesla) and
from different manufacturesrs. Furthermore they suspect that the scanning protocol
chosen and the sequence of data collection may influence the results obtained. The
author is not aware of any published studies supporting his colleagues' suspicions but it
is likely that the issue will come to light in the near future.
Comparisons with previous research
The literature relating to the association between genetic risk of schizophrenia and
structural brain abnormalities is discussed in Chapter 2A.
To date only a small number of structural brain imaging studies in schizophrenia have
been published with a VBM analysis. The largest VBM study is from the Netherlands
comparing 159 schizophrenic subjects with 158 controls13. The main findings are of
reduced grey matter density in the left amygdala and hippocampus and the insula,
posterior cingulate gyrus, thalamus, frontal and temporal lobes bilaterally. Grey matter
density is increased in the basal ganglia. These results are entirely consistent with our
findings. The frontal, temporal and insula findings are replicated in a German study of
48 patients, which also examined CSF and found increased ventricular volume14. A
recent study from Queen's Square (20 patients, 20 matched controls) reports reductions
of grey matter density in the mediodorsal thalamus and the ventral and medial prefrontal
cortices, the latter correlating positively with a family history of schizophrenia15 (a
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finding that was not replicated in this study). It is important to remember that the VBM
method has only been readily available for two years and it is therefore likely that the
majority of studies are still in progress or in press. A study of 34 first episode subjects
conducted in Edinburgh16 reports grey matter density reductions in the right anterior
cingulate, right medial frontal lobe, left middle temporal gyrus, left postcentral gyrus
and left limbic lobe. SVC within the amygdalo-hippocampal complex identifies
reductions in the right and left uncus and parahippocampal gyri and the right amygdala.
Again such findings are in broad agreement with this study.
Implications
Computational methods of data analysis such as VBM offer a number of advantages
over traditional ROI methods. As the comparison described in this chapter
demonstrates, VBM allows differences to be localised with great precision. It also
allows researchers to examine grey matter throughout the brain (rather than being
restricted to pre-specified regions). Once the expertise has been acquired, VBM ought
to be considerably less labour intensive than semi-automated ROI. However, the
'unique selling point' of computational analyses is that by producing results in the form
of Talairach co-ordinates they have the potential to facilitate direct comparisons of
functional and structural data. For these reasons, VBM is likely to become ever more
popular in structural brain imaging research.
However, VBM is not perfect. As discussed above, its validity with respect to white
matter and CSF is unclear. It is probably not as sensitive at detecting differences in sub-
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cortical grey matter as in cortical. It is also important to recognise that, despite being
highly computational, a degree of subjectivity remains in VBM and the conclusions
drawn from a VBM analysis may be partially dependent upon the statistical threshold
chosen. Finally the SVC facility is limited to spherical regions.
The outcome of this VBM versus ROI comparison is reassuring. VBM did not alter the
main conclusions drawn from the data but it added detail. One might reasonably
anticipate that the adoption of VBM will bring greater anatomical precision to the field
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2C: Study 3
Diffusion Tensor Imaging (DTI) and Proton Magnetic Resonance
Spectroscopy ('H-MRS) in Schizophrenic Subjects and Normal Controls.
N.B. The study described in this chapter has been published. A reprint of the
following paper is enclosed in a pocket attached to the inside of the back cover of
this thesis.
Steel R.M., Bastin M.E., McConnell S., Marshall I., Cunningham-
Owens D.G., Lawrie S.M., Johnstone E.C. & Best J.J.K. 2001.
"Diffusion Tensor Imaging (DTI) and Proton Magnetic Resonance
Spectroscopy (1H-MRS) in schizophrenic subjects and normal
controls." Psychiatry Research: Neuroimaging 106:161-170.
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Background, Aim & Hypothesis
A number of explanatory models have been proposed as candidates for the morbid
process underlying schizophrenia. However, no single theory has yet been developed
which successfully explains the onset, clinical and pathological features and course of
the disorder (see Chapter 1C). The 'Neurodevelopmental Hypothesis'1'2 proposes that
the disorder is due to developmental abnormalities arising before or around the time of
birth, the psychopathology emerging in early adult life as the affected neuronal systems
mature. It is suggested that the underlying pathology relates to disrupted neuronal
migration during very early life2'3. The evidence in favour of this theory is by no means
conclusive, but it finds support in the results of some post-mortem4'5'6'7 and in-vivo
structural brain imaging studies8'9'10'11.
The findings of functional imaging studies (PET12'13 and more recently fMRI14) suggest
that schizophrenia may be associated with abnormal 'connectivity' between different
brain regions. The 'Disconnection Hypothesis'15 proposes that the signs and symptoms
of schizophrenia can be understood in terms of a failure of integration of neurocognitive
tasks reflecting a pathophysiological process characterised by disrupted functional
connectivity between various brain regions. Precisely which neuronal connections (or
circuits) are disrupted in the disorder is currently unclear. Cases have been argued for
fronto-temporal pathways16'17, fronto-cingulate connections18 and trans-callosal fibres19.
259
If one combines the neurodevelopmental and disconnection hypotheses, the result is a
pathophysiological model in which the connections between various regions of the brain
have developed abnormally and are therefore unable to function normally (the
'Dysplasic Net Hypothesis'20). If this model is accurate, one might expect to find
(neurodevelopmental) abnormalities in the cyto-architecture of the white matter tracts
(connections) within the brain. The study presented in this chapter uses proton magnetic
resonance spectroscopy ('H-MRS) and diffusion tensor imaging (DTI) to examine the
anatomical basis of connectivity in the pre-frontal white matter.
'H-MRS
Proton magnetic resonance spectroscopy measures the concentration of various
biologically important metabolites in the brain. Although spatial resolution is relatively
poor compared to conventional MR imaging, (15 mm cubic voxels in this study), the
technique is useful because it allows brain chemistry to be studied in-vivo without the
use of radioactive tracers. Most studies report N-acetyl aspartate (NAA) concentrations
because the peak in the proton spectrum attributable to NAA is prominent, and can be
measured reliably21. NAA is found predominantly within neurons though its
intracellular function is unclear. It is thought to be a neuronal/axonal marker and its
concentration may therefore provide a measure of both the number and integrity of
neurons within a region of the brain. In connection with schizophrenia, many previous
studies have reported reduced NAA concentrations in certain brain regions, particularly
the hippocampus, frontal cortex and pre-frontal white matter22'23'24. In this study 'H-
MRS was used to measure NAA concentrations in pre-frontal white matter. Reductions
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in NAA in this region may reflect a structural abnormality, (such as reduced axonal
density or reduced viability of neurons), or it may reflect abnormal function of
structurally normal neurons whose axons travel to and from the frontal lobes.
DTI
In the brain, the rate at which water molecules diffuse along a particular direction (the
apparent diffusion coefficient, or ADC) can be measured in vivo from MR images by
applying a diffusion sensitising gradient in the direction of interest. Structures such as
myelin sheaths, axonal membranes and micro-filaments cause the diffusion to be slower
perpendicular to axons than parallel to them, thereby leading to different rates of
diffusion in different directions. This is reflected in differences between ADCs
measured in different planes (called 'diffusion anisotropy'). From a set of diffusion-
weighted images, a mathematical description of the rates of diffusion in three-
dimensional space (the 'apparent diffusion tensor - D') can be derived. The extent to
which diffusion is disrupted by cellular structures is then reflected in the degree of
asymmetry of the tensor. Measures of diffusion anisotropy are indicators of the
structural integrity of a neuronal tract. A commonly quoted diffusion anisotropy index
is the 'fractional anisotropy' (FA), which measures the fraction of the total magnitude of
9S 96
the apparent diffusion tensor that is anisotropic ' .
DTI is a relatively new technique and the literature relating to schizophrenia is small and
inconsistent (the study described in this chapter is only the fourth in the field).
Buchsbaum and colleagues reported reduced diffusion anisotropy in the white matter of
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the pre-frontal cortex in five schizophrenics compared with six controls27. Lim and
colleagues studied ten US army veterans with schizophrenia and found widespread
reductions in anisotropy throughout the brain28, whilst Foong and colleagues studied the
corpus callosum in twenty patients and reported reduced anisotropy in the splenium, but
not the genu29. The primary aim of the present study was to measure diffusion
anisotropy in the pre-frontal white matter. Diffusion anisotropy was also measured in a
control region (occipital white matter), which is not generally implicated in the
pathophysiology of schizophrenia.
Hypothesis
The study was designed to yield potentially complementary information from 'H-MRS
and DTI in the same patients and controls. The main hypothesis being tested was that
NAA concentrations and diffusion anisotropy would be abnormal in the pre-frontal lobe






Ten patients with established DSM-IV schizophrenia were compared with ten healthy
controls. Both male and female participants were studied. The groups were matched for
age (see Table 2Ci).
Subjects were selected from patients with an unambiguous clinical diagnosis of
schizophrenia. DSM-IV diagnosis was confirmed by SADS-L31 semi-structured
interview. Mean duration of illness was 15 years and all subjects were taking
antipsychotic medication at the time of the study (see Table 2Ci). Because the study
involved the piloting of a new technique (DTI) with a relatively long image acquisition
time (45 minutes when all went well, longer when technical problems arose), it was
decided to select patients who had participated in previous brain imaging studies. It was
felt that subjects with prior experience of an MRI scanner would be more likely to
tolerate the scanning procedure. (In the event, all subjects tolerated the procedure
without difficulty). Clinical and volume acquisition scans were therefore available for
every subject. Patients with gross structural brain abnormalities were not considered for
inclusion in this study. However, patients known to have morphological brain changes
consistent with schizophrenia (slightly reduced whole brain volume, enlarged lateral
ventricles) were included (see table 2Ci).
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Table 2Ci. Demographic, clinical and morphological details of subjects by group.
Values presented are the group means (SD), and volumes (SD) in
cm3 with the corresponding p-value and effect size.
Schizophrenic Control P Effect size
Number of Subjects 10 10 - -
Sex (Male/Female) 5/5 4/6 - -
Age (years) 34(14) 35 (7) - -
Duration of Illness (years) 15 (12) N/A - -
Whole Brain Volume 1229(123) 1259 (110) 0.62 -0.27
Left Lateral Ventricle Volume 5.9 (3.0) 3.7 (2.2) 0.12 +1.00
Right Lateral Ventricle Vol. 4.2 (2.7) 3.6 (1.8) 0.59 +0.50
Left Frontal Lobe Volume 69 (13) 70 (8) 0.94 -0.12
Right Frontal Lobe Volume 74 (13) 74 (9) 0.99 0.00
Left Amygdala-Hippocampus 4.1 (0.4) 4.5 (0.4) 0.18 -1.00
Rt. Amygdala-Hippocampus 4.7 (0.4) 4.7 (1.0) 0.98 0.00
effect size = (meansz-meancont.)/SDcont.
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Data Acquisition and Analysis
All imaging and spectroscopy data were collected on an Elscint 2T Prestige (Elscint,
Haifa, Israel) clinical scanner (horizontal bore inner diameter 57cm), equipped with a
15mTm"' actively shielded gradient set. The examination consisted of a T2-weighted fast
spin-echo sequence (TR/TE 4800/96; FOV 22 x 22cm; 10 axial slices beginning
approximately 10mm above the base of the temporal lobes; slice thickness 6mm; slice
gap 20%), a 3D gradient-echo volumetric sequence (TR/TE 28.5/9.254ms; FOV 18 x
18cm; slice thickness 1.5mm;) and then the following 'H-MRS and DTI protocols. The
complete examination took approximately 45 minutes.
Proton Magnetic Resonance Spectroscopy
Using the set of axial fast spin-echo images (described above) for positioning, two
PRESS-localised spectra (TR/TE 1500/145ms) were acquired from 15mm cubical
volumes of interest (VOIs) in left and right hemisphere frontal white matter
approximately 5mm from the most anterior part of the frontal horns in a line 45° from
the midline (see Figure 2Ci). This voxel location ensured that proton spectra were
acquired from homogenous white matter rather than from a heterogeneous mixture of
tissue types. Following localised shimming and water suppression calibration for each
VOI, 200 acquisitions with water suppression were collected. Eight acquisitions without
water suppression were also collected to serve as a phase reference. The VOI positions
within the head coil were noted, as was the scanner RF calibration figure to allow for the
effects of coil loading.
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Spectroscopy data were transferred to a Sun Ultra Sparc Station 10 (Sun Microsystems,
Mountain View, CA, USA) workstation for analysis. Analysis consisted of phase
correction using the water reference data32, and removal of the residual water signal
using Hankel-Lanczos singular value decomposition33. Spectral peak areas were
quantified using the MRUI software package34, which fitted Gaussian lineshapes to the
peaks corresponding to choline (3.2ppm), creatine (3.0ppm) and NAA (2.0ppm).
Finally, metabolite peak areas for each subject were corrected for coil loading and VOI
position within the head coil. The resulting 'institutional' units enabled between-subject
comparisons. An example of a 'H-MRS spectrum is shown in figure 2Cii.
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Figure 2Ci. A structural fast spin-echo image obtained at the level of the lateral
ventricles from a 27-year-old female schizophrenic subject in this
study. The box (□) indicates the position of the volume of interest
from which the proton spectrum (see Figure 2Cii) was acquired.
Figure 2Cii. The proton magnetic resonance spectrum from the VOI indicated








Diffusion-weighted echo-planar (DW-EP) images were obtained using a non-cardiac
gated, single-shot, spin-echo, half-Fourier sequence, in which two symmetric diffusion
sensitizing trapezoidal gradient pulses of 35ms duration, and 43.9ms separation were
applied sequentially along the six oblique gradient directions (G1 to G6) that constitute
the uniform diffusion gradient sampling scheme of Basser and Pierpaoli35. In each of
these six gradient directions 9 DW-EP images were acquired with a diffusion gradient
strength of ll.OmT m"1, giving an average value for Trace(b) of 686.55 ± 0.61(SD) s
mm"2 for G1 to G6. A total of 54 DW-EP images per slice position were collected, plus
9 baseline images (G°) with no diffusion weighting. Values for the elements of the b-
matrix were calculated numerically36. Other image acquisition parameters were as
follows: 10 axial slices coincident with those prescribed in the fast spin-echo sequence;
6 mm slice thickness; 20% slice gap; 128 x 72 half-Fourier image matrix (zero filled to
256 x 128); 44 x 22cm FOV; TE of 103ms. The time from acquisition of one image
slice to the next was 1.4s, so the effective TR was 14s. Patient head motion was
minimized through use of a Velcro strip, which was comfortably tightened around the
subject's forehead.
Magnitude Fourier transformed images in DICOM format were transferred from the
scanner to a Sun workstation and converted into Analyze (Mayo Foundation, Rochester,
MN, USA) readable form using software written in C. Within each slice the set of 9
images for each of the diffusion gradient directions G° to G6 were separately realigned
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to remove physiological motion using SPM9537, and then averaged to give seven high
38
signal-to-noise images . Geometric image distortions in the six DW-EP images arising
from the strong eddy currents present in the DTI experiment were corrected using a
modified version of the iterative cross-correlation algorithm suggested by Haselgrove
and Moore39'40.
Within each voxel the six elements of the apparent diffusion tensor D (Dxx, Dyy, Dzz, Dxy,
Dxz and Dyz) and the baseline T2 signal intensity were estimated by multivariate linear
regression41 from the measured signal intensity using a program written in Matlab (The
Mathworks, Natick, MA, USA). After diagonalization of D to yield the eigenvalues
(^-i= 1,2,3)5 maps of the fractional anisotropy (FA)26 were generated on a voxel-by-voxel
basis and converted into Analyze format. An example of an FA map is shown in figure
2Ciii.
FA measures the fraction of the total magnitude of the apparent diffusion tensor that is
anisotropic, and takes a value of 0 for an isotropic (cylindrically symmetric, X\ » X2
=A,3) medium (see expression below).
[3 l(Al-<D>)2 +(A2-<D>)2 +(A3-<D>)2)
V 2 V Af+A22+A2
Values for FA in frontal white matter were calculated from regions-of-interest (ROIs)
positioned by a radiologist to coincide with the centres of volumes of interest from
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which the proton spectra were obtained (see Figure 2Ci). In the occipital lobes ROIs
positioned manually (by the same radiologist) within the white matter adjacent to the
optic radiation.
Figure 2Ciii. A Fractional Anisotropy (FA) map at the level of the lateral




Results from the proton magnetic resonance spectroscopy are presented in Table
2Cii.
NAA concentrations were reduced in male and female schizophrenic subjects
compared with controls in both the right and left frontal white matter. The direction
and magnitude (10-15%) of this difference is consistent with previously published
data22'23'24. These findings failed to reach statistical significance (by one way
ANOVA using a 2-tailed significance level of 5%), but this may be due to the small
number of subjects in this pilot study.
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Table 2Cii. 1H MRS results by brain region, patient group and sex.
Values presented are the mean (SD) N-Acetyl Aspartate
peak areas in arbitrary units, p-value and the effect size.
Subjects Brain Region Schizophrenic Control P Effect Size (d)
Males Left Frontal 1072 (244) 1100 (218) 0.88 -0.13
Females Left Frontal 992 (196) 1235 (164) 0.09 -1.48
All Left Frontal 1027 (208) 1178 (186) 0.16 -0.81
Males Right Frontal 1065 (218) 1122 (143) 0.71 -0.40
Females Right Frontal 1019 (147) 1153(134) 0.20 -1.00
All Right Frontal 1039 (171) 1140 (157) 0.22 -0.64
effect size (d) = (meansz.-meanCont.)/SDCont.
273
DTI: results
Results from the diffusion tensor imaging are presented in Table 2Ciii.
As illustrated in bold type in Table 2Ciii, there were no consistent differences
between the FA values obtained from schizophrenics and controls. In schizophrenic
subjects diffusion anisotropy was slightly reduced in left frontal white matter, but
slightly increased in the other regions measured. All between group differences were
small, and none was close to statistical significance. The absence of any discernable
trend in these DTI data suggests that this was not simply a type-2 error caused by
small numbers.
Examining the data from male and female subjects separately (as illustrated in non-
bold type in Table 2Ciii) reveals that in male schizophrenics, anisotropy was slightly
(but not significantly) reduced in all four regions of interest, whilst in females the
only difference between the groups was a statistically significant (p<0.01) increase
in anisotropy in the right occipital region in the schizophrenics.
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Table 2Ciii. DTI results by brain region, group and sex.
Values presented are the mean (SD) Fractional Anisotropy (FA)
p-value and effect size.
Subjects Brain Region Schizophrenic Control P Effect Size (d)
Males Left Frontal 0.40 (0.08) 0.45 (0.06) 0.33 -0.86
Females Left Frontal 0.44 (0.11) 0.42 (0.09) 0.83 + 0.15
All Left Frontal 0.42 (0.09) 0.43 (0.08) 0.68 -0.22
Males Right Frontal 0.46 (0.15) 0.48 (0.50) 0.83 -0.31
Females Right Frontal 0.41 (0.08) 0.39 (0.05) 0.66 +0.37
All Right Frontal 0.43 (0.11) 0.42 (0.07) 0.82 +0.15
Males Left Occipital 0.44 (0.06) 0.44 (0.06) 0.95 -0.05
Females Left Occipital 0.46 (0.08) 0.45 (0.04) 0.77 +0.29
All Left Occipital 0.45 (0.07) 0.45 (0.05) 0.59 +0.06
Males Right Occipital 0.41 (0.02) 0.45 (0.08) 0.34 -0.46
Females Right Occipital 0.53 (0.04) 0.46 (0.02) >0.01 +3.29
All Right Occipital 0.47 (0.07) 0.45 (0.05) 0.90 +0.30
effect size = (meansz-meanCont.)/SDcont.
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Correlations
Correlations between 'H-MRS and DTI measures were inconsistent. Within the
schizophrenic group, NAA concentrations in the right frontal region showed a
significant positive correlation with FA in both the right and left frontal regions
(Pearson coefficients: Right 0.65, p<0.05; Left 0.69, p<0.05). However, no such
correlation was found in the control group (Pearson coefficients: Right 0.09, p>0.8;
Left 0.18, p>0.7). Furthermore, NAA in the left frontal region in schizophrenics
showed a weak negative correlation with the FA (Pearson coefficients: Right -0.3,
p>0.4; Left -0.2, p>0.5).
Correlations with volumetric data were also inconsistent. Within the schizophrenic,
but not the control group, NAA concentrations in the left frontal region correlated
strongly with the volume of the amygdalo-hippocampal complex on the left (Pearson
coefficient 0.92, p<0.05), however, there was no correlation between the same
measures on the right (Pearson coefficient 0.01, p=0.98). The FA showed no
correlation with any volumetric measures in either group. Neither 'H-MRS nor DTI




In this study schizophrenia appeared to be associated with reduced NAA
concentrations in the pre-frontal white matter, but with normal diffusion anisotropy
in the same region. These findings suggest that, whilst the neuronal tracts running to
and from the frontal lobes may be functionally abnormal in schizophrenic subjects,
they are structurally intact. This invites the conclusion that the aberrant functional
connectivity associated with schizophrenia is not attributable to abnormalities of
white matter cyto-architecture and that reduced NAA in the pre-frontal white matter
reflects abnormal function of structurally intact neurones.
Limitations
Power
The most obvious limitation of this study is its relatively small size (and consequent
limited statistical power). The consistent trend in the data suggesting reductions in
NAA concentrations (of a magnitude consistent with the established literature) did
not reach statistical significance (see Table 2Cii). The most likely explanation is that
this reflects a Type II error. In contrast, the total absence of any discernible trend in
the DTI data and the lack of any consistent correlations between the FA and any
other measures (such as NAA concentrations and regional brain volumes) do not
suggest a straightforward lack of power. Accurate estimation of power for the DTI
part of this study is difficult as the few published studies differ markedly in terms of
techniques employed and subjects recruited (most notably, none includes female
subjects - our data suggest there may be a male/female difference). One of the aims
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of this (pilot) study was to establish an estimate of effect size for future power
calculations.
Volume of interest
The volume of interest approach has inherent limitations particularly when applied to
white matter. It is difficult to ensure that the volume identified consistently reflects
the same anatomical structures within the brains of different subjects. One might
predict that as white matter tracts approach the cortex, diffusion anisotropy would
fall as the fibres spread out. In this study, the volumes of interest were placed
manually (always by the same experienced and experimentally blind radiologist).
The reliability of this placement was not measured. Another limitation of this
approach is that an apparently normal finding in the region studied does not rule out
the possibility of significant structural abnormalities in important adjacent structures.
'H-MRS
Single voxel proton MRS is slow and has a relatively poor spatial resolution. This
increases the potential for contamination of the white matter spectrum by signal
originating from grey matter and CSF. Such partial volume averaging is difficult to
avoid, but since the MRS VOI is placed within a large region of white matter, such
effects will be minimized. One new MRS technique, which could potentially
circumvent this problem is called 'chemical shift imaging' (CSI). This involves the
acquisition of a 2 (or 3) dimensional grid of spectra, the additional information
allowing estimation of the tissue composition of the volume of interest.
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DTI
DTI is a new technique and a number of issues relating to data acquisition and image
analysis arose during the course of this pilot study. First, because single-shot
diffusion-weighted echo-planar imaging suffers from artifacts caused by
susceptibility changes at air/tissue boundaries (e.g. frontal sinus), accurate diffusion
imaging data could not be obtained from all regions of the brain. Second, the
gradient strength (15mTm_1) and rise time (30mTnT'ms~') of the scanner's gradient
set were somewhat limited. This was reflected in the large field-of-view (44 x
22cm), relatively low image resolution (1.72 x 1.72mm voxels), low value of
diffusion-weighting (Trace(b) ~ 700smm"2) and long echo train (200ms). Also the
diffusion-weighted echo-planar imaging sequence could not be cardiac gated, which
may result in artefactual increases in diffusion anisotropy close to the ventricles. The
resulting FA maps therefore have relatively lower sensitivity and resolution than
ideally required. Nevertheless, the absolute values for the FA of white matter
reported in this study (-0.45) are in close agreement with those reported by Lim and
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colleagues . Finally, the raw data must be processed to remove the effects of eddy
currents and physiological movement before accurate diffusion anisotropy
information may be obtained42. In this study DTI data acquisition was therefore
limited to specific regions of interest and no attempt was made to acquire DTI data
from other regions of the brain.
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Comparisons with Similar Studies
Previous studies
1 *2122The H-MRS findings from this study were consistent with the existing literature ' ,
whilst the DTI findings were not27'28. However, DTI is a relatively new technique
and the literature relating to schizophrenia is small. At the time this study was
published, the literature relating to pre-frontal white matter in schizophrenia was
limited to two small case control studies, both reporting reductions in diffusion
anisotropy in association with schizophrenia.
Buchsbaum and colleagues27 compared five male schizophrenic subjects with six
male controls. They analysed their data using a statistical parametric mapping
approach, which is not easily translated into an effect size for a volume of interest
study (see Chapter 2B). However, the volume of interest examined in this study
approximated to the region of the brain in which Buchsbaum and colleagues found
the most highly statistically significant reduction in diffusion anisotropy.
The only previous study to employ similar techniques to this one was published by
Lim and colleagues in 199928. They report a statistically significant reduction in
diffusion anisotropy in frontal white matter in ten schizophrenic US army veterans
compared with ten male controls, (the largest effect size they report is 1.5 x SD
which, for n = 10, translates to power > 0.99 at a two-tailed significance level of
5%). However there are important differences between their subjects and the
subjects in this study. First, there is a large discrepancy in the age of subjects (mean
of 48 years in Lim study versus 34 years in this study). One could speculate that the
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differences they report are a consequence of decades of disease process or anti¬
psychotic exposure (although there was no correlation between fractional anisotropy
and duration of illness in the present study). Second, a number of the schizophrenic
subjects in the present study were known to have the characteristic macroscopic
structural brain abnormalities associated with schizophrenia (reduced whole brain
volume, increased ventricular size). It was anticipated, perhaps incorrectly, that pre¬
existing differences between the groups on established measures of brain structure,
would increase prospects of detecting corresponding between group differences
using DTI (i.e. increase the power of the study). Third, Lim et al. studied only male
subjects whilst half of the subjects in the present study were female. It is possible
that the different results may reflect male/female differences in diffusion anisotropy.
Table 2Ciii shows that whilst fractional anisotropy was reduced in male
schizophrenics (although the effect sizes -0.05 to -0.86 were smaller than those
reported by Lim et al.), it was actually increased in female schizophrenics. This
result, and in particular, the increased anisotropy in schizophrenic females in the
occipital region was not anticipated, and is not understood. There is a relative
paucity of imaging studies as a whole in female schizophrenic subjects, and this
finding requires further exploration.
Subsequent studies
Since the publication of this study, three subsequent DTI studies have reported
findings relating to diffusion anisotropy in the frontal white matter in schizophrenia.
Two studies employed a computational (SPM) analysis to examine diffusion
anisotropy of white matter throughout the brain. Both of these reported negative
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findings in the pre-frontal region that was examined in this study. Foong and
colleagues compared 14 patients (11 male, 3 female) with 19 controls and reported
no significant differences anywhere in the brain43. Agartz and colleagues, adopting a
similar approach, compared 20 schizophrenic subjects (11 male, 9 female) with 24
controls and found reductions in the splenium of the corpus callosum but nowhere
else44. The only study to report a positive finding was by Kubicki and colleagues
from Martha Shenton's group in Harvard. They compared 15 patients (male and
female) with 18 normal controls. The method involved careful placement of a
volume of interest within the uncinate fasciculus bilaterally. Although they found no
overall differences in fractional anisotropy between patients and controls, they did
report an asymmetry (FA: Left > Right) in normal subjects that was not present in
schizophrenic subjects45. No such asymmetry was idenntified in either group in this
study (see Table 2Ciii).
Although the three studies described above could be interpreted as validating of our
negative DTI result, a subsequent study from within this department comparing 30
patients (15male, 15 female) with 30 matched controls employing a computational,
voxel-based analysis technique has identified significant reductions in FA in the left
uncinate fasciculus and left superior longditudinal fasciculus46. Not only is this the
largest single study in the field, but the data was acquired on the latest generation of
scanner (GE Signa LX 1,5T) and the data analysis protocol has been refined since the
original study.
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Implications for Future Research
'H-MRS is a potentially useful adjunct to both structural and functional imaging
research. Meanwhile DTI has the potential to develop into a powerful technique for
the study of white matter in vivo. In the future it may usefully complement
functional imaging techniques by providing information about the structural basis of
abnormal functional connectivity. DTI certainly merits further development and
ultimately may prove to be a useful tool in schizophrenia research. At present the
research evidence is inconsistent. It is not possible to say for certain whether white
matter cyto-architecture is normal or abnormal in schizophrenia. Clearly larger
studies using proven techniques of data acquisition and analysis are required.
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The search for biological correlates of schizophrenia using in-vivo structural brain
imaging has undergone significant advances since Jacobi and Winkler's original
pneumo-encephalographic study of 19271. After a slow start, research took off
following the publication of the first case-control CT study in 19762. The field has
benefited enormously from technological advances, which have delivered finer
spatial resolution and superior soft-tissue discrimination, not to mention improved
safety (see Chapter 1C). A large body of work has built up, comprising several
hundred studies. Whilst many fundamental questions pertaining to brain structure in
schizophrenia remain unanswered, scientific consensus has been achieved in a
number of important areas (see Chapter ID).
It is now accepted that, as a group, patients with schizophrenia have smaller brains
and larger cerebral ventricles than healthy controls3 and that particular brain regions
are affected disproportionately4. It is also widely acknowledged that these
morphological features can be identified during the first psychotic episode5.
Griesinger's bold declaration in 1867 that "patients with so-called 'mental illnesses'
are really individuals with illnesses of the nerves and brain"6 would now be
considered incontrovertible (at least in relation to certain cases of schizophrenia).
Furthermore, the credibility of the pre-eminent contemporary aetiological theory of
schizophrenia, the "neurodevelopmental hypothesis"7, is largely attributable to its
compatibility with structural imaging findings.
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Each successive technological advance has brought both new insights and new
challenges. Whilst the relationship between schizophrenia and ventricular
enlargement was established by researchers employing pneumoencephalography and
CT, the structural brain abnormalities could not have been localised without the
superior white/grey matter discrimination offered by MRI. The results of MRI
studies conducted to date suggest that the brain regions of greatest relevance to
schizophrenia research may be the small and convoluted structures of the
limbic/medial temporal lobes (amygdala, hippocampus, para-hippocampus, insula
etc.)4 Adequate imaging of these structures requires spatial resolution of the order of
a millimetre combined with highly sensitive soft-tissue discrimination. MRI
machines meeting the required specification have only become available in the last
decade or so.
The study presented in Chapter 2C of this thesis demonstrates the types of difficulty
encountered by schizophrenia researchers endeavouring to work at the limits of
imaging technology. The early DTI literature described in that chapter is
characterised by inconsistency. There is no established consensus in relation to
methodology. Studies are small and technically flawed. It is perhaps not surprising
therefore that results and conclusions vary from study to study. It is interesting to
reflect that a little over 20 years ago the entire field of structural brain imaging in
schizophrenia was in a comparable, embryonic state. One might anticipate that, as
technology improves, techniques currently viewed as "cutting edge", (such as DTI)
may become routine. Meanwhile, hitherto unimaginable techniques may emerge.
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Whilst structural brain imaging research has undoubtedly benefited from
technological developments, it could be argued that it has failed fully to exploit
advances in data acquisition on account of limitations in computational methods.
This is a problem shared by all technology-led fields. For example, molecular
biology currently finds itself in a similar situation with vast amounts of data relating
to 'proteomics' and 'cDNA micro-assays' (the molecular correlates of gene
o
expression) lying dormant in anticipation of future advances in bio-informatics . An
MRI scan contains a vast amount of information relating to the three-dimensional
structure of the brain. However, conventional approaches to image analysis (such as
the Region of Interest analysis presented in Chapter 2A) are capable of dealing with
only a fraction of this data. Recently developed computational methods such as
Voxel-Based Morphometry (illustrated in Chapter 2B) and Shape Analysis (see
Chapter IE) are just beginning to unlock the full potential ofMRI.
Brain imaging research will probably continue to ride the advancing wave of
technology for years to come. However, sharper pictures and smarter computer
programmes are unlikely to unlock the secrets of schizophrenia unless they bring
about a conceptual shift. In the author's opinion, the failure of a whole generation of
biological researchers to identify anything approaching a pathognomonic marker for
this disorder is a reflection not of poor research but of a flawed concept.
Whilst Kraepelin's ambitious attempt to shoehorn his patients into a rigid 19th
century medical model was in many respects admirable, there is now powerful
evidence to suggest that it was wide of the mark (see Chapter 1B). The process by
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which Kraepelin's original concept of 'dementia praecox' evolved into our current
operational criteria for 'schizophrenia' is described in chapter 1 A. It is clear that this
process was driven as much by political expediency as by scientific rigor. The
notion that Spitzer and his successors, through some unprecedented act of
serendipity, may have chanced upon a "natural disease entity"9 is risible. It is almost
inconceivable that every patient who fulfils the ICD-10 or DSM-IV criteria for
schizophrenia shares a common "necessary and sufficient"10 "tangible morbid
process"11.
The creators of these diagnostic manuals do not claim to have found the holy grail of
psychiatry. As Nancy Andreasen and William Carpenter Jr. concede "the construct
must be recognised as provisional and based on a need to achieve consensus about
12definitions rather than on an understanding of pathophysiology and aetiology." To
the author's mind, this stance is more credible than that of critics such as Bentall who
advocate the wholesale abolition of the concept whilst failing to present a viable
alternative13. As argued in Chapter IB, it is undoubtedly better to use the current
concept as a starting point than to abandon it altogether. However, if advances in
imaging technology are to lead to genuine breakthroughs in the understanding of the
pathophysiological processes underlying the symptoms and behaviours that are
currently called 'schizophrenia', researchers must be prepared to think 'out of the
box'. Should researchers find themselves presented with data that are not easily
interpreted within the boundaries of the current concept then they ought to feel able
to question not only the data but also the concept. It would be an unfortunate irony if
the very operational definitions created to facilitate research were to become a barrier
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to scientific progress because researchers showed them too much respect. In the
author's view the contemporary search for reliable endophenotypic markers (as
illustrated in Chapter 2A) to act as intermediaries between pathophysiological theory
and clinical observation is a welcome step in this direction.
The uncomfortable situation facing contemporary schizophrenia researchers is that,
despite over 100 years of scientific endeavour, there are precious few certainties in
the field that we have chosen to study. The traditional assertion that psychosis is
categorically distinct from normality is by no means assured (it may be more
accurate to view psychosis as one end of a continuum14). It is not clear that the
Kraepelian distinction between schizophrenia and manic-depressive psychosis
reflects clinical reality (see Chapter IB). Finally, we can not be absolutely certain
that the collection of individuals brought together by their compatability with the
criteria listed under 'schizophrenia' in our diagnostic manuals have anything other
than this in common. The author draws comfort from the Chinese proverb: "To be
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Structural MRI of the brain in presumed carriers of genes
for schizophrenia, their affected and unaffected siblings
R M Steel, H C Whalley, P Miller, J J K Best, E C Johnstone, S M Lawrie
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Background: Schizophrenia is a highly heritable disorder associated with structural brain abnormali¬
ties. The aim of this study was to establish if the gene(s) for schizophrenia are associated with specific
abnormalities of brain structure.
Subjects: Six sibships from multiple affected families were recruited. Each sibship consisted of one
patient with schizophrenia, one "obligate carrier" without the disorder but with an affected child, and
one "non-affected non-carrier". Such sibships are very rare, but present a powerful opportunity to sepa¬
rate the associations of genotype and phenotype. Obligates presumably have the gene(s) but not the
disorder, affected siblings have both, whereas non-affected non-carrier siblings have neither.
Method: Brain MRI was conducted with a semiautomated region of interest analysis. The risk of false
positive findings was reduced by collapsing brain regions and sides into five regions and comparing
groups by repeated measures analysis of variance.
Results: In terms of whole brain volumes and volumes of cortical structures, obligates resembled their
non-affected non-carrier siblings, both groups having significantly greater volumes than their
schizophrenic siblings (p=0.01 and p=0.04). Obligates also had significantly smaller ventricles than
their schizophrenic siblings (p=0.03). However, with respect to the amygdalohippocampal complex,
the obligates' brains resembled those of their schizophrenic siblings, both groups showing a significant
reduction in volume when compared with their non-affected non-carrier siblings (p=0.001).
Conclusions: In the families studied, reductions in volumes of cortical structures and reductions in
whole brain volume seem to be associated with the phenotype of schizophrenia. By contrast, reduced
volume of the amygdalohippocampal complex seems to be associated with genetic risk for the disor¬
der even in the absence of disease.
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Data from postmortem and in vivo brain imaging studiesprovide powerful evidence that schizophrenia is associ¬ated with abnormalities of brain structure 1_J The most
consistently identified abnormalities include reduced whole
brain volume, increased lateral ventricle volume, and reduced
volumes of the temporal lobes and medial temporal lobe
structures. The origins and significance of these structural
abnormalities are, however, not well understood. The pre¬
eminent contemporary theory proposes that they arise as a
result of abnormal brain development.'1
Many cases of schizophrenia are familial. The epidemiologi¬
cal evidence from twin and adoption studies strongly suggests
that this familiality has a genetic origin.' However, to date,
attempts to identify specific genes that might be associated with
or even responsible for the disorder have proved inconclusive.6 7
It is generally accepted that, even in highly familial cases, the
development of schizophrenia is probably influenced by both
genetic and environmental factors. The relative importance of
genes versus environment in the development of the structural
brain abnormalities associated with the illness remains unclear.
The aim of this study was to establish if the gene(s) for
schizophrenia are associated with abnormalities of brain
structure. We specifically hypothesised that amygdalohippoc¬
ampal volumes are genetically mediated and tested this by




The study was designed to separate out the genetic risk for
schizophrenia from the illness itself (table 1). This was
achieved by recruiting persons who had apparently transmit¬
ted schizophrenia from one affected parent to one or more
Table 1 The study design can separate the effects of
gene(s) from the effects of illness
Inherited high Shows symptoms of
genetic risk schizophrenia
Affected sibling Yes Yes
Obligate Yes No
Unaffected sibling No No
affected children while remaining well themselves (so-called
"obligate carriers"). Data from these obligates were compared
with data from their schizophrenic siblings and their
non-affected, presumed non-carrier siblings (as they had
adult children without the disorder). An anonymised example
of an ideal obligate family tree is shown in figure 1.
Exclusion criteria reflecting known risk factors for altered
brain volume were age>65 years; alcohol dependence (past or
present); dementia, or other "organic" brain disease; and any
space occupying intracranial lesion.
Families showing the ideal pattern of inheritance described
in figure 1 are obviously rare. Family trees relating to 255 mul¬
tiply affected Scottish families (originally identified for the
Edinburgh high risk study8) were examined. Sixty obligates
were identified, 14 of whom had both an affected sibling and
Abbreviations: PSE, present state examination; SADS-L, schedule for
affective disorders and schizophrenia—lifetime version; NART, national
adult reading test
www.jnnp.com
456 Steel, Whalley, Miller, et al
Elderly OK) Drl
Middle Aged □ Ir
Young Adult








"i 5~ 5 6 ~i
a non-affected, non-carrier sibling. All 14 families were
contacted. Five families were unsuitable as one or more of the
siblings met the exclusion criteria listed above (most
exclusions were due to age). Of the remaining nine families,
three did not wish or were unable to participate. Data were
therefore obtained from six sibling "triples". Five of the
sibships were of the same sex (three female, two male); the
remaining family included a female patient and obligate and
a male non-carrier (who was a twin with the patient).
Personal data
All subjects were interviewed (by RMS) with the present state
examination (PSE)9 and the schedule for affective disorders
and schizophrenia—lifetime version (SADS-L).10 Premorbid
IQ was tested using the national adult reading test (NART)."
Descriptive information was gathered from case notes and
interviews (table 2 for details).
Imaging data
The MRI examinations included a dual spin echo sequence to
exclude any significant brain lesions and a rapid volume
acquisition sequence for volumetric data analysis. Any coil
inhomogeneities were corrected for by scanning a flood
phantom immediately after image acquisition and normalis¬
ing to this before analysis. Unfortunately, it was not possible
to examine all the subjects on the same machine. The first
three sibling triplets were scanned at the MRI Unit, City Hos¬
pital, Edinburgh before the unit closed, on a 1 tesla
Magnetom scanner (Siemens, Erlanger, Germany) using a
MPRAGE sequence, FOV 250 mm, flip angle 12°, TR=I0 ms,
TE=4 ms, TI=200 ms, and relaxation delay 500 ms, giving
128 partitions 1.88 mm thick. The remaining three triplets
were scanned at the Royal Infirmary, Edinburgh, with a 1
tesla Signa scanner (General Electric Company, Milwaukee,
USA) using a SPGR sequence, FOV 250 mm, flip angle 30°,
TR= 16.4 ms, TE=3.3 ms, RBW 8.93 KHz, giving 124
partitions 1.5 mm thick. Regions of interest were traced on a
slice by slice basis according to well established criteria using
the semiautomated computer programme "ANALYZE" (Mayo
Foundation, Rochester, MN, USA). Ail data were analysed by
the same experienced rater (HCW) who was blind to group
and has previously demonstrated high interrater and
intrarater reliability.8 Boundaries between brain regions were
determined in accordance with criteria described in previ¬
ously published studies from this department.8 Volumetric
data for the following brain regions were collected: whole
brain, third ventricle, fourth ventricle, right and left lateral
ventricles, prefrontal lobes, temporal lobes, caudate nuclei,
lentiform nuclei, thalamic nuclei, and amygdalohippocampal
complexes.
Statistical analysis
To reduce the chance of false positive findings, brain regions
and sides were collapsed into the following regions: whole
brain; cortical structures (prefrontal and temporal lobes);
subcortical structures (caudate, lentiform, and thalamus
nuclei); amygdalohippocampal complexes; and intracerebral
ventricular system (lateral, third, and fourth ventricles). The
null hypothesis was that there would be no difference between
the three groups in terms of regional brain volumes. This was
tested by repeated measures analysis of variance (ANOVA).
The volumes of each collapsed region in each of the three
subject groups was taken as a within subjects factor, with the
scanner entered as a between subjects factor.
Table 2 Demographic and clinical details of subjects by group
Schizophrenic Non-affected,
siblings Obligates non-carrier siblings
Age (y; mean (SD)) 46.2 (7.4) 49.0 (4.8) 45.2 (7.7)
NART IQ (mean (SD)) 95.6 (15.4) 107.4 (12.9) 97.3 (17.8)
Years in education (mean (SD)) 11.0 (0.9) 11.2 (2.4) 10.8 (1.6)
Current employment:
No 3 0 1
Part time 2 1 1
Full time 1 5 A
Marital status:
Single 4 0 0
Divorced 1 2 0
Married 1 4 6
Psychiatric history:
Psychotic 6 0 0
Non-psychotic 0 3 3
None 0 3 3
Duration of illness (y; mean (SD)) 20.8 (9.9) NA NA
Antipsychotic dose (mg/day chlorpromazine 342 (256) None None
equivalent!
Current symptoms:
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Table 3 Volumes of hrnin regions by group
Non-affected, Significant between
Schizophrenic non-carrier group differences by
siblings mean Obligates siblings mean repeated measures
Brain region (SD) mean (SD) (SD) ANOVA (df=2,3)
WtmW
Brain 1193.2 (50.2| 1259.2 (85.6) 1262.6 (68.0) SCHcOBL, NANC
(5=7.8, p=0.01|
Cortical
Structures 273.8 (9.5) 293.7 (16.0) 293.4 (13.4) SCH<OBL, NANC
Prefrontal lobe left 63.9 (6.3) 67.8 (6.1) 66.2 (3.4) (5=4.7, p=0.04)
Prefrontal lobe right 65.9 (3.0) 71.1 (6.4) 73.5 (7.5)
Temporal lobe left 70.9 (3.4) 75.6 (6.9) 74.2 (7.8)
Temporal lobe right 73.0 (2.4) 79.3 (8.4) 79.5 (6.9)
Subcortical
Structures 28.1 (2.4) 27.6 (3.0) 28.8 (2.7) No significant
Thalamus left 5.2 (0.3) 5.3 (0.5) 5.7 (0.5) between group
Thalamus right 5.2 (0.5) 5.4 (0.6) 5.7 (0.6) differences
Caudate left 4.0 (0.5) 3.9 (0.5) 3.8 (0.4) (F=3.2, p=0.095)
Caudate right 3.9 (0.5) 3.7 (0.7) 3.8 (0.3)
Lentiform nucleus left 4.9 (0.8) 4.6 (0.7) 4.8 (0.8)
Lentiform nucleus right 4.8 (0.6) 4.6 (0.8) 4.9 (0.7)
Amygdalohippocampal
complexes 7.8 (0.8) 8.4 (0.5) 8.8 (0.3) SCH, OBL<NANC
Left 3.6 (0.5) 3.9 (0.4) 4.1 (0.3) (5=16.5, p=0.001)
Right 4.1 (0.4) 4.5 (0.2) 4.7 (0.3)
Intracerebral
Ventricular system 16.6(6.4) 9.6 (5.2) 18.9 (11.4) OBL<SCH
Lateral ventricle left 7.0 (2.9) 5.0 (2.9) 10.3 (7.6) (5=5.4, p=0.03|
Lateral ventricle right 7.9 (4.4) 3.3 (1.8) 7.0 (2.9)
3rd Ventricle 0.9 (0.3) 0.6 (0.2) 0.9(1.0)
4th Ventricle 0.7 (0.3) 0.8 (0.5) 0.6 (0.1)
Volumes expressed in cm3.
RESULTS
Results from volumetric analysis of the MRI are shown in
table 3. There were no statistically significant group by scanner
interactions.
Differences between schizophrenic subjects and their
non-affected, non-carrier siblings were largely consistent with
the existing literature. Whole brain volume was significantly
smaller in the schizophrenic subjects (by about 5%), with a
disproportionate reduction in the volume of the amygdalohip-
pocampal complexes (12%). The expected increase in ven¬
tricular volume was, however, not found.
In terms of whole brain volume and volumes of cortical
structures, the obligates were indistinguishable from their
non-carrier siblings (and significantly larger than their
schizophrenic siblings). They also had significantly smaller
ventricles than their schizophrenic siblings. However, with
respect to the amygdalohippocampal complex, the obligates'
brains did not differ significantly from their schizophrenic
siblings' brains (both groups showing a significant reduction
in volume compared with the non-affected, non-carriers).
DISCUSSION
In this study, presumed carriers of the gene(s) for schizophre¬
nia ("obligates") were found to share a significant reduction
in amygdalohippocampal volume with their schizophrenic
siblings. However, by contrast with their affected siblings, they
were found not to have reduced frontal or temporal lobe or
whole brain volumes; nor did they have large ventricles. This
suggests genetic and phenotypic effects respectively.
The use of two separate MRI scanners in this study is an
obvious and potentially serious limitation. However, the risk of
bias was minimised by scanning all members of any given
family on the same machine and by entering the scanner as a
between subjects factor in the statistical analysis. Indeed, as
no significant scanner interactions were found, our study pro¬
vides some evidence that regional volumetric analyses are
reliable across scanners (although obviously this comparison
has low power).
One interesting and unexpected finding of this study was
the relatively high IQ of the obligates (as shown in table 2 their
average NART score of 107 was 10 points higher than either
their schizophrenic or non-affected siblings). This raises the
possibility that, amongst people at high genetic risk of schizo¬
phrenia, intelligence may be, or reflect, a protective factor,
although various interpretations of this finding are clearly
possible.
The design adopted for this study allows effects attributable
to genetic risk to be separated from effects of disease without
the need to identify the gene or genes responsible. The use of
siblings as controls also carries the advantages of eliminating
a number of potential sources of bias (reducing in particular
non-specific variance in regional brain volumes), thereby
increasing the power of the study. Sibling "triples" as
described above are very rare and any study of this design will
inevitably be small. Previous studies reporting volumetric data
from brain imaging in relatives of schizophrenic patients sug¬
gest a range of brain abnormalities with relatives falling mid¬
way between schizophrenic patients and normal controls.12
Most of these studies adopt a straightforward "schizophrenic
patients versus relatives versus controls" design which does
not allow persons with the gene(s) to be separated from those
without. The only previously published study of obligates13 did
not report amygdalohippocampal volumes but found in¬
creased left lateral ventricle volume (which we did not find).
That study adopted a slightly different design comparing nor¬
mal unrelated controls with obligates, schizophrenic patients,
and non-obligate relatives recruited from 16 multiply affected
families. This design did not allow such a clear separation of
genetic and environmental factors as the "sibling triples"
design described above.
In any condition with apparently familial and non-familial
cases, it can be argued that highly familial cases are
unrepresentative of the condition as a whole. This study
involved subjects from families inwhich schizophrenia was not
only unusually prevalent but also inherited in an apparently
dominant pattern. The genetic mechanisms involved in these
www.jnnp.com
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families may therefore be different from those acting in fami¬
lies with a non-dominant pattern of inheritance and may be of
little relevance to non-familial cases of schizophrenia. The data
from this study suggest that reduced volume of the amygdalo-
hippocampal complex in schizophrenia is genetically deter¬
mined whereas cortical changes and increased ventricular vol¬
ume are not (and are presumably associated with the
phenotype). However, data from the Edinburgh high risk
study3 does not support such a straightforward explanation. In
that study genetic liability to schizophrenia in those from mul¬
tiply affected families (with a range of patterns of inheritance)
was not linearly associated with amygdalohippocampal
volumes.12 The genetic mechanisms involved in the develop¬
ment of schizophrenia are, however, not well understood and
many different genes may be involved. We interpret our results
as suggesting that obligates in this study have inherited some
of the responsible genes (those causing amygdalohippocampal
change) but not others (those responsible for cortical changes
and symptoms). It seems likely that, even in families with an
apparently dominant pattern of inheritance, highly complex
gene-environment interactions are involved not only in the
development of symptoms, but also in the genesis of structural
brain abnormalities such as reduced brain volume and
enlarged ventricles.
Genetic research into schizophrenia is currently a highly
active area with many linkage and association studies in
progress. The data from this study suggest that genes may play
a part in the development of some, but not all, of the structural
brain changes associated with the condition.
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Abstract
Several proton magnetic resonance spectroscopy ('H MRS) studies in schizophrenia have found reduced A-acetyl
aspartate (NAA) concentrations in pre-frontal and temporal regions of the brain. Reductions in NAA may reflect
abnormalities of neuronal structure (e.g. reduced neuronal density or viability) or abnormalities of neuronal function.
Diffusion tensor imaging (DTI) measures diffusion anisotropy, an indicator of the structural integrity of a neuronal
tract. Both techniques were used to examine the anatomical basis of pre-frontal dysfunction in schizophrenia. Ten
patients with DSM-IV schizophrenia were compared with 10 healthy controls. 1H MRS and DTI were performed on
a clinical MR system and analysed with a region of interest approach. NAA concentrations and diffusion anisotropy
were measured in the same pre-frontal white matter region. Diffusion anisotropy was also measured in a control
region (occipital white matter). 'H MRS revealed non-significant but consistently reduced NAA concentrations (by
10-15%) in the pre-frontal white matter in schizophrenic subjects. Diffusion anisotropy measures revealed no such
differences between schizophrenics and controls. It is concluded that the abnormalities of 'connectivity' reported in
brain-imaging studies of schizophrenia may not be attributable to structural abnormalities of white matter and that
reduced NAA in the pre-frontal white matter may reflect abnormal function of structurally intact neurons. © 2001
Elsevier Science Ireland Ltd. All rights reserved.
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1. Introduction
No single theory has yet been developed which
successfully explains the onset, clinical and patho¬
logical features and course of schizophrenia. The
'Neurodevelopmental Hypothesis of Schizophre¬
nia' (Murray, 1994) proposes that the disorder is
due to developmental abnormalities arising be¬
fore or around the time of birth, the psy-
chopathology emerging in early adult life as the
affected neuronal systems mature. It is suggested
that the underlying pathology relates to disrupted
neuronal migration during very early life (Raedler
et al., 1998). The evidence in favour of this theory
is by no means conclusive, but it finds support in
the results of some post-mortem (Akbarian et al.,
1993) and in-vivo imaging (Kotrla and Wein¬
berger, 1995) studies.
The findings of functional imaging studies [PET
(Soares and Innis, 1999; Fu and McGuire, 1999)
and more recently fMRI (Kindermann et al.,
1997)] suggest that schizophrenia may be associ¬
ated with abnormal 'connectivity' between dif¬
ferent brain regions (Andreasen et al., 1998).
Precisely which aberrant connections are most
important in the patho-physiology of the disorder
is currently unclear. Cases have been argued for
fronto-temporal pathways (Woodruff et al., 1997),
fronto-cingulate connections (Fletcher et al.,
1999) and trans-callosal fibres (Crow, 1998). If it
is true that the connections between two regions
of the brain have developed abnormally, one
might expect to find abnormalities in the cyto-ar-
chitecture of the white matter tracts carrying ax¬
ons between those regions. This study uses proton
magnetic resonance spectroscopy ('H MRS) and
diffusion tensor imaging (DTI) to examine the
anatomical basis of connectivity in the pre-frontal
white matter.
1.1. 'H MRS
Proton magnetic resonance spectroscopy mea¬
sures the concentration of various biologically
important metabolites in the brain. Although spa¬
tial resolution is relatively poor compared to con¬
ventional MR imaging (15-mm cubic voxels in this
study), the technique is useful because it allows
brain chemistry to be studied in vivo without the
use of radioactive tracers. Most studies report
A-acetyl aspartate (NAA) concentrations because
the peak in the proton spectrum attributable to
NAA is prominent and can be measured reliably.
NAA is found predominantly within neurons
though its intracellular function is unclear. It is
thought to be a neuronal/axonal marker, and its
concentration may, therefore, provide a measure
of both the number and integrity of neurons
within a region of the brain. In connection with
schizophrenia, many previous studies have re¬
ported reduced NAA concentrations in certain
brain regions (Bertolino and Weinberger, 1999),
particularly the hippocampus, frontal cortex and
pre-frontal white matter. In this study 'H MRS
was used to measure NAA concentrations in pre¬
frontal white matter. Reductions in NAA in this
region may reflect a structural abnormality (such
as reduced axonal density or reduced viability of
neurons), or it may reflect abnormal function of
structurally normal neurons whose axons travel to
and from the frontal lobes.
1.2. DTI
In the brain, the rate at which water molecules
diffuse along a particular direction (the apparent
diffusion coefficient, or ADC) can be measured in
vivo from MR images by applying a diffusion
sensitising gradient in the direction of interest.
Structures such as myelin sheaths, axonal mem¬
branes and micro-filaments cause the diffusion to
be slower perpendicular to axons than parallel to
them, thereby leading to diffusion anisotropy in
the measured ADCs. From a set of diffusion-
weighted images, the apparent diffusion tensor,
D, can be derived. The extent to which diffusion
is disrupted by cellular structures is then reflected
in the degree of asymmetry of the tensor. Mea¬
sures of diffusion anisotropy are indicators of the
structural integrity of a neuronal tract. A com¬
monly quoted diffusion anisotropy index is the
fractional anisotropy, FA, which measures the
fraction of the total 'magnitude' of the apparent
diffusion tensor that is anisotropic (Basser, 1995;
Pierpaoli and Basser, 1996).
DTI is a relatively new technique and the liter-
R.M. Steel et al. /Psychiatry Research:
ature relating to schizophrenia is small and incon¬
sistent. Buchsbaum et al. (1998) reported reduced
diffusion anisotropy in the white matter of the
pre-frontal cortex in five schizophrenics compared
with six controls. Lim and colleagues (Lim et al.,
1999) studied 10 US army veterans with
schizophrenia and found widespread reductions
in anisotropy throughout the brain, whilst Foong
et al. (2000) studied the corpus callosum in twenty
patients and reported reduced anisotropy in the
splenium, but not the genu. The primary aim of
this study was to measure diffusion anisotropy in
the pre-frontal white matter. Diffusion anisotropy
was also measured in a control region (occipital
white matter) which is not generally implicated in
the pathophysiology of schizophrenia.
1.3. Hypothesis
The study was designed to yield potentially
complementary information from 1H MRS and
DTI in the same patients and controls. The main
hypothesis being tested was that NAA concentra¬
tions and diffusion anisotropy would be abnormal
in the pre-frontal lobe white matter, i.e. that
aberrant connectivity in schizophrenia has struc¬
tural and functional correlates.
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2. Method
2.1. Subjects
Ten patients with established DSM-IV
(American Psychiatric Association, 1994)
schizophrenia were compared with 10 healthy
controls. Both male and female participants were
considered, and the groups were matched for age
(see Table 1).
Subjects were selected from patients with an
unambiguous clinical diagnosis of schizophrenia
(DSM-IV diagnosis was confirmed by SADS-L
semi-structured interview). All had participated in
previous brain-imaging studies and were known
to be able to tolerate the scanning procedure.
Mean duration of illness was 15 years and all
subjects were taking antipsychotic medication at
the time of the study. Clinical and volume acqui¬
sition scans were available for every subject.
Patients with gross structural brain abnormalities
were not considered for inclusion in this pilot
study. However, patients known to have morpho¬
logical brain changes consistent with schizophre¬
nia (slightly reduced whole brain volume, en¬
larged lateral ventricles) were included (see Table
1).
Table 1
Demographic, clinical and morphological details of subjects by group*
Schizophrenic Control P Effect size
Number of subjects 10 10 - -
Sex (male/female) 5/5 4/6 - -
Age (years) 34(14) 35 (7) - -
Duration of illness (years) 15 (12) N/A - -
Whole brain volume 1229(123) 1259(110) 0.62 -0.27
Left lateral ventricle volume 5.9 (3.0) 3.7 (2.2) 0.12 + 1.00
Right lateral ventricle volume 4.2 (2.7) 3.6(1.8) 0.59 + 0.50
Left frontal lohe volume 69(13) 70(8) 0.94 -0.12
Right frontal lobe volume 74(13) 74 (9) 0.99 0.00
Left amygdala + hippocampus 4.1 (0.4) 4.5 (0.4) 0.18 -1.00
Right amygdala + hippocampus 4.7 (0.4) 4.7(1.0) 0.98 0.00
'Values presented are the group means (S.D.) and volumes (S.D.) in ml, with the corresponding P-value and the effect
size = (meansz - meancont )/S.D.cont
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2.2. Data acquisition and analysis
All imaging and spectroscopy data were col¬
lected on an Elscint 2T Prestige (Elscint, Haifa,
Israel) clinical scanner (horizontal bore inner di¬
ameter 57 cm), equipped with a 15 mT m_1
actively shielded gradient set. The examination
consisted of a T2-weighted fast spin-echo se¬
quence (TR/TE 4800/96; FOV 22 X 22 cm; 10
axial slices beginning approx. 10 mm above the
base of the temporal lobes; slice thickness 6 mm;
slice gap 20%), a 3D gradient-echo volumetric
sequence (TR/TE 28.5/9.254 ms; FOV 18 X 18
cm; slice thickness 1.5 mm) and then the fol¬
lowing 1H MRS and DTI protocols. The complete
examination took approximately 45 min.
2.3. Proton magnetic resonance spectroscopy
Using the set of axial fast spin-echo images for
positioning, two PRESS-localised spectra (TR/TE
1500/145 ms) were acquired from 15-mm cubical
volumes of interest (VOIs) in left and right hemi¬
sphere frontal white matter approximately 5 mm
from the most anterior part of the frontal horns
in a line 45° from the midline. This voxel location
ensured that proton spectra were acquired from
homogeneous white matter rather than from a
heterogeneous mixture of tissue types. Following
localised shimming and water suppression calibra¬
tion for each VOI, 200 acquisitions with water
suppression were collected. Eight acquisitions
without water suppression were also collected to
serve as a phase reference. The VOI positions
within the head coil were noted, as was the scan¬
ner RF calibration figure to allow for the effects
of coil loading.
Spectroscopy data were transferred to a Sun
Ultra Sparc Station 10 (Sun Microsystems, Moun¬
tain View, CA, USA) workstation for analysis.
Analysis consisted of phase correction using the
water reference data (Ordidge and Cresshull,
1986) and the removal of the residual water signal
using Hankel-Lanczos singular value decomposi¬
tion (Van den Boogaart, 1994). Spectral peak
areas were quantified using the MRUI software
package ((http://carbon.uab.es/mrui)), which
fitted Gaussian line shapes to the peaks corre¬
sponding to choline (3.2 ppm), creatine (3.0 ppm)
and NAA (2.0 ppm). Finally, metabolite peak
areas for each subject were corrected for coil
loading and VOI position within the head coil.
The resulting 'institutional' units enabled inter-
subject comparisons.
2.4. Diffusion tensor imaging
Diffusion-weighted echo-planar (DW-EP)
images were obtained using a non-cardiac gated,
single-shot, spin-echo, half-Fourier sequence, in
which two symmetric diffusion-sensitising trape- 3
zoidal gradient pulses of 35-ms duration and 43.9-
ms separation were applied sequentially along the
six oblique gradient directions (G1 to G6) that '
constitute the uniform diffusion gradient sam¬
pling scheme of Basser and Pierpaoli (Basser and
Pierpaoli, 1998). In each of these six gradient
directions, nine DW-EP images were acquired
with a diffusion gradient strength of 11.0 mT
m"1, giving an average value for Trace (b) of
686.55 ± 0.61 (S.D.) s mm"2 for G1 to G6. A total
of 54 DW-EP images per slice position were
collected, plus nine baseline images (G°) with no
diffusion weighting. Values for the elements of
the b-matrix were calculated numerically (Mat-
tiello et al., 1997). Other image acquisition
parameters were as follows: 10 axial slices coinci¬
dent with those prescribed in the fast spin-echo
sequence; 6-mm slice thickness; 20% slice gap;
128 X 72 half-Fourier image matrix (zero-filled to
256 X 128); 44 X 22 cm FOV; TE of 103 ms. The
time from acquisition of one image slice to the
next was 1.4 s, so the effective TR was 14 s.
Patient head motion was minimized through use
of a Velcro strip, which was comfortably tight¬
ened around the subject's forehead.
Magnitude Fourier transformed images in DI-
COM format were transferred from the scanner
to a Sun workstation and converted into Analyse
(Mayo Foundation, Rochester, MN, USA) read¬
able form using software written in C. Within
each slice the set of nine images for each of the
diffusion gradient directions G° to G6 were sepa¬
rately realigned to remove physiological motion
using SPM95 ((http://www.fil.ion.ucl.ac.
uk/spm)), and then averaged to give seven high
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signal-to-noise images (Bastin et al., 1998). Geo¬
metric image distortions in the six DW-EP images
arising from the strong eddy currents present in
the DTI experiment were corrected using a modi¬
fied version of the iterative cross-correlation algo¬
rithm suggested by Haselgrove and Moore
(Haselgrove and Moore, 1996; Bastin, 1999).
Within each voxel the six elements of the ap¬
parent diffusion tensor D (Dxx, Dyy, Dzz, Dxy,
Dxz and D ) and the baseline T2 signal intensity
were estimated by multivariate linear regression
(Basser et al., 1994) from the measured signal
intensity using a program written in Matlab (The
Mathworks, Natick, MA, USA). After diagonali-
sation of D to yield the eigenvalues (\, = 1A3),
maps of the fractional anisotropy, FA (Pierpaoli
and Basser, 1996)
I /(\: ~ </>»2
FA - 1/ f 1/ +<V-<.P»' + p3-<P>:)
y 2 V + ^2 + ^3
were generated on a voxel-by-voxel basis and
converted into Analyze format. The fractional
anisotropy measures the fraction of the total
'magnitude' of the apparent diffusion tensor that
is anisotropic, and takes a value of 0 (see formula
above) for an isotropic (cylindrically symmetric,
» \2 = ^3) medium. Values for FA in frontal
white matter were calculated from regions-of-in-
terest (ROIs) positioned by a radiologist (JJKB)
to coincide with the centres of volumes of interest
from which the proton spectra were obtained. In
the occipital lobes ROIs were drawn by the radi¬
ologist to lie in the white matter adjacent to the
optic radiation.
3. Results
Fig. 1 shows a structural fast spin-echo image,
an FA map and a proton spectrum obtained from
a 27-year-old female schizophrenic patient who
participated in this study. The spectrum has been
acquired from the predominantly white matter
VOI indicated in the structural image. Note that
although the baseline of this spectrum is rela¬
tively noisy, as is typical in clinical MRS studies,
the NAA peak is still well resolved.
3.1. 'H MRS
As illustrated in Table 2, NAA concentrations
were reduced in male and female schizophrenic
subjects compared with controls in both the right
and left frontal white matter. The direction and
magnitude (10-15%) of this difference is consis¬
tent with previously published data (Bertolino
and Weinberger, 1999). These findings failed to
reach statistical significance (by one way ANOVA
using a 2-tailed significance level of 5%), but this
may be due to the small number of subjects in
this pilot study.
3.2. DTI
As illustrated in Table 3, when data from all
subjects (male and female) were analysed there
were no consistent differences between the FA
values obtained from schizophrenics and controls.
In schizophrenic subjects, diffusion anisotropy was
slightly reduced in left frontal white matter, but
slightly increased in the other regions measured.
All between-group differences were small and
none was close to statistical significance. The
absence of any discernible trend in these DTI
data suggests that this was not simply a type-2
error caused by small numbers.
Table 3 also shows the FA values for males and
females, analysed separately. In male schizo¬
phrenics, anisotropy was slightly reduced in all
four ROIs, but the findings were not statistically
significant. In females the only difference between
the groups was a statistically significant (P < 0.01)
increase in anisotropy in the right occipital region
in the schizophrenics.
3.3. Co/relations
Correlations between 'H MRS and DTI mea¬
sures were inconsistent. Within the schizophrenic
group, NAA concentrations in the right frontal
region showed a significant positive correlation
with FA in both the right and left frontal regions
(Pearson coefficients: Right 0.65, P < 0.05; Left
0.69, P < 0.05). However, no such correlation was
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Fig. 1. A structural fast spin-echo image (a); a fractional anisotropy, FA, map (b); and a proton spectrum (c) obtained at the level of
the lateral ventricles from a 27-year-old female schizophrenic subject in this study. The VOI from which the proton spectrum was
acquired is indicated on the fast spin-echo image (□). The IV-acetyl aspartate (NAA), choline (CHO) and creatine (CR) peaks are
also indicated on the spectrum. In the FA map, high diffusion anisotropy is indicated by light pixels.
found in the control group (Pearson coefficients: schizophrenics showed a weak negative correla-
Right 0.09, P>0.8; Left 0.18, P>0.7). Further- tion with the FA (Pearson coefficients: Right
more, NAA in the left frontal region in — 0.3, P > 0.4; Left -0.2, P> 0.5).
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Table 2
4k1 H MRS results by brain region, patient group and sex*
Subjects Brain region Schizophrenic Control P Effect size (d)
Males Left frontal 1072(244) 1100 (218) 0.88 -0.13
Females Left frontal 992(196) 1235 (164) 0.09 -1.48
All subjects Left frontal 1027(208) 1178(186) 0.16 -0.81
Males Right frontal 1065(218) 1122(143) 0.71 -0.40
Females Right frontal 1019(147) 1153(134) 0.20 -1.00
All subjects Right frontal 1039(171) 1140(157) 0.22 -0.64
"Values presented are the mean (S.D.) IV-acetyl aspartate peak areas in arbitrary units, P-value and the effect size = (meansz —
meancont.)/S-D.conl
Correlations with volumetric data were also
inconsistent. Within the schizophrenic, but not
the control group, NAA concentrations in the left
frontal region correlated strongly with the volume
of the amygdalo-hippocampal complex on the
left (Pearson coefficient 0.92, P < 0.05); however,
there was no correlation between the same mea¬
sures on the right (Pearson coefficient 0.01, P =
0.98). The FA showed no correlation with any
volumetric measures in either group. Neither 'H
MRS nor DTI measures correlated with the dura¬
tion of illness.
4. Discussion
In this study schizophrenia was found to be
associated with reduced NAA concentrations in
the pre-frontal white matter, but with normal
diffusion anisotropy in the same region. These
findings suggest that, whilst the neuronal tracts
running to and from the frontal lobes may be
functionally abnormal in schizophrenic subjects,
they are structurally intact. The authors conclude
that the aberrant functional connectivity reported
in schizophrenia may not be attributable to
Table 3
Fractional anisotropy by group, all subjects*
Brain region Schizophrenic Control P Effect size (d)
Left frontal 0.42 (0.09) 0.43 (0.08) 0.68 -0.22
Right frontal 0.43 (0.11) 0.42 (0.07) 0.82 + 0.15
Left occipital 0.45 (0.07) 0.45 (0.05) 0.59 + 0.06
Right occipital 0.47 (0.07) 0.45 (0.05) 0.90 + 0.30
Fractional anisotropy hy group, males only*
Left frontal 0.40 (0.08) 0.45 (0.06) 0.33 -0.86
Right frontal 0.46 (0.15) 0.48 (0.50) 0.83 -0.31
Left occipital 0.44 (0.06) 0.44 (0.06) 0.95 -0.05
Right occipital 0.41 (0.02) 0.45 (0.08) 0.34 -0.46
Fractional anisotropy by group, females only*
Left frontal 0.44 (0.11) 0.42 (0.09) 0.83 + 0.15
Right frontal 0.41 (0.08) 0.39 (0.05) 0.66 + 0.37
Left occipital 0.46 (0.08) 0.45 (0.04) 0.77 + 0.29
Right occipital 0.53 (0.04) 0.46 (0.02) >0.01 + 3.29
"Values presented are the mean (S.D.), P-value, and effect size = (meansz-meancont )/S.D.cont
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abnormalities of white matter cyto-architecture
and that reduced NAA in the pre-frontal white
matter may reflect abnormal function of struc¬
turally intact neurons.
The study successfully measured reductions in
NAA concentrations of a magnitude consistent
with the established literature. In contrast, the
DTI results were characterised by the absence of
any discernible trend and by the lack of any
consistent correlation between the fractional
anisotropy and NAA concentrations and volumet¬
ric data. The positive findings of previously pub¬
lished DTI studies have not been replicated. The
authors acknowledge that the discrepancies
between studies may be a consequence of limited
statistical power. However, accurate estimation of
power is difficult when the few published studies
differ markedly in terms of techniques employed
and subjects recruited. This is the first DTI study
in schizophrenia to include female subjects and
the data suggest a male/female difference.
DTI is a relatively new technique and the liter¬
ature relating to pre-frontal white matter in
schizophrenia is limited to two small case control
studies. Buchsbaum et al. (1998) compared five
male schizophrenic subjects with six male con¬
trols. They analysed their data using a statistical
parametric mapping approach, which is not easily
translated into a predicted effect size for a region
of interest study. The region of interest examined
in this study approximated to the region of the
brain in which Buchsbaum and colleagues found
the most highly statistically significant reduction
in diffusion anisotropy.
The study by Lim et al. (1999) is the only study
in the literature to employ similar techniques to
this study. They report a statistically significant
reduction in diffusion anisotropy in frontal white
matter in 10 schizophrenic US army veterans
compared with 10 male controls, (the largest ef¬
fect size they report is 1.5 X S.D. which, for n = 10,
translates to power > 0.99 at a two-tailed signifi¬
cance level of 5%). However, there are important
differences between their subjects and the sub¬
jects in this study. Firstly, there is a large discrep¬
ancy in the age of subjects (mean of 48 years in
the Lim study vs. 34 years in this study). It is
possible that the differences they report are a
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consequence of decades of disease process or
neuroleptic exposure (although there was no cor¬
relation between fractional anisotropy and dura¬
tion of illness in this study). Secondly, the
schizophrenic subjects in this study were known
to have the characteristic macroscopic structural
brain abnormalities associated with schizophre¬
nia. It was anticipated, perhaps incorrectly, that
pre-existing differences between the groups on
established measures of brain structure would
increase prospects of detecting corresponding
between-group differences using DTI (i.e. in¬
crease the power of the study). Finally, the dif¬
ferent results may reflect male/female differ¬
ences in diffusion anisotropy. Lim et al. (1999)
studied only male subjects whilst half of the sub¬
jects in this study were female. Table 3 shows that
whilst fractional anisotropy was reduced in male
schizophrenics (although the effect sizes -0.05 to
-0.86 were smaller than those reported by Lim
et al., 1999), it was actually increased in female
schizophrenics. This result and, in particular, the
increased anisotropy in schizophrenic females in
the occipital region was not anticipated and is not
understood. There is a relative paucity of imaging
studies as a whole in female schizophrenic sub¬
jects and this finding requires further exploration.
Single voxel proton MRS is slow and has a
relatively poor spatial resolution. This increases
the potential for contamination of the white mat¬
ter spectrum by signals originating from the grey
matter and CSF. Such partial volume averaging is
difficult to avoid, but since the MRS VOI is
placed within a large region of white matter, such
effects will be minimized. Additionally, the
chemical shift imaging (CSI) technique, which
allows the acquisition of a two- (or three-)dimen-
sional grid of spectra, may prove very useful in
studies such as this where specific lesions are not
evident.
DTI is a new technique and a number of issues
relating to data acquisition and image analysis
arose during the course of this pilot study. Firstly,
because single-shot diffusion-weighted echo-
planar imaging suffers from artifacts caused by
susceptibility changes at air/tissue boundaries
(e.g. frontal sinus), accurate diffusion imaging data
could not be obtained from all regions of the
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brain. Secondly, the gradient strength (15 mT
m "1) and rise time (30 mT itT1 ms~') of the
scanner's gradient set were somewhat limited.
This was reflected in the large field-of-view (44 X
22 cm), relatively low image resolution (1.72 X 1.72
mm voxels), low values of diffusion-weighting
(Trace(fi) ~ 700 s mm-2) and long echo train
(200 ms). Also the diffusion-weighted echo-planar
imaging sequences could not be cardiac gated,
which may result in artefactual increases in dif¬
fusion anisotropy close to the ventricles. The re¬
sulting FA maps, therefore, have relatively lower
sensitivity and resolution than ideally required.
Nevertheless, the absolute values for the FA of
white matter reported in this study (~ 0.45) are in
close agreement with those reported by Lim et al.
(1999). Finally, the raw data must be processed, to
remove the effects of eddy currents (Bastin and
Armitage, 2000) and physiological movement be¬
fore accurate diffusion anisotropy information
may be obtained. In this study DTI data acquisi¬
tion was, therefore, limited to specific regions of
interest and no attempt was made to acquire DTI
data from other regions of the brain.
The ROI approach has inherent limitations
particularly when applied to white matter. It is
difficult to ensure that the region identified con¬
sistently reflects the same anatomical structures
within the brains of different subjects. One might
predict that as white matter tracts approach the
cortex, diffusion anisotropy would fall as the fi¬
bres spread out. Our regions of interest were
placed manually (always by the same experienced
and experimentally blind radiologist) and we did
not measure the reliability of this placement.
Another limitation of this approach is that an
apparently normal finding in the region studied
does not rule out the possibility of significant
structural abnormalities in important adjacent
structures.
DTI has the potential to develop into a power¬
ful technique for the study of white matter in
vivo. In the future it may usefully complement
functional imaging techniques by providing infor¬
mation about the structural basis of abnormal
functional connectivity. DTI certainly merits fur¬
ther development through pilot studies and ulti¬
mately may prove to be a useful tool in
schizophrenia research. Clearly larger studies us¬
ing proven techniques of data acquisition and
analysis are required.
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